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4 SUMMARY 
Background: Safe, effective and affordable drug combinations against falciparum malaria are 
urgently needed for the poor populations in malaria endemic countries. Chloroquine (CQ) 
combined with methylene blue (MB) is one promising new regimen because Methylene blue (MB) 
has a similar mode of action as chloroquine (CQ) and is also cheaply available. 
Objectives: The primary objective of this study was to evaluate a efficacious dose of CQ-MB and to 
investigate whether there is any improvement having 4 instead of 2 drug intakes per day.  
Methods: In this hospital-based randomized controlled trial (ISRCTN36731786), 435 children (6-
59 months) with uncomplicated falciparum malaria were treated in Burkina Faso. All study children 
received a total dose of 25mg/kg of CQ over a period of three days. The children were randomized 
to 2 or 4 times (2 groups) MB intake per day with 36, 54, or 72 mg/kg (3 levels). Primary outcome 
were the incidence of relevant adverse events and treatment failures. Patients were hospitalised for 
4 days and followed-up until day 14. 
Results: Three relevant adverse events occurred of which one was probably attributed to the study 
medication. In the per protocol analysis, there were no dose or group specific effects. Overall 
clinical and parasitological failure rates by day 14 were 10% [95% CI (7.5%, 14.0%)] and 24% 
[95% CI (19.4%, 28.3%)] respectively.  
Conclusion: MB in combination with CQ appears to be safe and effective against malaria in Africa, 
but given its short half life and the high background resistance against CQ a more effective partner 
drug needs to be identified. 
 
5 INTRODUCTION 
Malaria is responsible for 1.5 – 2.7 million deaths per year and represents one of the five major 
disease burdens responsible for the mortality in children less than five years especially in African 
countries (WHO 1997, Breman et al. 2004). Only a few safe and effective chemotherapeutic agents 
are presently affordable for most sub-Saharan African (SSA) populations (Bloland et al. 2000; 
Winstanley 2001). Although a small number of new malaria drugs including artemisinin derivates 
have been developed in recent years, these are usually too expensive for unsubsidised use in SSA. 
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The increasing resistance of Plasmodium falciparum to chloroquine and other antimalarials like 
sulphadoxine/ pyrimethamine supports the urgent need for development of new drugs against 
malaria (Trapé 2001). The combination of the drugs chloroquine (CQ) and methylene blue (MB) is 
a promising new regimen (Schirmer 2003, Mandi et al. 2005, Meissner et al. 2005). 
MB was already successfully used over 100 years ago for the treatment of malaria, even in children 
(Guttmann and Ehrlich 1891; Ehrlich 1913; Ferreira 1893). It was forgotten as other drugs (e.g. 
chloroquine) were introduced on the market. MB is a registered drug for the treatment of 
methemoglobinemia and in cancer treatment at i.v. dosages of 1-2 mg/kg (Küpfer et al. 1994). In 
recent years in vitro experiments have confirmed the antimalarial potency of MB (Amaral et al. 
2001). MB has been shown to specifically inhibit the glutathione reductase of the malarial parasite 
(Sarma et al. 2003). Furthermore it has the potential to reverse grade I/II CQ resistance (Färber et 
al. 1998; Meierjohan et al. 2002). 
In our previous studies, the oral combination of CQ and MB has been shown to be safe in adults 
and children of Burkina Faso with and without G6PD deficiency. However, using 4 mg/kg/day of 
MB in the combination was not sufficiently effective against malaria in our study children 
(Meissner et al. 2005). As there are published observations in adults and children showing that MB 
has been safe and effective in dosages 10 times higher than in our studies,  and MB often was given 
in these studies in several daily doses and over prolonged periods of time (up to several weeks), it 
appears promising and justified, to increase the MB dose stepwise until the desirable therapeutic 
efficacy is reached, unless there are unexpected safety problems which would be prohibitive of 
further dose increments. 
The primary objective of this study was therefore to determine a safe and effective dose (36, 54, 72, 
or 168 mg/kg) and dosing regimen (2x versus 4x daily) of MB for co-administration with a 
conventional dose of CQ as an affordable new drug combination for the treatment of uncomplicated 
falciparum malaria in western African children. 
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6 MATERIAL AND METHODS 
6.1 Study area and study subjects 
The study was conducted in July until November 2004 in the District Hospital of Nouna in the 
province of Kossi in north-western Burkina Faso. In June/July 2004, the community was  informed, 
field staff was trained, and pilot testing of methods took place. The town has about 20000 
inhabitants of different ethnic groups. Most people living in nearby villages are farmers. Formal 
health services in this province are restricted to the district hospital and to 22 small health centres. 
Access to health services is limited, particularly during the rainy season (Müller et al. 2003a). The 
area is highly endemic for P. falciparum malaria (Müller et al. 2001). CQ is currently still the first-
line treatment in Burkina Faso. Day 14 CQ clinical failure rates in the villages surrounding Nouna 
town were shown to be around 10% in recent years (Müller et al. 2003b).  
Children with Burkinabe nationality aged 6-59 months with uncomplicated falciparum malaria 
(axillary temperature ≥ 37.5°C and ≥ 2.000 P. falciparum asexual parasites per µl blood) whose 
parents or caretaker had given informed consent were enrolled into the study. Children with 
complicated or severe malaria (repeated vomiting, seizures or other neurological impairment), 
hyperparasitaemia (>100000 /µl) or any other apparent significant disease (e.g. pneumonia, 
meningitis, hepatitis, severe diarrhoea, measles, severe malnutrition) were excluded from the trial. 
6.2 Study objectives 
The primary objective of this study was to determine a safe and effective dose (36, 54, 72, or 168 
mg/kg) and dosing regimen (2x versus 4x daily) of MB for co-administration with a conventional 
dose of CQ as an affordable new drug combination for the treatment of uncomplicated falciparum 
malaria in western African children. 
The secondary objectives of this study were:  
• to compare efficacy of a twice daily dose regimen with a four times daily dose regimen. 
• to study the pharmacokinetics of the combination of CQ-MB in children with uncomplicated 
falciparum malaria in western Africa 
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6.3 Primary endpoints 
Composite primary endpoint: 
1. Incidence of relevant adverse events 
2. Incidence of treatment failures (TF) 
Justification: The composite primary endpoint will be used mainly for the decision to go ahead with 
the next dose level or to stop the dose finding (see design of the trial, chapter 6.5).  
6.4 Secondary endpoints 
• Incidence of early treatment failure (ETF) 
• Incidence of late clinical failures (LCF) 
• Incidence of late parasitological failures (LPF) 
• Incidence of late parasitological failures (CPF)  
(post hoc: not mentioned as secondary endpoint in the protocol) 
• Fever clearance time 
• Parasite clearance time 
• Change in haemoglobin after 4 (or 7) and 14 days compared to baseline 
• Incidence of observed serious adverse events over the 14 days observation period  
(safety, not mentioned as secondary endpoint in the protocol) 
• Incidence of observed and self-reported non-serious adverse events over the 14 days observation 
period 
• Whole blood CQ and MB kinetics (mean AUC, Cmax, Tmax, elimination half life) 
• Monitoring of concomitant drug intake 
• G6PD assessment based on PCR 
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Table 6-1: Definitions 
Term Definition 
Age  If a full date of birth is known, the exact age can be calculated 
using the date of informed consent and date of birth. If the actual 
day of the birth date is unknown, it is set to 15. If day and month 
are missing the 1st of July is considered as the date of birth.  
Baseline values Directly after the written informed consent a blood sample will be 
taken for the baseline measurements (Laboratory baseline values). 
Those values are considered as baseline values. 
Change under treatment Any change under treatment is defined as post-baseline value 
minus baseline value. If more than one value is available the last 
value will be taken for the difference. 
D0, D1, D2, D3 For the definition of days the latest WHO Definition is used 
(WHO 2003). The day that the patient is enrolled and receives the 
first dose of medicine is designated as D0. Thereafter, the schedule 
follows with D1, D2, etc.  
D0=[0h, 24h], D1=(24h, 48h], D2=(48h, 72h], D3=(72h, 96h] 
D14 For this analysis we define D14 as the 14th day after first drug 
intake, but with the tolerance of –1 and +3 calendar days.  
D14=(312h, 432h]  
D28 For this analysis we define D28 as the 28th day after first drug 
intake, but with the tolerance of –3 and +3 calendar days.  
D28=(600h, 768h] 
G6PD-deficiency A subject is considered G6PD-deficient for the current study in 
case of a positive result of a diagnostic test (modified Beutler-
Mitchell-Test) carried out on blood samples taken for baseline 
measurement prior to administration of study drugs. The G6PD 
status was analyzed only in case of clinical decisions.  
Severe acute haemolysis Haemoglobin ≤ 5 g/dl or received blood transfusion according to 
clinical judgement of study physician.  
Severe methaemo-
globinaemia 
Methaemoglobin > 25% 
Severe acute neurological 
disorder 
Acute change in consciousness, ≥ 2 convulsions 
AEs The adverse event (=AE) defined in the protocol is used, but blue 
urine is expected for all children in the CQ+MB treatment group 
and it is not considered as an adverse event for the analysis. Only 
AEs after initiation of study treatment will be tabulated (ICH-E3). 
Relevant adverse event If one of the following criteria is fulfilled between the first drug 
intake and 24h after the last drug intake. 
• Acute haemolysis 
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Term Definition 
• Methaemoglobinaemia  
• Severe acute neurological disorders possibly, probably, or 
definitely related to the study drug  
• Study drug related SAE 
Severe malaria A patient is counted as having severe malaria if one of the 
following criteria is fulfilled (WHO 2003) 
• Prostration (inability to sit upright in a child normally able to 
do so, or to drink in the case of children too young to sit) 
• Impaired consciousness 
• Respiratory distress (acidotic breathing / severe acidosis) 
• Multiple convulsions  
• Circulatory collapse 
• Pulmonary oedema 
• Abnormal bleeding 
• Jaundice (= Hyperbilirubinemia) 
• Haemoglobinuria 
• Severe anaemia (Hb < 5g/dl) 
• Hyperparasitaemia (>500.000/µl) 
• Persistent vomiting 
Parasitaemia Positive measurement of P. falciparum with or without P. ovale 
and P. malariae 
ETF A patient is counted as early treatment failure (=ETF) if one of the 
following criteria is fulfilled (WHO Definition).  
• Development of danger signs (clinically defined, based on 
judgement of study physicians) on D1-D3 in the presence of 
parasitaemia. 
• Severe malaria on D1-D3 
• D2: parasites > baseline count 
• D3: Fever (≥37.5°C) and parasitaemia (parasites > 0) 
• D3: ≥ 25% of baseline parasites  
LCF (14, WHO) A patient is not an ETF and is counted as late clinical failure 
(=LCF) if one of the following criteria is fulfilled (WHO 
Definition).  
• Development of danger signs (clinically defined, based on 
judgement of study physicians) on D4-D14 in the presence of 
parasitaemia 
• Severe malaria on D4-D14  
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Term Definition 
• Fever (≥37.5°C) and parasitaemia > 0 on D4-D14 
LCF (28,WHO) See LCF (14, WHO), only the time periods are different: 
D4-D28 instead of D4-D14. Therefore all patients which are LCF 
(14, WHO) are LCF (28, WHO) as well.  
TF (14, WHO) A patient is considered as treatment failure (day 14) if he/she is 
ETF or LCF(14,WHO) (WHO Definition). 
TF (28, WHO) A patient is considered as treatment failure (day 28) if he/she is 
TF(14) or LCF(28) (WHO Definition). 
LPF (14, WHO)  A patient who is not ETF or LCF(14, WHO) earlier is considered 
as late parasitological failure in case of parasitaemia > 0 on D14 
and a measured temperature < 37.5°C (WHO Definition).  
LPF (28, WHO) A patient (only for the third dose level) who is not ETF or 
LCF(14,WHO) earlier is considered as late parasitological failure 
(28) in case of: parasitaemia > 0 on D7-D28 and a measured 
temperature < 37.5°C. 
CPF (14, WHO) A patient is considered as clinical or parasitological failure (day 
14) if he/she is ETF or LCF(14,WHO) or LPF(14, WHO). 
(ETF+LCF+LPF=1-ACPR) 
CPF (28, WHO) A patient is considered as clinical or parasitological failure (day 
28) if he/she is ETF or LCF(28,WHO) or LPF(28, WHO). 
(ETF+LCF+LPF=1-ACPR) 
ACPR (14, WHO) Absence of parasitaemia on D14 irrespective of axillary 
temperature without previously meeting any criteria of ETF, 
LCF (14, WHO) or LPF (14, WHO).  
ACPR (28, WHO) Absence of parasitaemia on D28 irrespective of axillary 
temperature without previously meeting any criteria of ETF, 
LCF (28, WHO) or LPF (28, WHO).  
Fever clearance time time from begin of treatment to the first of two consecutive 
measurements of an axillary temperature < 37.5°C during the full 
hospitalization (D0-D3) time of the child 
Parasite clearance time time from begin of treatment to the first time when the 
parasitaemia is not detectable anymore during the full 
hospitalization time (D0-D3) of the child 
ETF=1 => LCF(14) =0,  LPF(14)=0,  LCF(28)=0,  LPF(28)=0 , TF(14)=1, TF(28)=1, ACPR(14)=0,  ACPR(28)=0 
ETF=0, LCF(14) =1 =>  LPF(14)=0,  LCF(28)=1,  LPF(28)=0 , TF(14)=1, TF(28)=1,  ACPR(14)=0,  ACPR(28)=0 
ETF=0, LCF(14) =0,  LPF(14)=1 =>  LCF(28)=0,  LPF(28)=1 , TF(14)=0, TF(28)=0,  ACPR(14)=0,  ACPR(28)=0 
ETF=0,  LCF(14) =0,  LPF(14)=0,  LCF(28)=1 =>  LPF(28)=0, TF(14)=0, TF(28)=1,  ACPR(14)=1,  ACPR(28)=0 
ETF=0,  LCF(14) =0,  LPF(14)=0,  LCF(28)=0   LPF(28)=1 =>   TF(14)=0, TF(28)=0,  ACPR(14)=1,  ACPR(28)=0 
ETF=0,  LCF(14) =0,  LPF(14)=0,  LCF(28)=0   LPF(28)=0 =>   TF(14)=0, TF(28)=0,  ACPR(14)=1,  ACPR(28)=1 
with: 1=failure, 0=no failure 
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Comment: All patients are ETF, LCF(14), LPF(14) or ACPR(14). Additionally in the third level all 
patients are ETF, LCF(28), LPF(28) or ACPR(28).  
Comment: PCR information of recrudescence regarding day 28 for level 3 was added (only the 
same type/stream of p.faliciparum)  or reinfection (with a new type/stream of p.falciparum): A 
patient who was initially LCF (or LPF) becomes a no LCF (or no LPF) if only new streams of 
p.falciparum can be found via PCR method at day 14 or 28 respectively. Only in 5 patient were 
only new streams found (409, 412, 456, 505, 521), the first 3 were already treatment failures until 
day 14; the other two were considered as ACPR(28) instead of failures.   
6.5 Study design 
Single-centre, uncontrolled trial on the safety and efficacy of CQ in fixed doses combined with 
increasing total doses of MB given in two different dosage regimens, A and B, intending either to 
achieve high maximum concentration or inhibitory maintenance concentrations of MB (parallel and 
randomised) in young children of Nouna Health District, north-western Burkina Faso. The 1:1 
randomisation into the two groups per dose level was implemented using a computer generated 
randomisation list (block randomisation) created in Heidelberg. Telephone or fax randomisation 
was not feasible due to the instable communication system.  
The dose escalation process for a dosage regimen group went into the next higher dose level if  
1. the safety aspect was fulfilled (i.e. one-sided 95% confidence interval for the incidence of 
relevant AEs below 0.1) and 
2. the efficacy criterion (i.e. one-sided 95% confidence interval for the incidence of TF below 
0.15) was fulfilled at most in one dose level. I.e. the mentioned criterion had to be 
confirmed in a second dose level to conclude efficacy. 
The process stopped if one of the two criteria was not fulfilled or the highest dose level was 
reached. Formally the safety scoring group had to decide whether to proceed to the next level or 
not. All people in this group were fully integrated in the trial process, therefore a quick decision 
was expected. In case of not finding a common consensus the DSMB was involved. 
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Figure 6-1: Project flow with dose escalation 
6.6 Laboratory work-up 
Venous blood samples were taken. Determination of Hb, methaemoglobinaemia and malaria 
parasitaemia will be done in the laboratory of CRSN with routine methods. From the baseline 
blood, an EDTA blood sample will be stored for phenotypical emergency G6PD deficiency 
determination in case of acute haemolysis (modified Beutler-Mitchell test). A filterpaper blood 
sample will be stored for retrospective genotypical determination of G6PD status in Germany. For 
assessing possible correlations between safety and efficacy of the study treatments and the 
population kinetics of the study drugs, whole blood concentrations of CQ and MB will be 
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determined in all study participants on day 3 from dried filter paper samples. Drug concentrations 
will be determined by HPLC and mass spectrometry methods recently developed, and will be the 
basis for calculation of population kinetics (AUC, Cmax, Tmax, elimination half life). More 
information see trial protocol.  
6.7 Sample size justification 
The study had a sequential character and should show with sufficient power (80%) if there is an 
efficient and safe CQ+MB regimen. In case of no safe CQ+MB regimen the study should be 
stopped with a clear evidence for an unsafe CQ+MB regimen. 
In a first calculation it was assumed that the safety and efficacy endpoint are independent of each 
other. This allows explicit calculation of the probability for different study outcomes. For sample 
size calculation three overall outcomes are considered: S – the study was stopped because of a 
safety failure; E – the study was stopped because of evidence for sufficient efficacy; U – the study 
was stopped because of an indecisive situation (no safety failure or no proof of efficacy). 
In the following, the Null hypothesis for the probability of a relevant adverse event pS is set to 
H0,Safety: pS ≥ 0.1. Two possible Null hypotheses for the probability of a treatment failure pE will be 
considered: H0,Efficacy I : pE ≥ 0.1 and H0,Efficacy II : pE ≥ 0.15. 
As sample size for a dose regimen the following numbers are considered: N=60, 65, 70. 
The following safety and efficacy scenarios for the sequence of for studies are considered. A 
scenario is described by two vectors pS, pE which describe the level specific safety and treatment 
failure rates. The first number of a vector belongs to level 1, ... , the fourth number of a vector 
belongs to level 4. 
 
Scenario I  describes a situation of increasing loss of safety and marginal efficacy: 
   pS = (0.015, 0.025, 0.050, 0.100) 
   pE = (0.100, 0.100, 0.100, 0.100) 
Scenario II describes a situation of increasing loss of safety and increasing efficacy: 
   pS = (0.015, 0.025, 0.050, 0.100) 
   pE = (0.050, 0.025, 0.015, 0.015) 
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Scenario III describes a situation of insufficient safety and insufficient efficacy: 
   pS = (0.10, 0.10, 0.10, 0.10) 
   pE = (0.15, 0.15, 0.15, 0.15) 
 
Scenario IV describes a situation of sufficient safety and marginal efficacy: 
   pS = (0. 015, 0. 015, 0. 015, 0. 015) 
   pE = (0.100, 0.100, 0.100, 0.100) 
 
Scenario V describes a situation of sufficient safety and increasing efficacy: 
   pS = (0.015, 0.015, 0.015, 0.015) 
   pE = (0.100, 0.050, 0.025, 0.025) 
 
An appropriate study size and testing strategy should result in the following decisions: 
Scenario I: Study should stop before arriving in the highest dose regimen. 
Scenario II: Stop study early enough in low dose levels with sufficient safety 
Scenario III: Stop study because safety and efficacy are not given 
Scenario IV: Study should not stop because of safety failure but may end indecisive with  
   respect to efficacy 
Scenario V: Study should detect this scenario as one with enough efficacy and safety. 
 
The following table summarises the probabilities for the three study outcomes (S – the study was 
stopped because of a safety failure; E – the study was stopped because of evidence for sufficient 
efficacy; U – the study was stopped because of an indecisive situation (no safety failure or no proof 
of efficacy) for the three sample sizes and two testing strategies for efficacy under consideration. 
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Table 6-2: Simulations for the sample size calculation 
  H0, Efiicacy I: pE ≥ 0.10 H0, Efiicacy II: pE ≥ 0.15 
N Scenario S E U S E U 
60 I 0.699 0.000 0.301 0.670 0.119 0.211 
 II 0.644 0.204 0.152 0.524 0.464 0.012 
 III 1.000 0.000 0.000 1.000 0.000 0.000 
 IV 0.643 0.000 0.356 0.615 0.135 0.251 
 V 0.634 0.047 0.319 0.507 0.452 0.041 
65 I 0.340 0.005 0.655 0.328 0.140 0.531 
 II 0.277 0.553 0.170 0.228 0.749 0.023 
 III 1.000 0.000 0.000 1.000 0.000 0.000 
 IV 0.266 0.006 0.729 0.256 0.152 0.591 
 V 0.237 0.398 0.366 0.199 0.700 0.101 
70 I 0.510 0.002 0.489 0.481 0.188 0.330 
 II 0.426 0.440 0.134 0.348 0.641 0.011 
 III 1.000 0.000 0.000 1.000 0.000 0.000 
 IV 0.309 0.003 0.688 0.290 0.245 0.466 
 V 0.278 0.360 0.362 0.211 0.754 0.035 
Probability of study outcome (S, E, U) under different sample sizes (N=60,65,70) and testing strategies (I, II) 
Simulations were also done assuming correlation between the safety and efficacy outcome. The 
simulation do not show substantial deviation from the results calculated for the independence 
model. 
Table 6-2 shows, that the sample size 60 has not enough power (~37 % under H0, Efiicacy I: pE ≥ 0.10 
and ~ 50% under H0, Efiicacy II: pE ≥ 0.15) to detect the relevant scenario V. For sample size 65 and 
under H0, Efiicacy II the power is ~80% to prove the safety aspect. The chance to end up with an 
efficacy result is 70% for this setting. Also for scenario IV there is a high probability (~75%) not to 
end up with a safety failure. Scenario I and scenario II are also covered with sufficient statistical 
quality. Changing the Null hypothesis for efficacy to H0, Efiicacy I would create disadvantage for 
scenario V. The advantages gained through a higher sample size (N=70) are not substantial. 
Therefore, it is recommended to include 65 patients per dose level in each arm. Assuming 10% drop 
outs results in a sample size of 72 children per dose level in each arm. This sums up to a total 
sample size of 576 children. 
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6.8 Statistics 
6.8.1 Analysis of the primary endpoint 
The significance level (type I error) for all analysis was set to 0.05. The two primary endpoints 
were tested hierarchically. Therefore, no adjustments for multiple tests were necessary. The analysis 
was done for the FAS. The PP set was used as sensitivity analysis. Each of the safety and efficacy 
test of hypotheses will be performed per dosage regimen and dose level. The so called efficacy test 
is not a classical test versus placebo but a test against an a priori specified margin (here 15%). 
Further comparisons between groups and levels were done exploratory, see below. The hypotheses 
by group and level were as follows: 
1. H0,Safety: pS ≥ 0.1  versus  H1,Safety: pS < 0.1 
2. H0,Efficacy : pE ≥ 0.15  versus  H1,Efficacy : pE < 0.15 
where pS denotes the incidence of RAE and pE the incidence of TF(14, WHO). The tests were 
performed using exact one-sided 95% confidence intervals for the incidences of RAE or TF 
respectively.  
6.8.2 Analysis of the secondary endpoints  
All analyses for the secondary analyses have explorative character. Descriptive statistics, 
95% confidence intervals, Wilcoxon-Mann-Whitney tests (U-Test, WMW), continuity corrected 
Chi-Square tests (Chi), Kruskal-Wallis tests (KW), Wilcoxon-Sign-Rank test (WSR), F-Tests / 
Wald tests (F) or Likelihood-Ratio tests (LR) in case of parametric models, Chi-Square tests (Cox) 
in case of time to event analyses were used. 
In case of time to event analyses (fever clearance, parasite clearance) a Cox model was used with 
interaction group*level (SAS procedure phreg). The interaction was eliminated in case of a 
corresponding p-value above 0.2. The two main effects group and level left in the model. No further 
covariates were used.  
In case of the treatment failure rates a logistic model was used with interaction group*level (SAS 
procedure logistic, LR-Tests). The interaction was eliminated in case of a corresponding p-value 
above 0.2. The two main effects group and level left in the model. No further covariates were used.  
In case of the analysis of the changes of Hb from baseline (day 4 – baseline, day 14 – baseline) a 
linear regression model was used with interaction group*level (SAS procedure glm, F-Tests). The 
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interaction was eliminated in case of a corresponding p-value above 0.2. The two main effects 
group and level left in the model. No further covariates were used.  
6.8.3 Missing Values 
In case of missing information for binary primary or secondary endpoints, the corresponding value 
was set to failure. For the secondary endpoints fever and parasite clearance time, techniques for 
censored observations was used. No imputation process was applied. 
When there are two parasite counts or lab values given: the latest was used. For the fever 
measurement on one day the maximum per day was used. If a patient had no parasitological data on 
D2 but on D3 this was not considered as failure just due to missing data 
6.8.4 Software 
Evaluations were carried out using the software package SAS® System 8.2 or 9.1 (SAS Inc., 
Cary/NC, USA). 
6.9 Defintions of analysis populations 
Two analysis sets will be defined: the Safety Set (SAF) and Full Analysis Set (FAS) are identical in 
this trial and the Per-Protocol Set (PP). 
• Safety Set (SAF) = Full Analysis Set (FAS): This analysis set will consist of all patients 
who received active trial medication at least once (not based on pharmacokinetic 
confirmation). Patients are analysed as randomised (ITT). 
• Per-Protocol (PP) Set (SAS variable pp_extra): This analysis set will consist of all 
patients included in the full analysis set and treated on D0-D2: twice per day for patients in 
the group 2x and four times per day for patients in the group 4x. The following patients will 
be excluded:  
o Patients who vomited and the drug was not given again  
o Patients who vomited and it is unclear whether it was given again  
o Patients who violate inclusion/exclusion criteria  
o Patients without blue urine 
o Patients who dropped out early (before day 14) 
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o Patients without information on D14 
o Patients treated (D4-D13) with although no fever and/or no parasites 
Patients who got the wrong concentration could have been excluded as well but they were not. 
There were 36 children who got a higher dose than intended at level 1 which was conservative for 
decision making. However, in some situations the subgroup of “patients in PP with correct dose” 
(PP set in the strong sense) was considered (SAS variable pp).  
6.10 Interventions 
All study children received a standard total dose of 25mg/kg of CQ syrup (10mg/ml) over a period 
of three days (first and second day: 10mg/kg, third day: 5mg/kg). Chloroquine was taken from the 
essential drug stock of the Ministry of Health.  
Depending on the dose level, doses of MB of 36, 54, and 72 mg/kg were given respectively. The 
fourth dose level with 168 mg/kg was not performed (see chapter 7.1). At each dose level children 
were randomized to two or four MB doses per day (2x versus 4x daily). MB (Mayrhofer 
Pharmazeutika, Linz/Austria) was given as a 1.77% or 2.4 % solution with fruit flavouring and 
honey supplement to mask the bitter taste.  
Administration of study medications was directly supervised by a study physician or a study nurse 
and in case of vomiting within 30 minutes, the drugs were one-time re-administered. 
Study participants were hospitalized for 72 hours. At least once during the time of hospitalisation 
the colour of the urine was checked to assess MB compliance through visual observation. Children 
were systematically examined on day 0, 1, 2, 3, 4, 14 (and day 28 in level 3). Blood samples were 
processed with standard methods in the Centre de Recherche en Santé de Nouna (CRSN). 
Methaemoglobin formation was monitored twice daily on day 0 and once on day 1, 2 and 3. Other 
laboratory parameters like liver enzymes, serum creatinine or the phenotypical G6PD status were 
available at any time if clinically indicated. Based on filter paper blood samples, the G6PD 
genotype was determined in Germany. 
All children having fever ≥ 38.5°C received standard doses of paracetamol (= acetaminophen; 10 
mg/kg every 6 hours) until symptoms subsided (taken from the essential drug stock of the Ministry 
of Health, product description: paracetamol tablets). 
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All indicated drugs were allowed, except other western antimalaria drugs, antibiotics with 
antimalarial efficacy, dapsone and other sulfones, acetanilide and phenacetin, nalidixic acid, 
niridazole, nitrofurantoins and sulphonamides from beginning of treatment until end of follow-up. 
6.11 Ethical, organizational and regulatory aspects 
The trial was conducted in accordance with local laws and the internationally established principles 
for Good Clinical Practice (including statistical monitoring and site monitoring) which had their 
origin in the Declaration of Helsinki of the World Medical Association and in accordance with the 
“Note for Guidance on Clinical Investigation of Medicinal Products in Children” (CPMP 1997). 
The study protocol was approved by the ethics committees in Heidelberg and Burkina Faso. A 
scientific advisory board was established and it gave advice during the planning phase. The safety 
scoring group decided whether to proceed to the next level or not. The safety of the trial was also 
monitored by a data safety monitoring board (DSMB). The statistical site was at the IMBI. The 
statistical analysis of this study was carried out by the independent statisticians Prof. Dr. Ulrich 
Mansmann and Dr. Steffen Witte. It was the responsibility of the independent statisticians to ensure 
that all relevant statistical aspects were considered. From the investigator site in Nouna Théophile 
Tapsoba was involved. 
• Sponsor: DSM Fine Chemicals Austria 
• Principal investigator: PD Dr. med. Olaf Müller   
• Biometricians: Prof. Dr. rer. nat. Ulrich Mansmann (responsible) and Dr. sc. hum. Steffen 
Witte  
• Trial Coordinator in Germany: Dr. med. Peter Meissner, MSc Trop Paed  
• Trial Coordinator in Burkina Faso: Dr. Bocar Kouyaté, MPH 
• Study team (alphabetical order): Dr. rer. nat. Jürgen Burhenne, Dipl. Biol. Boubacar 
Coulibaly, Dr. Mandi Germain, PD Dr. med. Albrecht Jahn, Prof. Dr. rer. nat. Ulrich 
Mansmann, PD Dr. med. Dipl. Phys. Gerd Mikus, PD Dr. med. Olaf Müller, Dr. med. Jens 
Rengelshausen, Dipl.-Ing.(FH) Klaus-Dieter Riedel, Dr. rer. nat. Wolfgang Schiek, Prof. Dr. 
med. Heiner Schirmer, Théophile Tapsoba, Prof. Dr. med. Ingeborg Walter-Sack, Dr. sc. 
hum. Steffen Witte 
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• Steering Committee: PD Dr. med. Olaf Müller, PD Dr. rer. nat. Ulrich Mansmann, Prof. Dr. 
med. Ingeborg Walter-Sack, Dr. rer. nat. Wolfgang Schiek, Dr. Bocar Kouyaté  
• Scientific advisory Board (SAB): PD Dr. med. Christoph Hatz, Prof. Dr. med. Walter E. 
Haefeli, Prof. Dr. med. Katja Becker-Brandenburg 
• Safety scoring group: Dr. Bocar Kouyaté, Dr. Mandi Germain, PD Dr. Olaf Müller, Prof. 
Dr. Ingeborg Walter-Sack, Dr. Peter Meissner 
• Data safety monotoring board (DSMB): Prof. Dr. rer. nat. Heiko Becher, Dr. med. August 
Stich, Prof. Dr. Innocent Pierre Guissou 
After having received detailed information from the study physician about all risks and benefits of 
the study through translation of a detailed research consent form into the local language, caretakers 
were asked for their written consent. They were clearly informed that they could withdraw from the 
study at any time and without disadvantage. A standard blood transfusion service was available at 
the hospital and study physicians and emergency medications were available 24 hours per day. All 
children in the specified age group who were presented to the hospital during the study period for 
other conditions besides malaria also received free treatment. 
7 RESULTS 
The main results are already published (Meissner et al. 2006). This report gives the same results 
plus some additional information which can not be published in a short journal paper.  
7.1 Recruitment of patients 
The first patient was enrolled on the 21st of July 2004, the last on the 31st of October 2004 (Table 
7-1). In total 435 children with uncomplicated malaria were enrolled (Figure 7-1, Table 12-1).  
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Table 7-1: Date of enrolment by dose level 
Dose Level First patient enrolled Last patient enrolled Last visit done  
1 21 July 2004 19 Aug 2004 1 Sept 2004 
2 24 Aug 2004 23 Sept 2004 6 Oct 2004 
3 30 Sept 2004 31 Oct 2004 26 Nov 2004 
4 none none none 
 
There was no formal stop of patient recruitment fulfilled (neither the safety criteria nor the efficacy 
criteria was fulfilled, see chapter 7.6). However, the recruitment was stopped nearly at the end of 
the third dose level in the end of October 2004 due to the end of the malaria season. Not enough 
children could have been enrolled in the end of the year. 
 
 
Figure 7-1: Recruitment of patients 
7.2 Analysis Sets and Compliance 
vomiting (no trial medication, level 1: 10, level 2: 2, level 3: 8), and 3 children (all in level 2) did 
Out of the 435 enrolled children 20 (4.6%) were excluded from the full analysis set due to repeated 
Dose finding trial - BlueCQ-3-Report 
 
 Page 28 of 149   
not receive any trial medication due to other reasons. Therefore 412 patients (2x daily: 197, 4x daily 
215) were in the a priori defined full analysis set for the intention to treat analysis. 
ut of those 412 patients 48 were not in the per-prococol set due to various reasons (Table 12-2 to 
able 12-5), mainly due to vomiting (14 children) or due to missing information on D14/D28. 
Therefore the per-protocol set for the PP analysis consists of 364 (2x daily: 173, 4x daily 191) 
atients, see Figure 7-2.   
ut of the 364 patients there were 36 children who got a higher dose than intended at level 1 (104-
18, 120-125, 127, 129-131, 133-143). One patient (119) in the FAS got also a wrong concentration 
ut was not in the PP set anyway.  
he mean time from baseline blood measurement to the first treatment was 2.0 +/– 0.7h (2x daily) 
and 2.0 +/– 0.6h (4x daily) with a total range of 0.5 to 5.2h and therefore much shorter than in the 
mer trial (CQ: 7.8 +/– 2.3h, CQ-MB: 7.4 +/– 2.5h) (Witte et al. 2006), see Table 12-17 and Table 
2-14 for level 1, Table 12-15 for level 2, and Table 12-16 for level 3. 
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th of April, 21st of July, and 12th of December 2005 due to minor changes. No formal 
monitoring was done. The final analysis run in May 2005.  
Randomized 
n=435 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7-2: Flow chart of patients 
7.3 Quality of Data 
Double data entry was performed in Nouna. Inconsistencies were checked generating queries. In 
total 242 inconsistency checks were programmed. The investigators solved all queries. The data 
base was first closed in January 2005 and reopened on the 17th of February, 9th of March, 29th of 
March, 26
 
-/-/0 - Lost-to follow up -  0/0/1 
 
0/3/1 - Lost-to follow up -  0/1/0 
4/0/3 - missing data on D14 - 1/2/7
2/0/0 - antimalarial treatment - 3/0/0
0/0/0 - Eligibility - 1/0/0 
0/0/0 - death - 0/1/0 
3/3/2 - Vomiting - 4/0/2 
1/2/0 - other - 0/1/0 
2x - exclusion - 4x 
 
(level 1 / level 2 / level 3) 
4x: n=78/78/62 
 
(level 1 / level 2 / level 3) 
2x: n=79/77/61 
7/2/8 - vomiting - 3/0/0 
0/3/0 - no first treatment - 0/0/0 
 
FAS: n=72/72/53 
 
 
FAS: n=75/78/62 
 
day 1-4: n=70/76/60 
 
day 1-4: n=68/67/51 
 
PP on day 14: n=66/73/53  PP on day 14: n=62/64/47 
 
PP on day 28: n=-/-/47 
 
PP on day 28: n=-/-/52 
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7.4 Demographic characteristics of study subjects 
 The current malaria disease episode when the patients was enrolled was 
s had any prior 
treatment of the current disease episode. In total there were 321 (78.5%) children with G6PD 
ssful (Table 12-9).  
Comparing the levels (two groups pooled) there was no difference found regarding sex 
6PD deficiency (pChi=0.1274). But there were 
differences between the levels regarding age (pKW=0.0124) with an increasing age from level to 
r of the design no 
randomization between level was possible. Some imbalances between the levels were therefore 
expected. Post-hoc sensitivity analyses were not done. 
The prevalence of the genetic resistance for CQ (pfcrt T76) is 52.6% (3 missings), comparable 
between groups (pChi=0.3186, 2x daily: 50.0%, 4x daily: 54.9%) but not between levels 
(pChi<0.0001) with increasing resistance from level to level (level 1: 39.0%, level 2: 56.0%, level 3: 
65.5%).  
7.5 Laboratory baseline data 
Mean haemoglobin [g/dl] at baseline was 9.6 +/– 1.0 (range: 6.9 to 14.2), mean methaemoglobin 
[g/dl] was 1.2 +/– 0.5 (range: 0.2 to 2.9). The median parasite density (P. faliciparum) was 24800 
(range: 1050 to 100000).  
Out of 412 children 218 (52.9%) were boys. The mean age was 33.3 +/– 15.1 months (range: 6 to 
59). The average weight was 12.1 +/– 3.0 kg (range: 5 to 20). Other prior illnesses were captured 
for 21.7% of the children.
on average 2.2 +/– 1.1 days (range: 1 to 14). Nearly one third (30.3%) of the patient
sufficient (PCR method), 50 (12.2%) heterozygote deficient, and 38 (9.3%) homozygote deficient 
(3 missing values). The statistics were presented for all patients in the FAS, over both groups and 
all three dose levels. 
The two groups were comparable, the randomization was succe
(pChi=0.6384), weight (pKW=0.1125), and G
level (level 1: 31.6 months, level 2: 32.1 months, level 3: 36.9 months), length of the current 
disease episode (pKW<0.0001) with a shorter mean episode in the first level (level 1: 1.9 days, 
level 2: 2.5 days, level 3: 2.3 days), other prior illnesses (pChi=0.0081) with a higher rate in the 
second level (level 1: 14.5%, level 2: 29.3%, level 3: 20.9%), and prior treatment of the current 
disease episode (pChi=0.0233) with a decrease from level to level (level 1: 37.4%, level 2: 30.0%, 
level 3: 21.7%). The descriptive statistics were presented by level in Table 12-6 for level 1 Table 
12-7 for level 2 and Table 12-8 for level 3. Due to the sequential characte
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The
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0.3721), p site =0 there 
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wer than 10% un er %.  give .7.9. 
 two groups were comparable, the randomization was successful (Table 12-13).  
Comparing th levels o groups  there wa
(pKW= ara  density (pKW .4115). But was a difference between the levels 
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Firs po  incidence of r vant adverse e  (RAE): In th S in level 1 n
o  2 each group one AE occurred, in level 3 one  occurred in 
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Table 7-2: Number of RAEs with one-sided CI by analysis population, group, and level 
Analysis set level Statistic 2x daily 4x daily Total 
FAS 1 events/N (%) 0/72 (0.0%) 0/75 (0.0%) 0/147 (0.0%) 
 
 
 
2 
exact 95% CI [0%, 4.99%] [0%, 4.80%] [0%, 2.48%] 
To l 
P 
events/N (%) 0/64 (0.0%) 0/73 (0.0%) 0/137 (0.0%) 
To l 
P * 
events/N (%) 0/64 (0.0%) 0/73 (0.0%) 0/137 (0.0%) 
To l 
events/N (%) 
exact 95% CI 
1/72 (1.4%) 
[0%, 6.42%] 
1/78 (1.3%) 
[0%, 5.94%] 
2/150 (1.3%) 
[0%, 4.14%]   
 3 events/N (%) 0/53 (0.0%) 1/62 (1.6%) 1/115 (0.9%) 
  exact 95% CI [0%, 6.72%] [0%, 7.42%] [0%, 4.06%] 
 ta events/N (%) 1/197 (0.5%) 2/215 (0.9%) 3/412 (0.7%) 
  exact 95% CI [0%, 2.39%] [0%, 2.90%] [0%, 1.87%] 
      
P 1 events/N (%) 0/62 (0.0%) 0/66 (0.0%) 0/128 (0.0%) 
  exact 95% CI [0%, 5.78%] [0%, 5.44%] [0%, 2.84%] 
 2 
  exact 95% CI [0%, 5.60%] [0%, 4.93%] [0%, 2.66%] 
 3 events/N (%) 0/47 (0.0%) 1/52 (1.9%) 1/99 (1.0%) 
  exact 95% CI [0%, 7.55%] [0%, 8.80%] [0%, 4.70%] 
 ta events/N (%) 0/173 (0.0%) 1/191 (0.5%) 1/364 (0.3%) 
  exact 95% CI [0%, 2.11%] [0%, 2.46%] [0%, 1.30%] 
      
P 1 events/N (%) 0/45 (0.0%) 0/47 (0.0%) 0/92 (0.0%) 
  exact 95% CI [0%, 7.87%] [0%, 7.55%] [0%, 3.93%] 
 2 
  exact 95% CI [0%, 5.60%] [0%, 4.93%] [0%, 2.66%] 
 3 events/N (%) 0/47 (0.0%) 1/52 (1.9%) 1/99 (1.0%) 
  exact 95% CI [0%, 7.55%] [0%, 8.80%] [0%, 4.70%] 
 ta events/N (%) 0/156 (0.0%) 1/172 (0.6%) 1/328 (0.3%) 
  exact 95% CI [0%, 2.34%] [0%, 2.73%] [0%, 1.44%] 
* PP in the strong sense 
Sensitivity analysis based on PP: The PP analysis comes to the sam alysis 
based on the FAS with ITT principles. 
e conclusion as the an
Second primary endpoint, incidence of treatment failures (TF): In the FAS 84/412 treatment failures 
were counted. In all cases the upper bound of the one-sided 95% confidence interval was larger than 
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the a priori specified 15% margin, see Table 7-3. In none of the cases the hypotheses could be 
rejected on the 5% α-level.  
Table 7-3: Number of TF with one-sided CI by analysis population, group, and level 
Analysis set level statistic 2x daily 4x daily Total 
FAS 1 events/N (%) 15/72 (20.8%)  13/75 (17.3%)  28/147 (19.0%)
  exact 95% CI [0%, 30.25%]  [0%, 26.14%]  [0%, 25.17%] 
(%) 5/64 ( 7.8%)  13/73 (17.8%)  18/137 (13.1%)
  exact 95% CI [0%, 15.73%]  [0%, 26.81%]  [0%, 18.86%] 
6%)  5/52 ( 9.6%)  10/99 (10.1%) 
events/N (%) 4/45 ( 8.9%)  3/47 ( 6.4%)  7/92 ( 7.6%) 
 [0%, 15.68%]  [0%, 13.82%] 
 7.8%)  13/73 (17.8%)  18/137 (13.1%)
99 (10.1%) 
  exact 95% CI [0%, 21.08%]  [0%, 19.16%]  [0%, 16.53%] 
 2 events/N (%) 13/72 (18.1%)  18/78 (23.1%)  31/150 (20.7%)
  exact 95% CI [0%, 27.17%]  [0%, 32.28%]  [0%, 26.86%] 
 3 events/N (%) 11/53 (20.8%)  14/62 (22.6%)  25/115 (21.7%)
  exact 95% CI [0%, 32.01%]  [0%, 33.03%]  [0%, 29.02%] 
 Total events/N (%) 39/197 (19.8%) 45/215 (20.9%) 84/412 (20.4%) 
  exact 95% CI [0%, 25.05%]  [0%, 26.02%]  [0%, 23.93%] 
         
PP 1 events/N (%) 6/62 ( 9.7%)  4/66 ( 6.1%)  10/128 ( 7.8%) 
  exact 95% CI [0%, 18.21%]  [0%, 13.33%]  [0%, 12.89%] 
 2 events/N 
 3 events/N (%) 5/47 (10.
  exact 95% CI [0%, 21.08%]  [0%, 19.16%]  [0%, 16.53%] 
 Total events/N (%) 16/173 ( 9.2%) 22/191 (11.5%) 38/364 (10.4%) 
  exact 95% CI [0%, 13.71%]  [0%, 16.04%]  [0%, 13.46%] 
         
PP * 1 
  exact 95% CI [0%, 19.20%] 
 2 events/N (%) 5/64 (
  exact 95% CI [0%, 15.73%]  [0%, 26.81%]  [0%, 18.86%] 
 3 events/N (%) 5/47 (10.6%)  5/52 ( 9.6%)  10/
 Total events/N (%) 14/156 ( 9.0%) 21/172 (12.2%) 35/328 (10.7%) 
  exact 95% CI [0%, 13.67%]  [0%, 17.10%]  [0%, 13.90%] 
* PP in the strong sense 
Sensitivity analysis based on PP: The PP analysis where patients with missing information were 
eliminated instead of counted as failures the rates are lower. In all but one group*level 
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combinations the upper bound of the confidence interval is larger than 15%, only for level 1 in the 
4x-daily-group the upper bound is 13.33%.  
7.7 Secondary endpoint analyses  
 
734] nor a linear level effect pLR=0.1594 
(pLR=0.3565) [pLR=0.3236] (interaction eliminated in all cases). Considered level as a factor a clear 
 the strong sense: pLR=0.0192] with 2.3% for level 1, 5.1% in level 2 and 0% 
set) [PP set in the strong sense] there were 55/412=13.3% (28/364=7.7%) 
ue to 
missing inform
7.7.3 Incidence of treat lures (TF
The incidence of treatment failures was already di
and level, no group and/or level comparison  so far b ed here
I AS (PP set) [P the str there 2=20.4 =10.4%) 
[ =10.7%] TF afte e Ta e 12-8  12-71 (Table 12-75). In a 
l el there is nei effect  (pLR= =0.3439] nor a level effect 
p =0.5917 (p =0.5129) [p =0.6032] could be found in this trial (interaction eliminated in all 
cases, level was mode ). Considered level as pLR=0 0.3666) 
[ LR e c uld b
7.7.1 Incidence of early treatment failure (ETF) 
In the FAS (PP set) [PP set in the strong sense] there were 29/412=7.0% (10/364=2.7%) 
[9/328=2.7%] ETF, see Table 12-84 and Table 12-71 (Table 12-75). In a linear model there was
neither a group effect pLR=0.9836 (pLR=0.2484) [pLR=0.3
difference between level could be found in the PP set in this trial, FAS: pLR=0.1701 (PP set: 
pLR=0.0196) [PP set in
in level 3 in the PP set. However, this result is based on pretty sparse data. The main reasons for 
being a ETF were 12 times due to missing information and 5 times due to fever(>=37,5°C) on D3 
(WHO) and parasite count > 0.  
7.7.2 Incidence of late clinical failures (LCF) 
In the FAS (PP 
[26/328=7.9%] LCF after 14 days, see Table 12-71 (Table 12-75). The main reasons for being LCF 
were 28 times due to fever(>=37,5°C) and parasite count>0 on D4-D14 (WHO) and 22 times d
ation.  
ment fai ) 
scussed in the primary analysis, but only by group 
 was done ut mention . 
n the F P set in ong sense] were 84/41 % (38/364
35/328 r 14 days, se ble 7-3, Tabl 5 and Table
inear mod ther a group  pLR=0.7847 0.4814) [pLR
LR LR LR
lled linear  a factor: .8636 (p =LR
p =0.4042] the sam onclusion co e drawn.  
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In the FAS (PP set) [PP set in the strong sense] there were 32/115=27.8% (16/99=16.2%) 
[16/99=16.2%] TF after 28 days at level 3 (not captured for level 1 and 2), see Table 12-71 (Table 
. %-points higher than for the TF after 14 days. 
4(WHO) and parasitaemia > 0. 
.7.5 Incidence of late parasitological failures (CPF) 
The analysis of CPF (=ETF+LCF+LPF=1-ACPR) not originally mentioned in the trial protocol but 
st
 the FAS (PP ) [PP sense /412= 34.1%) 
14/328=34.8%] PF aft ble 1 model there is neither a group 
ffect pLR=0.1718 (pLR= 22] ect p 0.9940) 
LR=0.7182] could be found in this trial (interaction elim odelled 
r). Considere el 587 =0.30 clusion 
ould be drawn.  
PP set in the strong sense] there were 76/115=66.1% (60/99=60.6%) 
0/99=60.6%] fter 28 days for level 3 (not captured at level 1 and 2), see Table 12-88. 
Tab -4: O  par ays b
L
(N
evel 
N=13
 3 
) 
12-75)  The rates are roughly 5
7.7.4 Incidence of late parasitological failures (LPF)  
In the FAS (PP set) [PP set in the strong sense] there were 87/412=21.1% (86/364=23.6%) 
[79/328=24.1%] LPF after 14 days, see Table 12-71 (Table 12-75). The main reason for being LCF 
was due to Temperature < 37,5°C on D1
7
was added po  hoc.  
In set set in the strong ] there were 166 40.3% (124/364=
[1  C er 14 days, see Ta 2-86. In a linear 
e 0.2621) [pLR=0.38 nor a level eff LR=0.6002 (pLR=
[p inated in all cases, level was m
linea d lev as a factor: pLR=0.3 (pLR=0.2396) [pLR 13] the same con
c
In the FAS (PP set) [
[6 CP  aF
le 7 verview of efficacy ameters after 14 d y level (PP) 
 evel 1 L
=128) (
2 Level
7) (N=99
Total 
(N=364) 
     
- ETF 3 (2.3%) 7 (5.1%) 0 (0.0%) 10 (2.7%) 
- LCF 7 (5.5%) 11 (8.0%) 10 (10.1%) 28 (7.7%) 
- LPF 30 (23.4%) 36 (26.3%) 20 (20.2%) 86 (23.6%) 
- ACPR 88 (68.8%) 83 (60.6%) 69 (69.7%) 240 (65.9%) 
     
- TF (ETF or LCF) 10 (7.8%) 18 (13.1%) 10 (10.1%) 38 (10.4%) 
- CPF (TF or LPF) 40 (31.3%) 54 (39.4%) 30 (30.3%) 124 (34.1%) 
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7.7.6 Fever clearance time 
There is no group*level interaction (time to event analysis). Modeling group and level no group 
effect can be found (FAS: pCox=0.7863; PP: pCox=0.8615) but a strong level effect (FAS: 
pCox<0.0001; PP: pCox<0.0001) with a shorter median fever clearance time in the third dose group 
(Table 7-5). Fever measurements were not taken by night, the corresponding Kaplan-Meier curve 
has therefore some steps (Figure 7-3).  
 
Table 7-5: Median fever clearance time and 95% confidence intervals 
Analysis set level 2x daily 4x daily Total 
FAS 1 6.00 [5.47, 10.50] 5.83 [5.30, 6.58] 5.88 [5.55, 6.92] 
 2 5.34 [4.12, 5.85] 5.40 [2.17, 6.22] 5.37 [4.62, 5.82] 
 3 4.38 [1.55, 5.95] 1.85 [1.37, 5.73] 2.10 [1.55, 5.70] 
 Total 5.55 [5.27, 5.85] 5.57 [5.08, 5.88] 5.55 [5.30, 5.78] 
     
PP 1 5.89 [5.47, 10.50] 5.83 [5.23, 6.82] 5.83 [5.48, 6.82] 
 2 5.31 [4.12, 5.80] 5.28 [1.52, 6.22] 5.30 [4.45, 5.70] 
 70] 
 Total 5.48 [4.80, 5.78] 5.42 [4.72, 5.88] 5.46 [5.15, 5.73] 
5.31 [4.12, 5.80] 5.28 [1.52, 6.22] 5.30 [4.45, 5.70] 
 3 1.88 [1.52, 5.72] 1.58 [1.23, 5.73] 1.82 [1.45, 5.70] 
 Total 5.43 [4.58, 5.77] 5.35 [4.42, 5.82] 5.40 [4.72, 5.70] 
3 1.88 [1.52, 5.72] 1.58 [1.23, 5.73] 1.82 [1.45, 5.
     
PP* 1 5.80 [5.40, 10.37] 5.62 [4.93, 6.82] 5.79 [5.40, 6.82] 
 2 
* PP set in the strong sense 
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re  Kaplan-Meier curve or fever clearance by ose level (PP) 
T em  are summarised in the ables Table 12-36 to T ble 12-53 and the inta
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7.7.7 Parasite clearance time 
There is no group*level interaction (time to event analysis). Modeling group and level no group 
effect can be found (FAS: pCox=0.3247; PP: pCox=0.2647) and no level effect (FAS: pCox=0.6857; 
PP: pCox=0.2387) with a shorter median fever clearance time in the third dose group (Table 7-6). 
Blood measurements were only taken once per day, the corresponding Kaplan-Meier curve has 
therefore some steps (Figure 7-4).  
Further information about the clearance is given in Table 12-91, Table 12-92, and Table 12-93. 
 
Table 7-6: Median parasite clearance time and 95% confidence intervals 
Analysis set level 2x daily 4x daily Total 
FAS 1 67.57 [66.57, 68.42] 68.10 [67.68, 68.43] 67.93 [67.03, 68.33] 
 2 68.13 [67.67, 68.95] 67.77 [67.32, 68.68] 68.00 [67.62, 68.68] 
 3 69.02 [68.27, 69.43] 68.10 [67.48, 68.68] 68.40 [68.08, 68.87] 
 Total 68.27 [67.82, 68.75] 68.03 [67.68, 68.33] 68.10 [67.87, 68.40] 
     
PP 1 67.50 [66.55, 68.28] 67.98 [67.03, 68.42] 67.80 [67.02, 68.28] 
 2 68.23 [67.67, 69.02] 67.77 [67.25, 68.70] 67.98 [67.58, 68.70] 
 3 69.02 [68.40, 69.43] 68.10 [67.48, 68.87] 68.53 [68.05, 69.05] 
 Total 68.25 [67.78, 68.80] 68.00 [67.62, 68.33] 68.07 [67.82, 68.40] 
     
68.53 [68.05, 69.05] 
Total 68.31 [67.78, 68.90] 68.00 [67.57, 68.42] 68.09 [67.82, 68.47] 
PP* 1 67.02 [66.22, 68.28] 68.00 [66.97, 68.57] 67.57 [66.93, 68.40] 
 2 68.23 [67.67, 69.02] 67.77 [67.25, 68.70] 67.98 [67.58, 68.70] 
 3 69.02 [68.40, 69.43] 68.10 [67.48, 68.87] 
 
* PP set in the strong sense 
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Figure 7 e e-4: Kaplan-Meier curv  for parasit  clearance by dose level (PP) 
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7.7.8 Change in haemoglobin after 4 (or 7) and 14 days compared to baseline 
This analysis is based on FAS: There was no Hb measurement done for the third dose level after 14 
days due to administrative reasons. However, for all three levels there was no difference regarding 
on of the data is comparable.   
.92+/–0.05 days (13.01+/–0.33 days). A difference in the change of Hb 
rding the decrease of Hb (data not shown).  
 
the Hb changes between the groups (2x daily versus 4x daily), see Table 12-18 and Table 12-24 for 
level 1, Table 12-19 and Table 12-25 for level 2, Table 12-20 and Table 12-26 for level 3. When 
using the our understanding of the WHO definition the start of treatment is considered as the start 
of the first day rather than the calendar day; those data can be found in Table 12-21 and Table 12-33 
for level 1, Table 12-22 and Table 12-34 for level 2, and Table 12-23 and Table 12-35 for level 3. 
The interpretati
In all three levels (pooled the two groups) a significant decrease of the Hb measurement was found 
after 4 days and in all two levels still a significant decrease of the Hb measurement was found after 
14 days (level 1: pWSR=0.0322, level 2: pWSR=0.0041, see Table 12-30 and Table 12-31), but the 
decrease is smaller than after 4 days and not significant without pooling the data (lower power). 
The time between baseline measurement and day 4 (day 14) measurement was 70.2+/–1.1 hours 
(312.1+/–7.8 hours) or 2
from baseline to day 4 between the levels (pF=0.1068) and groups (2x versus 4x) (pF=0.3967) 
cannot be shown (parametric linear model, F-Test, type III, level as linear covariate, interaction 
term eliminated). A difference in the change of Hb from baseline to day 14 between the levels 
(level 1 versus level 2: pF=0.5484) and groups (2x versus 4x: pF=0.1453) cannot be shown 
(parametric linear model, F-Test, type III, interaction term eliminated).  
When selecting the PP set or the PP set in the strong sense, there is also no difference between 
groups and levels rega
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Table 7-7: Haemog p and level (FAS) lobin and change of haemoglobin by grou
 level 1 level 2 level 3 
Ch acar teristic 2x 4x 2x 4x 2x 4x 
Ha oglobin[g/dl] at Baseline em
- N 72 75 72 78 53 62 
- M nea  +/- SD 9.7 +/- 1.1 9.7 +/- 1.1 9.5 +/- 1.0 9.7 +/- 1.2 9.6 +/- 0.9 9.4 +/- 0.8 
- 9  C5% I mean [9.43; 9.93] [9.48; 9.99] [9.28; 9.75] [9.45; 9.98] [9.36; 9.83] [9.21; 9.63]
       
Ha oglobin[g/dl] at Day4 em
- N 68 70 67 77 51 61 
- M ane  +/- SD 8.8 +/- 0.9 8.9 +/- 1.0 8.9 +/- 1.1 8.8 +/- 1.2 8.9 +/- 1.0 8.8 +/- 1.1 
- 95% CI mean [8.55; 9.01] [8.69; 9.17] [8.57; 9.14] [8.47; 9.03] [8.61; 9.17] [8.55; 9.11]
       
Haemoglobin[g/dl] at Day14 $ 
- N 67 70 64 73 - - 
- Mean +/- SD 9.4 +/- 1.0 9.5 +/- 1.2 9.4 +/- 0.9 9.3 +/- 1.1 - - 
- 95% CI mean [9.20; 9.68] [9.24; 9.82] [9.20; 9.68] [9.02; 9.53] - - 
       
Change in Haemoglobin[g/dl] Day4-Baseline 
- N 68 70 67 77 51 61 
- Mean +/- SD -0.8 +/- 0.7 -0.8 +/- 0.9 -0.7 +/- 0.9 -1.0 +/- 1.0 -0.7 +/- 0.8 -0.6 +/- 0.9
- 95% CI mean [-1.0; -0.7] [-1.0; -0.6] [-0.9; -0.4] [-1.2; -0.7] [-0.9; -0.5] [-0.8; -0.4]
- p-value * <0.0001 <0.0001 <0.0001 <0.0001 <0.0001  
       
Change in Haemoglobin[g/dl] Day14-Baseline $ 
- N 67 70 64 73 - - 
- Mean +/- SD -0.2 +/- 1.0 -0.2 +/- 1.3 -0.1 +/- 1.0 -0.5 +/- 1.2 - - 
- 95% CI mean [-0.4; 0.0] [-0.5; 0.1] [-0.3; 0.1] [-0.7; -0.2] - - 
- p-value * 0.1058 0.1651 0.3081 0.0029 - - 
       
$ including data from days 12-16, * Wilcoxon-Sign-Rank Test 
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7.7.9 Incidence of observed serious adverse events 
There were 3 in 412 (0.7%, one-sided 95% CI [0%, 1.87%], two-sided 95% CI [0.15%, 2.11%) 
patients with serious adverse events (Table 7-8 and Table 12-95). All SAEs were also RAEs and 
vice versa. In the following narratives of the three patients are presen
One 13 mo No. 203, G6PD sufficient, body weight = 7kg, group = 4x daily, level = 2), 
includ , r d on the 2 ad t e)” 
(MedD A m: Diarrhoea), started on the 25. Aug 2004, ped on the 3 ug 2004. 
She E was rat e ol, 
Debridat, C racefal), Metronidazol. This SAE was rated as RAE due to “Study drug 
related SAE”.  
One 53 m uffi l = 
2), inc de first treated on the 17 pt 2004 had “Paludisme grave” (MedDRA 
preferred on t 04 e He 
was e ly The SAE was rated “unrelated” treated with Ceftriaxon, 
Genta c nsid  A ere 
neurological disorders”. 
One hom  4x 
daily, ve domized and first treated on the 12. Oc 4 had “Anem grave Hb 
,7” (MedDRA preferred term: Anaemia), started on the 15. Oct 2004, stopped on the 27. Oct 2004. 
Clinically there were no signs of haemolysis and total serum bilirubin was normal on day 3. His Hb 
Oct 2004. He was late clinical failure. The SAE was 
rated as “possibly related”and treated with Ceftriaxon and Iron. This SAE was rated as RAE due to 
ted. 
nths old girl (
ed andomized and first treate 4. Aug 2004 h  “Diarrhée(Gas ro-enterite fébril
R  preferred ter stop 1 A
 was late clinical failure. The SA ed as “possibly r lated” and treated with Paracetam
efadroxil (O
onths old boy (No. 312, G6PD s cient, body weight = 16kg, group = 2x daily, leve
lu d, randomized and . Se
term: Cerebral malaria), started he 18. Sept 20 , stopped on th  20. Sept 2004. 
ar  treatment failure. as and 
my in, Sulfadoxa/Pyrimethamin (Fa ar). This SAE was rated as R E due to “Sev
 28 months old boy (No. 461, G6PD ozygote deficient, body weight = 13kg, group =
le l = 3), included, ran t 200 ie 
4
was 8.7 g/dl at baseline 8.6 g/dl on the 27. 
“Acute haemolysis”. 
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Table 7-8: Serious adverse events (FAS) 
Level  2x daily 4x daily Total 
1 Num. of Pat. with ≥1 0/72  (0% )  SAE  (0%) 0/75 ) 0/147 (0%
 Num. of SAE 0 0 
2 Num. of Pat. with ≥ 1/72 1.3 ) 
 Num. of SAE 1 1 2 
 of Pat. with ≥1 0/53 (  (1.6% %) 
 Num. of SA 0 1 
Total Num. of Pat. with ≥1 1/197 ( 5 (0.9% 7%) 
 Num. of S 1 2 
. 
1 SAE  (1.4%) 1/78 ( %) 2/150 (1.3%
3 Num. SAE 0%) 1/62 ) 1/115 (0.9
E 1 
SAE 0.5%) 2/21 ) 3/412 (0.
AE  3 
 
7.7.10 Incidence of o rved d non e eve
egarding AEs and riou 4 days observation period no group difference can 
e found (Table 7-9), whereas less adverse events were reported in level 2 and 3. This may be due 
porting d ng the linica  no in  events 
an be seen with highe B doses (Table 12-94).  
ategorizing the AE rdin ing p T) (but also high-level-terms 
LT) or high-level-gr up-terms (HLG 2 99), that in this trial more children in 
daily group vom ted tha  grou se pe  Table 
2-96 to Table 12-10 On th gardi  opp ed. No 
efinite conclusion ca e drawn due to sparse data. 
bse and self-reporte -serious advers nts  
R  non-se s AEs over the 1
b
to an underre uri  conduct of the c l trial. However, crease of adverse
c r M
C s acco g to MedDRA us referred terms (P
(H o T)) showed (Table 1 -
the 2x it n in the 4x daily p (but higher do r drug intake), see
1 7. e other hand re ng diarrhoea the osite was observ
d n b
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Table 7-9: Overvie up and level (FAS) w of AEs and non-serious AEs by gro
Level  2x daily 4x daily Total 
1 Num. of Pat. with ≥1 AE 25/72 (34.7%) /75 (30.7%) %)23 48/147 (32.7
 Num. of AE 30 
 ≥1 AE 72 (12.5% 15.4%) 0%)
. of AE 9 12 
3 Num. of Pat. with ≥1 AE 5/53 ( 9.4%) 10/62 (16.1%) 15/115 (13.0%)
 Num. of AE 7 11 18 
ith ≥1 AE 39/197 (19.8%) 45/215 (20.9%) 84/412 (20.4%)
 Num. of AE 46 50 96 
1 non-SAE 25/72 (34.7%) 23/75 (30.7%) 48/147 (32.7%)
15 (13.0%)
n-SAE 38/197 (19.3%) 44/215 (20.5%) 82/412 (19.9%)
27 57 
2 Num. of Pat. with 9/ ) 12/78 ( 21/150 (14.
 Num 21 
Total Num. of Pat. w
     
1 Num. of Pat. with ≥
 Num. of non-SAE 30 27 57 
2 Num. of Pat. with ≥1 non-SAE 8/72 (11.1%) 11/78 (14.1%) 19/150 (12.7%)
 Num. of non-SAE 8 11 19 
3 Num. of Pat. with ≥1 non-SAE 5/53 ( 9.4%) 10/62 (16.1%) 15/1
 Num. of non-SAE 7 10 17 
Total Num. of Pat. with ≥1 no
 Num. of non-SAE 45 48 93 
 
7.7.11 Whole blood CQ and MB kinetics  
The presentation of mean AUC, Cmax, Tmax, elimination half life is not part of this report. 
7.7.12 Monitoring of concomitant drug intake 
Table 12-54 to Table 12-57 show the given concomitant drug intake by medication group 
(antibiotics, antihistaminics, antimalarials, antipyretics, others). Table 7-10 gives the number of 
patients with medication (by medication group) for the PP population (see Table 12-58 for FAS). 
No difference can be seen between groups. No difference can be seen between levels for antibiotics, 
antihistaminics, and other medications whereas more antimalarials and less antipyretics were taken 
in level 3.  
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Table 7-10: Number of patients with concomitant medication by group and level (PP) 
Medication level 2x daily 4x daily Total 
Antibiotic 1 26/62 ( 41.9%) 21/66 ( 31.8%) 47/128 ( 36.7%) 
 2 18/64 ( 28.1%) 23/73 ( 31.5%) 41/137 ( 29.9%) 
 3 13/47 ( 27.7%) 23/52 ( 44.2%) 36/99 ( 36.4%) 
 Total 57/173 ( 32.9%) 67/191 ( 35.1%) 124/364 ( 34.1%) 
     
Antihistaminic 1 1/62 ( 1.6%) 1/66 ( 1.5%) 2/128 ( 1.6%) 
 2 1/64 ( 1.6%) 3/73 ( 4.1%) 4/137 ( 2.9%) 
3 1/47 ( 2.1%) 2/52 ( 3.8%) 3/99 ( 3.0%) 
 Total 3/173 ( 1.7%) 6/191 ( 3.1%) 9/364 ( 2.5%) 
   
Antimalarial 1 23/62 ( 37.1%) 19/66 ( 28.8%) 42/128 ( 32.8%) 
151/364 ( 41.5%) 
     
.7%) 58/137 ( 42.3%) 
    
Other 1 29/62 ( 46.8%) 32/66 ( 48.5%) 61/128 ( 47.7%) 
3 25/47 ( 53.2%) 24/52 ( 46.2%) 49/99 ( 49.5%) 
 
  
 2 27/64 ( 42.2%) 27/73 ( 37.0%) 54/137 ( 39.4%) 
 3 24/47 ( 51.1%) 31/52 ( 59.6%) 55/99 ( 55.6%) 
 Total 74/173 ( 42.8%) 77/191 ( 40.3%) 
Antipyretic 1 23/62 ( 37.1%) 25/66 ( 37.9%) 48/128 ( 37.5%) 
 2 21/64 ( 32.8%) 37/73 ( 50
 3 10/47 ( 21.3%) 15/52 ( 28.8%) 25/99 ( 25.3%) 
 Total 54/173 ( 31.2%) 77/191 ( 40.3%) 131/364 ( 36.0%) 
 
 2 35/64 ( 54.7%) 32/73 ( 43.8%) 67/137 ( 48.9%) 
 
 Total 89/173 ( 51.4%) 88/191 ( 46.1%) 177/364 ( 48.6%) 
 
7.7.13 G6PD assessment based on PCR 
As presented in section 78.5% of the children were G6PD sufficient. In 8 children the Hb value 
ere 
tion between G6PD status and Hb drop >3g/dl 
about 2 (21.5%) children were expected to be G6PD deficient and 6 (78.5%) sufficient. But due to 
dropped >3g/dl, 4 of these were found to be G6PD deficient (homozygote) and the other 4 w
G6PD sufficient. Under the hypotheses of no rela
sparse data this hypothesis is difficult to investigate (pFisher=0.0693).  
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Table 7-11: G6PD status at baseline 
 2x daily 4x daily Total 
G6PD status (PCR method)   pChi=0.4011 
- sufficient 154 (78.6%) 167 (78.4%) 321 (78.5%) 
- heterozygot deficient 27 (13.8%) 23 (10.8%) 50 (12.2%) 
3 
- homozygote deficient 15 (7.7%) 23 (10.8%) 38 (9.3%) 
- Missing 1 2 
 
8 DISCUSSION 
Safety judgement: Safety for all three dose levels reached. No increase of adverse events can be 
e to 
PP set the one-sided confidence interval for the whole 
ose 
een levels there were some 
 
l 2). 
evel 
. To 
ut, 
ood 
r drug. MB has a short plasma half life (15 hours) and – in analogy to the 
 the 
ens, 
B in combination with other drugs in different SSA 
populations. 
seen with higher MB doses.  
Efficacy judgment: So called efficacy was not shown in FAS, but the combination has the chanc
reach the predefined margin: In the 
population for the treatment failures was [0%, 13.5%] with a point estimate of 10.4%. But even 
10% is still too high. In total the combination of MB and CQ seems to be effective.  
Group comparison: 2x versus 4x: no difference could be found. This trial gives no reason for a d
regimen of 4x daily instead of 2x. 
Level comparison: Starting from inhomogeneous baseline data betw
difference between levels (quicker fever clearance time at level 3 with less children with
antipyretics, more reported adverse events in level 1, more early treatment failures in leve
However, focusing on the treatment failure after 14 days no level effect could be found. All l
effects could be related to a time influence or other reasons of bias.  
Conclusion: Our results demonstrate for the first time that MB, a cheap drug which is registered in 
most countries, is safe and could be effective in combination with CQ against malaria in SSA
investigate the efficacy of MB a controlled trial with MB versus CQ-MB would be necessary. B
however, given the high background resistance in most SSA countries, CQ is no longer a g
choice as a partne
artemisinin combination schemes – needs to be combined with a locally effective partner drug when 
given in a three day regimen (Greenwood et al. 2005). Further studies are needed to assess
importance of possible rare side effects such as haemolysis, to study simpler treatment regim
and determine the full potential of M
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11 APPENDIX: FIGURES 
 
 
Figure 11-1: Haemoglobin over time of all patients (calendar days)  
 
Figure 11-2: Haemoglobin over time of all patients (WHO days) 
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Figure 11-3: Haemoglobin over time by group (calendar days) 
 
Figure 11-4: Haemoglobin over time by group (WHO days) 
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Figure 11-5: Haemoglobin over time by level (calendar days) 
 
Figure 11-6: Haemoglobin over time by level (WHO days) 
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ays) Figure 11-7: Haemoglobin over time by group and level (calendar d
 
Figure 11-8: Haemoglobin over time by group and level (WHO days) 
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Figure 11-9: ln(parasite count) over time (calendar day) 
Figure 11-10: ln(parasite co HO day) 
 
unt) over time (W
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dar day) Figure 11-11: ln(parasite count) over time by group (calen
 
Figure 11-12: ln(parasite count) over time by group (WHO day) 
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ar day) Figure 11-13: ln(parasite count) over 
Figure 11-14: ln(parasite count) 
time by level (calend
 
over time by level (WHO day) 
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Figure 11-15: ln(parasite count) over time by group and level (calendar day) 
 
Figure 11-16: ln(parasite count) over time by group and level (WHO day) 
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12 APPENDIX: TABLES 
Table 12-1: cruiting of ents for all levels (FAS)  Re pati
Week from - to N N(%)cumulative 
1 19/07/2004 - 25/07/2004 3 3(  0.7%) 
2 26/07/2004 - 01/08/2004 21 24(  5.8%) 
8/200  0 /2004 ( 5%) 
8/200 1 /2004 ( .1%) 
8
8/200 004 ) 
8/200 0 /2004 ( .3%) 
8 06/09/2004 - 12/09/2004 29 
9 13/09/2004 - 19/09/2004 34 266( 64.6%) 
10 20/09/2004 - 26/09/2004 31 297( 72.1%) 
11 27/09/2004 - 03/10/2004 23 320( 77.7%) 
12 04/10/2004 - 10/10/2004 21 341( 82.8%) 
0/2004 - 1 0/2004 376( .3%) 
0/200 2 /2004 ( .8%) 
0/200 004 ) 
3 
4 
5 
6 
7 
0
0
1
2
3
2/0
9/0
6/0
3/0
0/0
4 -
4 - 
4 -
4 -
4 - 
8/08
5/08
/0
/0
5/09
4
5
2
3
2
8 
2 
3 
2 
4 
72
124
14
17
203
17.
 30
35
43
 49
232( 56.3%) 
/200  22
 29
8/2
8/2
004 7( 
9( 
.7
.4%
%) 
13 
4 
5 
1
1
2
1/1
8/1
5/1
7/1
4/10
/1
3
2
1
5 
3 
3 
 91
 96
00
1
1
4 - 
4 -
399
41 31 0/2 2(1 .0%
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Table 12-2: Analysis sets and nce fo evel 1 protocol complia r L
 
2x daily 
N(%) 
4x daily 
N(%) 
Total 
N(%) 
Included pat. (informed consent) 9(100.  78(100.0%) 157(100.0%) 7 0%)
- Pat. without trial medication (Repeated vomiting) 7(  8.9%) 3(  3.8%) 10(  6.4%) 
- Pat. without trial medication (Other reason) 0(  0.0%) 0(  0.0%) 0(  0.0%) 
Pat. in FAS 2( 91.1%) 75( 96.2%) 147( 93.6%) 
- Pat. who vomited and the drug was not given again 3(  3.8%) 4(  5.1%) 7(  4.5%) 
- Pat. who vomited and it is unclear whether it was 
given again 
0(  0.0%) 0(  0.0%) 0(  0.0%) 
- Pat. who violate inc clu riter  1.3% (  0.
- Pat. without blue ur 0 %) .0%  0.
- Withdrawal of informed consent .0
- Adverse event  0.0% (  0.
- Investigators judgement 0(  0.0%) 1(  0.6%) 
- Lost to follow 0(  0.0%) 0(  0.0%) 0(  0.0%) 
- Death 0(  0.0%) 0(  0.0%) 0(  0.0%) 
- No Information on D14 given 4(  5.1%) 1(  1.3%) 5(  3.2%) 
- treated (D4-D13) with antimalarials although no fever 
and/or no parasites 
2(  2.5%) 3(  3.8%) 5(  3.2%) 
Pat. in PP set  84.6% 8( 81
- Pat. who got the wro ntr of MB  24.4% 6( 22.
Pat. in PP set with co 0.3
7
lusi
ine 
on/ex sion c ia 0(  0.0%) 
.0
0(  0.0%) 
0(  0.0%) 
1(  1.3%) 
1( 
0( 
0( 
0( 
) 
) 
 
) 
1
0
6%) 
0%) 
0%) 
0%) 
(  0  0
 0
0( 
0( %)  0.
up 
62( 78.5%) 
17( 21.5%) 
45( 57.0%) 
66(
9(
7(
) 
) 
 
12
3
9
.5%)
9%)
%)
 
 
 
ng  
rrec
co
t 
nce
co
ati
ra
on 
ion
 
 
1
4ncent  of MB  6 %) 2( 58.6
% are based ncluded nts
 
 on all i
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Table 12-3: Analysis sets and nce fo evel 2 protocol complia r L
 
2x daily 
N(%) 
4x daily 
N(%) 
Total 
N(%) 
Included pat. (informed consent) 7(100.  78(100.0%) 155(100.0%) 7 0%)
- Pat. without trial medication (Repeated vomiting) 2(  2.6%) 0(  0.0%) 2(  1.3%) 
- Pat. without trial medication (Other reason) 3(  3.9%) 0(  0.0%) 3(  1.9%) 
Pat. in FAS 2( 93.5%) 78(100.0%) 150( 96.8%) 
- Pat. who vomited and the drug was not given again 3(  3.9%) 0(  0.0%) 3(  1.9%) 
- Pat. who vomited and it is unclear whether it was 
given again 
0(  0.0%) 0(  0.0%) 0(  0.0%) 
- Pat. who violate inc clu riter  0.0% (  0.
- Pat. without blue 0 %) .0%  0.
- Withdrawal of informed consent 
- Adverse event  0.0% (  0.
- Investigators judgement 0(  0.0%) 0(  0.0%) 
- Lost to follow up 3(  3.9%) 2(  2.6%) 5(  3.2%) 
- Death 0(  0.0%) 1(  1.3%) 1(  0.6%) 
- No Information on D14 given 0(  0.0%) 2(  2.6%) 2(  1.3%) 
- treated (D4-D13) with antimalarials although no fever 
and/or no parasites 
0(  0.0%) 0(  0.0%) 0(  0.0%) 
Pat. in PP set  93.6% 7( 88
- Pat. who got the wro ntr of MB  0.0% (  0.
Pat. in PP set with 
7
lusi
ne 
on/ex sion c ia 0(  0.0%) 
.0
1(  1.3%) 
1(  1.3%) 
0(  0.0%) 
0( 
0( 
0( 
0( 
) 
) 
 
) 
0
1
0%) 
0%) 
6%) 
6%) 
uri (  0  0
 0
0( 
1( .0%)  0.
64( 83.1%) 
0(  0.0%) 
64( 83.1%) 
73(
0( 
3(
) 
) 
 
13
0
1
.4%)
0%) 
4%)
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Table 12-4: Analysis sets and protocol comp nce for Level 3 lia
 
2x daily 
N(%) 
4x daily 
N(%) 
Total 
N(%) 
Included pat. (informed consent) 61(100.0%) 62(100.0%) 123(100.0%) 
- Pat. without trial medication (Repeated vomiting) 8( 13.1%) 0(  0.0%) 8(  6.5%) 
- Pat. without trial medication (Other reason) 0(  0.0%) 0(  0.0%) 0(  0.0%) 
Pat. in FAS 53( 86.9%) 62(100.0%) 115( 93.5%) 
- Pat. who vomited and the drug was not given again 2(  3.3%) 2(  3.2%) 4(  3.3%) 
- Pat. who vomited and it is unclear whether it was 
given again 
0(  0.0%) 0(  0.0%) 0(  0.0%) 
- Pat. who violate i /ex  crit a 0(  0.0% (  0.
- Pat. without blu %) 0( .0%  0.
- Withdrawal of in 0( 
- Adverse event 0(  0.0% (  0.
- Investigators judgement 0(  0.0%) 0(  0.0%) 
- Lost to follow up 1(  1.6%) 1(  1.6%) 2(  1.6%) 
- Death 0(  0.0%) 0(  0.0%) 0(  0.0%) 
- No Information on D14 given 3(  4.9%) 7( 11.3%) 10(  8.1%) 
- treated (D4-D13) with antimalarials although no fever 
and/or no parasites 
0(  0.0%) 0(  0.0%) 0(  0.0%) 
Pat. in PP set 52( 83.9% 9( 80.
- Pat. who got the w nce n of 0 %) 0( .0%  0.
Pat. in PP set wit 2(
ncl
uri
me
usi
ne 
d c
on
on
clus
 
ion eri  0(  0.0%) 
.0
0(  0.0%) 
0(  0.0%) 
0(  0.0%) 
) 
) 
 
) 
0
0
0%) 
0%) 
0%) 
0%) 
e 
for
0(  0  0
 0
0( 
0( sent .0%)  0.
47( 77.0%) 
.0
47( 77.0%) 
) 
) 
 
9
9
5%)
0%) 
%)
 
 
ron
or
g  
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(  0  0
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Table 12-5: Analysis sets and protocol compliance for all levels 
 
2x daily 
N(%) 
4x daily 
N(%) 
Total 
N(%) 
Included pat. (informed consent) 217(100.0%) 218(100.0%) 435(100.0%) 
- Pat. without trial medication (Repeated vomiting) 17(  7.8%) 3(  1.4%) 20(  4.6%) 
- Pat. without trial medication (Other reason) 3(  1.4%) 0(  0.0%) 3(  0.7%) 
Pat. in FAS 197( 90.8%) 215( 98.6%) 412( 94.7%) 
- Pat. who vomited and the drug was not given again 8(  3.7%) 6(  2.8%) 14(  3.2%) 
- Pat. who ear whether it was 
given again 
0(  0.0%) 0(  0.0%) 0(  0.0%) 
. 1(  1 .
- Pat. without b . (  0
- Withdrawal of .
- Adverse event . 0(  1 .
- Investigators judgement 1(  0.5%) 0(  0.0%) 1(  0.2%) 
- Lost to follow up 4(  1.8%) 3(  1.4%) 7(  1.6%) 
- Death 0(  0.0%) 1(  0.5%) 1(  0.2%) 
- No Information on D14 given 7(  3.2%) 10(  4.6%) 17(  3.9%) 
- treated (D4-D13) w antimalarials although no fever 
and/or no parasites 
2(  0.9%) 3(  1.4%) 5(  1.1%) 
Pat. in PP set 9  191( 
- Pat. who got t   conc n of M 7. 19( 36
Pat. in PP set w 1
vomited and it is uncl
- Pat. who violate inclusion/exclusion criteria 
rin
med
0
0
1
1
(  0
(  0
(  0
(  0
3( 7
(  
6( 7
0%)
0%)
5%)
5%)
 
 
 
 
0.5%
0.0
0.0
0.0%
) 
) 
(  0
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2%) 
%) 
%) 
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 c
0 %) 
%) 
.0
.2onsent 0(  1(
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.7%)
8%)
.9%
87.6
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8.
%) 
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Table 12-6: Demographics by group for Level 1 (FAS) 
Characteristic 
2x daily 
(N=72) 
4x daily 
(N=75) 
Total 
(N=147) 
Sex    
- male 37( 51.4%) 42( 56.0%) 79( 53.7%) 
- female 35( 48.6%) 33( 44.0%) 68( 46.3%) 
e[months] 
72 75 147 
n +/- SD 33.7+/-16.0 29.5+/-15.9 31.6+/-16.0 
 6.0, 59.0 6.0, 55.0 6.0, 59.0 
ight[kg] 
72 75 147 
n +/- SD 12.2+/- 3.1 11.4+/- 3.1 11.8+/- 3.1 
 7.0, 20.0 6.0, 17.5 6.0, 20.0 
her prior illnesses    
- No 4( 85.5%) 
- Yes 
t disease 
D 
 1.0,  4.0 1.0,  4.0 
t of current 
 
48( 66.7%) 44( 58.7%) 92( 62.6%) 
hod) 
eficient 
 
    
Ag    
- N 
- Mea
- Median 36.0 31.0 34.0 
- Min, Max
    
We    
- N 
- Mea
- Median 12.0 11.0 11.5 
- Min, Max
    
Ot
59( 84.3%) 65( 86.7%) 12
11( 15.7%) 10( 13.3%) 21( 14.5%) 
- Missing 2 0 2 
 
th of curren
   
Leng
episode[days] 
   
- N 71 74 145 
- Mean +/- S
 Median 
2.0+/- 0.8 
2.0 
1.9+/- 0.8 
2.0 
1.9+/- 0.8 
2.0 -
- Min, Max 1.0,  4.0 
    
Prior treatmen
disease episode
   
- No 
- Yes 24( 33.3%) 31( 41.3%) 55( 37.4%) 
    
G6PD status (PCR met    
- sufficient 
- heterozygot d
56( 77.8%) 
9( 12.5%) 
56( 75.7%) 
9( 12.2%) 
112( 76.7%) 
18( 12.3%) 
- deficient
- Missing 
7(  9.7%) 
0 
9( 12.2%) 
1 
16( 11.0%) 
1 
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Table 12-7: Demographics by group for Level 2 (FAS) 
Characteristic 
2x daily 
(N=72) 
4x daily 
(N=78) 
Total 
(N=150) 
Sex    
- male 36( 50.0%) 
- fema 36( 50.0%) 9( 50.0%) 50.0%) 
    
Age[months]    
- N 72 78 150 
- Mean 32.5+/-14.6 
- Medi 33.5 34.0 4.0 
- Min, 6.0, 58.0 6.0, 59.0 , 59.0 
    
Weight[kg]    
- N 72 78 150 
- Mean +/- SD 11.8+/- 3.0 12.0+/- 3.1 
- Medi 12.0 12.0 
- Min, 7.0, 18.0 6.0, 20.0 6.0, 20.0 
   
Other prior illnesses    
- No 
- Yes 19( 26.4%) 25( 32.1%) 44( 29.3%) 
   
Length of current disease 
episode[days] 
   
- N 78 150 
- Mean 1.0 2.6+/- 1.7 2.5+/- 1.4 
- Medi 2.0 2.0 
- Min, 1.0,  7.0  14.0 
    
Prior treatment of cu
diseas
   
- No 53( 73.6%) 2( 66.7%) 70.0%) 
- Yes 19( 26.4%) 6( 33.3%) 30.0%) 
    
G6PD status (PCR method)    
- suff 56( 77.8%) 61( 78.2%) 117( 78.0%) 
- hete 13( 18.1%) 11( 14.1%) 24( 16.0%) 
- defi 3(  4.2%) 6(  7.7%)  6.0%) 
 39( 50.0%) 
3
75( 50.0%) 
75( le 
 +/- SD 31.8+/-14.6 32.1+/-14.5 
3an 
 Max 6.0
11.9+/- 3.1 
an 12.0 
 Max 
 
53( 73.6%) 53( 67.9%) 106( 70.7%) 
 
72 
 +/- SD 2.4+/- 
an 2.0 
 Max 1.0, 14.0 1.0,
rrent 
e episode 
5
2
105( 
 45(
icient 
got deficient rozy
cient 9( 
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Table 12-8: Demographics by group for Level 3 (FAS) 
Characteristic 
2x daily 
(N=53) 
4x daily 
(N=62) 
Total 
(N=115) 
Sex    
- male 24( 45.3%) 
- fema 29( 54.7%) 2( 35.5%) 44.3%) 
    
Age[months]    
- N 53 62 115 
- Mean 39.2+/-12.5 
- Medi 38.0 36.0 6.0 
- Min, 7.0, 58.0 8.0, 59.0 , 59.0 
    
Weight[kg]    
- N 53 62 115 
- Mean +/- SD 13.2+/- 3.0 12.0+/- 2.6 
- Medi 13.0 12.0 
- Min, 7.0, 19.0 6.5, 17.0 6.5, 19.0 
   
Other prior illnesses    
- No 91( 79.1%) 
- Yes 7( 13.2%) 17( 27.4%) 24( 20.9%) 
   
Length of current disease 
episode[days] 
   
- N 62 115 
- Mean 1.0 2.4+/- 1.0 2.3+/- 1.0 
- Medi 2.0 2.0 .0 
- Min, 1.0,  5.0 .0,  5.0   5.0 
    
Prior treatment of cu
diseas
   
- No 42( 79.2%) ( 77.4%) 8.3%) 
- Yes 11( 20.8%) ( 22.6%) 1.7%) 
    
G6PD status (PCR method)    
- suff 42( 80.8%) 50( 82.0%) 92( 81.4%) 
- hete 5(  9.6%) 3(  4.9%) 8(  7.1%) 
- defi 5(  9.6%) 8( 13.1%) 11.5%) 
- Miss 1 1 2 
 40( 64.5%) 
2
64( 55.7%) 
51( le 
 +/- SD 35.0+/-14.9 36.9+/-13.9 
3an 
 Max 7.0
12.5+/- 2.8 
an 12.0 
 Max 
 
46( 86.8%) 45( 72.6%) 
 
53 
 +/- SD 2.2+/- 
an 2
 Max 1 1.0,
rrent 
e episode 
48
14
90( 7
 225(
icient 
got deficient rozy
cient 13( 
ing 
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Table 12-9: Demographics by group for all Levels (FAS) 
Characteristic 
2x daily 
(N=197) 
4x daily 
(N=215) 
Total 
(N=412) 
Sex  =0.1527  pChi
- male 
- female 0( 50
    
Age[months]   pWMW=0.0613 
- N 197 215 412 
- Mean +/- SD 34.7+/-14.8 31.9+/-15.2 33.3+/-15.1 
- Median 36.0 35.0 35.5 
- Min, Max 6.0, 59.0 6.0, 59.0 6.0, 59.0 
    
Weight[kg   
- N 1 21
- Mean +/- SD 
- Median 12.0 12.0 
- Min, Max 7.0, 20.0 6.0, 20.0 
    
Other prior illnesses   
- No 158( 81.0%) 163( 75.8%) 321( 78.3%) 
- Yes 37( 19.0%) 52( 24.2%) 
- Missing 2 0 2 
    
Length of current disease 
episode[days] 
  
- N 
- Mean +/- SD .2+/- +/- 1
- Median 2.0 2.0 
- Min, Max 1.0,  7.0 1.0, 14.0 
    
Prior treatment of cur t 
disease episode 
  
- No 143( 72.6%) 287( 69.7%) 
- Yes 54( 27.4%) 71( 33.0%) 125( 30.3%) 
    
G6PD status (PCR method)   
- sufficient 
- heterozygot deficient 7( 1  10
- deficient 15(  7.7%) 23( 10.8%) 38(  9.3%) 
- Missing 1 2 3 
9
10
7( 49.2%
.8%
) 
) 
121( 56.3%) 
94( 43.7%) 
218( 52.9%) 
194( 47.1%) 
] pWMW=0.1226 
412 
12.0 
6.0, 20.0 
p
97
/- 
 
3.
 
5 
12.3+ 0 11.8+/- 3.0 12.1+/- 3.0 
Chi=0.2011 
89( 21.7%) 
pWMW=0.8046 
410 
2.0 
1.0, 14.0 
p
196 214 
2 0.9 2.3 .3 2.2+/- 1.1 
ren Chi=0.2158 
144( 67.0%) 
p
321( 78.5%) 
50( 12.2%) 
Chi=0.4011 
154( 78.
3.
6%
8%
) 
) 
167( 78.4%) 
23(2 .8%) 
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Table 10: Baseline la up for Leve (FAS)  12- boratory by gro l 1 
Characteristic 
2x daily 
(N=72) 
4x daily 
(N=75) 
Total 
(N=147) 
Haemoglobin[g/dl]    
- N 147 
- Mean +/- SD .7+/- 
- Median 9.5 9.8 9.6 
- Min, Max 8.1, 14.2 6.9, 14.1 6.9, 14.2 
    
MetHb[%]    
- N 72 75 147 
- Mean +/- SD 1.4+/- 0.6 1.5+/- 0.6 1.5+/- 0.6 
- Median 1.4 1.5 1.4 
- Min, Max 0.2,  2.9 0.4,  2.9 
   
P. falciparum[/µl]  
- N 72 75 
- Mean +/- SD 
- Median 25000.0 26000.0 
- Min, Max 2600.0, 95000.0 1050.0, 98000.0 
72 75 
9 1.1 9.7+/- 1.1 9.7+/- 1.1 
0.2,  2.9 
147 
25000.0 
 
  
34616.7+/-24055.0 32662.4+/-27448.9 
1050.0, 98000.0 
33619.6+/-25772.8 
 
Table 11: Baseline labor y b up for Leve (FAS)  12- ator y gro l 2 
Characteristic 
2x daily 
(N=72) 
4x daily 
(N=78) 
Total 
(N=150) 
Haemoglobin[g/dl]    
- N 78 
- Mean +/- SD .5+ +/ /- 1.1 
- Median 9.4 9.5 
- Min, Max 8.0, 12.5 8.0, 14.1 
    
MetHb[%]    
- N 72 78 
- Mean +/- SD 1.1+/- 0.4 1.0+/- 0.4 
- Median 1.0 1.0 
- Min, Max 0.4,  2.6 0.3,  2.3 
    
P. falciparum[/µl]  
- N 78 
- Mean +/- SD 
- Median 22750.0 26250.0 25000.0 
- Min, Max 2000.0, 96500.0 2000.0, 96500.0 
72 
/- 
150 
.6+
9.4 
8.0, 14.1 
150 
1.1+/- 0.4 
1.0 
0.3,  2.6 
150 
9 1.0 9.7 - 1.2 9
 
72 
 
31913.9+/-27945.4 31159.0+/-23504.1 
2000.0, 96000.0 
31521.3+/-25646.9 
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Table 12-12: Baseline laboratory by group for Level 3 (FAS) 
Characteristic 
2x daily 
(N=53) 
4x daily 
(N=62) 
Total 
(N=115) 
Haemoglobin[g/dl]    
- N 53 62 115 
- Mean +/- SD 9.6+/- 0.9 9.4+/- 0.8 9.5+/- 0.8 
- Median 9.5 9.3 9.4 
- Min, Max 8.0, 11.5 8.0, 11.1 8.0, 11.5 
    
MetHb[%]   
- N 5 62 115 
- Mean +/- SD 1.1+/- 0.4 
- Median 1.1 1.0 1.0 
- Min, Max 0.3,  2.1 0.2,  2.6 0.2,  2.6 
    
P. falciparum[/µl]    
- N 53 62 115 
- Mean +/- SD 38981.1+/-27084.3 33857.4+/-26386.0 
- Median 32000.0 19000.0 23000.0 
- Min, Max .0,  
 
 3 
1.1+/- 0.5 1.1+/- 0.5 
29477.4+/-25169.4 
2000.0, 90000.0 2500 100000 2000.0,  100000 
 
Table 12-13: Baseline laboratory by group for all Levels (FAS) 
Characteristic 
2x daily 
(N=197) 
4x daily 
(N=215) 
Total 
(N=412) 
Haemoglobin[g/dl]   pWMW=0.8443 
- N 197 215 
- Mean +/- SD 9.6+/- 1.0 9.6+/- 1.1 /- 1.0 
- Median 9.5 9.5 
- Min, Max 8.0, 14.2 6.9, 14.1 
    
MetHb[%]   
- N 
- Mean +/- SD .2+/- +/- 0
- Median 1.1 1.1 
- Min, Max 0.2,  2.9 0.2,  2.9 
    
P. falciparum[/µl]   
- N 197 215 
- Mean +/- SD 34803.0+/-26361.4 32922.0+/-25858.6 
- Median 25500.0 24000.0 
- Min, Max 
412 
9.6+
9.5 
6.9, 14.2 
p
1.2+/- 0.5 
WMW=0.8166 
412 
1.1 
0.2,  2.9 
p
197 215 
1 0.5 1.2 .5 
WMW=0.2217 
412 
24800.0 
31198.5+/-25327.9 
1050.0, 98000.0 2000.0,  100000 1050.0,  100000 
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Table 12-14: Compliance by group for Level 1 (FAS) 
 
2x daily 
(N=72) 
4x daily 
(N=75) 
Number of P ake
(1) 
at. with drug int    
- Da 70( 93.3%) 
- Day1, Day2 70( 93.3%) 
- D Day2, Day3 70( 93.3%) 
  
Blue urine at least once   
- Yes 70( 97.2%) 74( 98.7%) 
- No 0(  0.0%) 
- n plicable 1(  1.3%) 
   
Tim eatment[hour]  
- N 75 
- Mean +/- SD 2.3+/-0.7 
- Median 2.1 
- p5, p25, p75, p95 1.4, 1.8, 2.6, 3.7 
- Min, Max 1.3, 4.2 
y1 
ay1, 
ot ap
e to
69( 95.8%) 
68( 94.4%) 
68( 94.4%)  
 
0(
2(  2.8%) 
2.3+/-0.8 
0
  
72 
2.3 
.5
0.0
 
, 5
%) 
.2 
 tr
1.2, 1.8, 2.7, 3.8 
time to treatment: from first lab measurement to first treatment 
 
Table 12-15: Compliance by group for Level 2 (FAS) 
 
2x daily 
(N=72) 
4x daily 
(N=78) 
Number of P ake
(1) 
at. with drug int    
- Day1 77( 98.7%) 
- Day1, Day2 77( 98.7%) 
- D Day2, Day3 77( 98.7%) 
  
Blue urine at least once   
- Yes 0( 97.2%) 77( 98.7%) 
- No 0(  0.0%) 
- n plicable 1(  1.3%) 
   
Tim ea  
- N 78 
- Mean +/- SD 2.0+/-0.5 
- Median 2.1 
- p5, p25, p75, p95 1.2, 1.5, 2.3, 3.0 
- Min, Max 1.1, 3.4 
68( 94.4%) 
67( 93.1%) 
67( 93.1%) ay1, 
ot ap
e to
 
 
7
0(
2(  2.8%) 
1.9+/-0.5 
1
  
72 
1.9 
.2
0.0
 
, 3
%) 
.2 
 tr tment[hour] 
1.2, 1.6, 2.3, 2.9 
time to treatment: from first lab measurement to first treatment 
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Table 12-16: Compliance by group for Level 3 (FAS) 
 
2x daily 
(N=53) 
4x daily 
(N=62) 
Number of P ake
(1) 
at. with drug int    
- Da 61( 98.4%) 
- Day1, Day2 60( 96.8%) 
- D Day2, Day3 60( 96.8%) 
  
Blue urine at least once   
- Yes 51( 96.2%) 61( 98.4%) 
- No 0(  0.0%) 
- n plicable 1(  1.6%) 
   
Tim eatment[hour]  
- N 62 
- Mean +/- SD 1.5+/-0.4 
- Median 1.5 
- p5, p25, p75, p95 1.0, 1.2, 1.8, 2.3 
- Min, Max 0.7, 2.9 
y1 
ay1, 
ot ap
e to
52( 98.1%) 
51( 96.2%) 
51( 96.2%)  
 
0(
2(  3.8%) 
1.6+/-0.5 
0
  
53 
1.6 
.6
0.0
 
, 2
%) 
.8 
 tr
0.9, 1.3, 2.0, 2.6 
time to treatment: from first lab measurement to first treatment 
 
Table 12-17: Compliance by group for all Levels (FAS) 
 
2x daily 
(N=197) 
4x daily 
(N=215) 
Number of P ake
(1) 
at. with drug int    
- Day1 208( 96.7%) 
- Day1, Day2 207( 96.3%) 
- D Day2, Day3 207( 96.3%) 
  
Blue urine at least once   
- Yes 1( 97.0%) 212( 98.6%) 
- No 0(  0.0%) 
- n plicable 3(  1.4%) 
   
Tim ea  
- N 215 
- Mean +/- SD 2.0+/-0.6 
- Median 1.9 
- p5, p25, p75, p95 1.1, 1.5, 2.3, 3.1 
- Min, Max 0.7, 4.2 
189( 95.9%) 
186( 94.4%) 
186( 94.4%) ay1, 
ot ap
e to
 
 
19
0(
6(  3.0%) 
2.0+/-0.7 
0
  
197 
1.9 
.5
0.0
 
, 5
%) 
.2 
 tr tment[hour] 
1.1, 1.5, 2.3, 3.1 
time to treatment: from first lab measurement to first treatment 
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Table 12-18: Changes from baseline in lab-data by study day for level 1 (2x daily, FAS) 
Characteristic Day2-Baseline Day3-Baseline Day4-Baseline Day14-Baseline 
Haemoglobin[g/dl]     
- N 72 68 68 67 
Mean +/- SD -0.6+/-0.7 -0.8+/-0.6 -0.8+/-0.7 -0.2+/-1.0 
 Median -0.5 -0.7 -0.8 -0.2 
5, p , , -0.4, 0.0 -1.7, -1.3, -0.5, 0.3 -1.6, -0.9, 0.3, 1.6 
-4.1, 0.5 -3.5, 0.6 -3.5, 0.8 -2.6, 1.9 
95% CI mean (-0.7; -0.4) -0.9; -0.6) (-1.0; -0.7) (-0.4; 0.0) 
% CI median (-0.6; -0.3) -0.9; -0.6) (-1.0; -0.6) (-0.4; 0.1) 
Value (1) <.0001 <.0001 <.0001 0.1058 
 
 iparum[/µl] 
 N 
Mean +/- SD 5+/-45 4+/-2 1+/-2 1+/-2
- Median
5, p7  -2
, 42
 -4
0, 6
 -5
, -
 -5
, 2
- Min, Max .0, 231 .0, 13 .0, -2 .0, 41
95% CI mean 6; ; - ; - ; -
% CI medi 0; - ; - ; - ; -
Value (1) <.0001 <.0001 <.0001 <.0001 
falciparum)[/µl]     
- N 72 68 68 67 
- Mean +/- SD -0.7+/-1.3 -5.3+/-3.6 -8.4+/-3.1 -7.7+/-4.1 
- Median -0.7 -4.5 -9.9 -9.9 
- p5, p25, p75, p95 -2.7, -1.3, -0.2, 1.5 -11.2, -9.4, -2.8, 0.6 -11.3, -10.7, -5.4, -2.5 -11.2, -10.7, -4.3, 1.0 
- Min, Max -5.3, 2.9 -11.5, 1.2 -11.5, -1.2 -11.5, 1.8 
- 95% CI mean (-1.0; -0.4) (-6.1; -4.4) (-9.1; -7.6) (-8.7; -6.7) 
- 95% CI median (-1.0; -0.4) (-5.4; -3.5) (-10.1; -9.0) (-10.1; -8.9) 
- p-Value (1) <.0001 <.0001 <.0001 <.0001 
- 
-
- p5, p2
- Min, Max 
75, p95 -1.5, -0.9 -0.2, 0.1 -1.5, -1.0
- (
- 95
 p-
(
-
    
P. falc
-
    
72 68 68 67 
- -7953.
 
415.3 -32687. 4812.5 -34878. 3683.5 -30985. 9618.0 
-11150.0 -25890.0 -26000.0 -25000.0 
- p5, p2 5, p95 -49900.0,
-2150.0
7750.0,  
500.0 
-77450.0,
-16750.
6 0
8000.0,  
000.0 
-78500.0,
-18750.0
0 0
1530.0,  
4500.0 
-78500.0,
-15000.0
6 0
2600.0,  
3000.0 
0-76000 00.0 -9500 00.0 -9500 00.0 -9500 00.0 
-  (-18625. 2718.6) (-38693.2 26681.5) (-40610.8 29145.5) (-38209.5 23760.7) 
- 95
 p-
an (-18700.
 
7500.0) (-42000.0 21000.0) (-43700.0 21000.0) (-42400.0 21000.0) 
-
 
ln(P. 
    
(1) Wilcoxon Signed Rank Test; Day14 is including Day 13-15 
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Table 12-19: Changes from baseline in lab-data by study day for level 2 (2x daily, FAS) 
Characteristic Day2-Baseline Day3-Baseline Day4-Baseline Day14-Baseline 
Haemoglobin[g/dl]     
- N  71    
     
    
     
    
    
     
    
     
68 67 64
- Mean +/- SD 
 
-0.5+/-0.7 -0.6+/-0.8 -0.7+/-0.9 -0.1+/-1.0 
- Median -0.5 -0.7 -0.5 -0.1
- p5, p25, p75, p95 -1.7, -0.9, 0.0, 0.5 -2.1, -1.2, -0.1, 0.4 -2.6, -1.3, -0.2, 0.5 -1.6, -0.8, 0.6, 1.5 
- Min, Max -2.2, 1.2 -2.3, 1.3 -2.7, 1.2 -1.9, 2.2 
- 95% CI mean (-0.6; -0.3) (-0.8; -0.5) (-0.9; -0.4) (-0.3; 0.1) 
- 95% CI median (-0.7; -0.4) (-0.8; -0.4) (-0.7; -0.3) (-0.4; 0.0) 
- p-Value (1) 
 
<.0001 <.0001 <.0001 0.3081 
P. falciparum[/µl]
  - N 71 68 67 64
- Mean +/- SD -14252.1+/-26194.9 -28979.6+/-26242.1 -30295.8+/-27212.2 -25037.2+/-28635.5 
- Median -9000.0 -18600.0 -21000.0 -16500.0 
- p5, p25, p75, p95 -58000.0, -28000.0, 
1500.0, 16500.0 
-89010.0, -44275.0,  
-8675.0, -2200.0 
-89500.0, -47000.0,  
-9000.0, -2400.0 
-85000.0, -42000.0,  
-6300.0, 10500.0 
- Min, Max -80000.0, 92000.0 -95890.0, -1500.0 -96500.0, 9000.0 -90000.0, 42000.0 
- 95% CI mean (-20452.4; -8051.9) (-35331.5; -22627.6) (-36933.4; -23658.2) (-32190.1; -17884.3) 
- 95% CI median (-15000.0; -4500.0) (-30000.0; -12500.0) (-30800.0; -13000.0) (-29000.0; -11500.0) 
- p-Value (1) 
 
<.0001 <.0001 <.0001 <.0001 
ln(P. falciparum)[/µl]
  - N 71 68 67 64
- Mean +/- SD 
 
-0.7+/-1.2 -4.9+/-2.6 -8.4+/-2.8 -6.6+/-4.3 
- Median -0.7 -4.6 -9.4 -8.7
- p5, p25, p75, p95 -2.8, -1.4, 0.1, 1.1 -9.5, -6.0, -3.0, -1.3 -11.3, -10.4, -7.6, -3.2 -11.4, -10.2, -1.9, 0.3 
- Min, Max -4.1, 2.0 -11.4, -0.4 -11.5, 0.5 -11.4, 3.1 
- 95% CI mean (-1.0; -0.4) (-5.5; -4.3) (-9.0; -7.7) (-7.7; -5.5) 
- 95% CI median (-0.9; -0.5) (-5.2; -4.1) (-9.7; -8.6) (-9.5; -5.4) 
- p-Value (1) <.0001 <.0001 <.0001 <.0001 
(1) Wilcoxon Signed Rank Test; Day14 is including Day 13-15 
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Table 12-20: Changes from baseline in lab-data by study day for level 3 (2x daily, FAS) 
Characteristic Day2-Baseline Day3-Baseline Day4-Baseline Day14-Baseline Day28-Baseline 
Haemoglobin[g/dl]      
- N 53 52 51   
- Mean +/- S -0.5+/-0.6 -0.8+/-0.8 -0.7+/-0.8   
-  
- p5, p25, p .9, , ,   
- Min, Max -2.2, 0.6 -2.2, 1.3 -2.8, 1.2   
- 95% CI mea (-0.7; -0.4) -1.0; -0.6) -0.9; -0.5)   
- 95% CI med (-0.8; -0.4) -1.1; -0.5) -0.9; -0.4)   
- p-Value (1 <.0001 <.0001 <.0001   
     
P.      
53 52 51 50 49 
- Mean +/- S -22994.3+/-2 3+/-2 3+/-2 0+/-2 1+/-33603.1 
- -23000.0 
- p5, p25, p 0, -3
.0, 3
 -5
, -
 -5
, -
 -6
, -
 -54500.0,  
, 18000.0 
- Min, Max -83000.0, 12 .0, -2 00, -25 00, -25 00, 82000.0 
- 95% CI mea -29550.7; -1 1; - ; - ; - ; -23052.1) 
- 95% CI med 4500.0; - 0; - ; - ; - ; -19500.0) 
- p-Value (1 <.0001 <.0001 <.0001 <.0001 <.0001 
     
ln(P.      
53 52 51 50 49 
- Mean +/- S -1.2+/-1.5 -5.5+/-2.2 -9.5+/-2.1 -8.5+/-2.9 -7.4+/-4.3 
- -9.9 
- p5, p25, p .7, , 6, -3.3, 0.3 
- Min, Max -9.3, 0.6 -11.2, -2.0 -11.5, 2.5 
- 95% CI mea (-1.6; -0.8) -6.1; -4.9) -10.1; -8.9) -9.3; -7.7) (-8.6; -6.1) 
- 95% CI med (-1.2; -0.6) -5.5; -4.5) -10.6; -9.9 10.0; -9.1 10.3; -7.8) 
- p-Value (1 <.0001 <.0001 <.0001 <.0001 <.0001 
D 
Median -0.6 -0.8 -0.7  
75, p95 -1.6, -0 -0.1, 0.5 -2.0, -1.3 -0.3, 0.7 -2.2, -1.2 -0.2, 0.4 
n (  (  
ian (  (  
) 
 
 falciparum[/µl] 
- N 
D 3786.6 -39027. 6841.7 -39185.
-18500.0 -32650.0 -32000.0 -31350.0 
7273.0 -38807. 7134.8 -32704.
Median 
75, p95 -75000.
-6500
5500.0,  
000.0 
-89750.0,
-17650.0
7750.0,  
4350.0 
-90000.0,
-17000.0
8000.0,  
4500.0 
-89800.0,
-17000.0
1000.0,  
4500.0 
-90000.0,
-15500.0
500.0 -99700 500.0 -1000 00.0 -1000 00.0 -1000
n ( 6437.9) (-46500. 31554.5) (-46855.9 31514.6) (-46518.6 31095.4) (-42356.0
ian (-2 8000.0) (-46800. 20900.0) (-43500.0 21000.0) (-43500.0 20000.0) (-40000.0
) 
 
 falciparum)[/µl] 
- N 
D 
Median -0.9 -4.8 -10.0 -9.9 
75, p95 -3.6, -1 -0.3, 0.3 -10.4, -5.8  -4.0, -3.2 -11.4, -10.8, -9.4, -5.0 -11.4, -10.6
-11.5, -1.8 
, -5.9, -2.5 -11.4, -10.
-11.5, -1.8 
n (  (  (  
ian (  ( ) (- ) (-
) 
(1) Wilcoxon t; Day14 is inclSigned Rank Tes uding Day 13-15 / Day28 is including Day 25-30 
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Table 12-21: Changes from baseline in lab-data by WHO-Day for level 1 (2x daily, FAS) 
Characteristic D1-Baseline D2-Baseline D3-Baseline D14-Baseline 
Haemoglobin[g/dl]     
- N 68 68  63 
Mean +/- SD -0.8+/-0.6 -0.8+/-0.7  -0.2+/-1.0 
- Median -0.7 -0.8  -0.2 
5, p , , -  , 0.3, 1.6 
-3.5, 0.6 -3.5, 0.8  -2.6, 1.9 
95% CI mean (-0.9; -0.6) -1.0; -0.7)  (-0.4; 0.1) 
% CI median (-0.9; -0.6) -1.0; -0.6)  (-0.4; 0.2) 
Value (1) <.0001 <.0001  0.1657 
 
 iparum[/µl] 
 N 
Mean +/- SD 4+/-2 1+/-2 3+/-2 0+/-2
- Median
5, p7  -4
0, 6
 -5
, -
 -5
, -
 -5
, 1
- Min, Max .0, 13 .0, -2 .0, -2 .0, 41
95% CI mean 2; - ; - ; - ; -
% CI medi 0; - ; - ; - ; -
Value (1) <.0001 <.0001 <.0001 <.0001 
- 
- p5, p2
- Min, Max 
75, p95 -1.5, -1.0 -0.4, 0.0 -1.7, -1.3 0.5, 0.3 -1.6, -0.9
- (  
- 95
 p-
(  
-
    
P. falc
-
    
68 68 68 63 
- -32687.
 
4812.5 -34878. 3683.5 -35471. 3977.1 -32127. 9579.6 
-25890.0 -26000.0 -26000.0 -27000.0 
- p5, p2 5, p95 -77450.0,
-16750.
8000.0,  
000.0 
-78500.0,
-18750.0
1530.0,  
4500.0 
-78500.0,
-19000.0
2050.0,  
4500.0 
-78500.0,
-16000.0
5900.0,  
6700.0 
-95000 000.0 -95000 600.0 -95000 600.0 -95000 000.0 
-  (-38693. 26681.5) (-40610.8 29145.5) (-41275.0 29667.6) (-39576.5 24677.5) 
- 95
 p-
an (-42000.
 
21000.0) (-43700.0 21000.0) (-44000.0 21500.0) (-42400.0 21000.0) 
-
(1) Wilcoxon Signed Rank Test 
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Table 12-22: Changes from baseline in lab-data by WHO-Day for level 2 (2x daily, FAS) 
Characteristic D1-Baseline D2-Baseline D3-Baseline D14-Baseline 
Haemoglobin[g/dl]     
- N 68 67  64 
- Mean +/- SD -0.6+/-0.8 -0.7+/-0.9  -0.1+/-1.0 
- Median -0.7 -0.5  -0.1 
- p5, p25, p75, p95 -2.1, -1.2, -0.1, 0.4 -2.6, -1.3, -0.2, 0.5  -1.6, -0.8, 0.6, 1.5 
- Min, Max -2.3, 1.3 -2.7, 1.2  -1.9, 2.2 
- 95% CI mean (-0.8; -0.5) (-0.9; -0.4)  (-0.3; 0.1) 
- 95% CI median (-0.8; -0.4) (-0.7; -0.3)  (-0.4; 0.0) 
- p-Value (1) 
 
<.0001 <.0001  0.3081 
    
     
    
     
P. falciparum[/µl]
  - N 68 68 67 64
- Mean +/- SD 
 
-28916.3+/-26303.9 -29935.6+/-27171.3 -30769.4+/-27120.6 -25037.2+/-28635.5 
- Median -18600.0 -20500.0 -22000.0 -16500.0
- p5, p25, p75, p95 -89010.0, -44275.0,  
-8675.0, -2000.0 
-89500.0, -46000.0,  
-8600.0, -2400.0 
-89850.0, -47000.0,  
-10000.0, -2500.0 
-85000.0, -42000.0,  
-6300.0, 10500.0 
- Min, Max -95890.0, -1500.0 -96500.0, 9000.0 -96500.0, -2000.0 -90000.0, 42000.0 
- 95% CI mean (-35283.2; -22549.4) (-36512.4; -23358.7) (-37384.6; -24154.2) (-32190.1; -17884.3) 
- 95% CI median (-30000.0; -12500.0) (-30800.0; -13000.0) (-31000.0; -13000.0) (-29000.0; -11500.0) 
- p-Value (1) <.0001 <.0001 <.0001 <.0001 
(1) Wilcoxon Signed Rank Test 
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Table 12-23: Changes from baseline in lab-data by WHO-Day for level 3 (2x daily, FAS) 
Characteristic D1-Baseline D2-Baseline D3-Baseline D14-Baseline D28-Baseline 
Haemoglobin[g/dl]      
- N 52 51    
- Mean +/- S -0.8+/-0.8 -0.7+/-0.8    
- Median -0.8 -0.7    
- p5, p25, p .3, ,    
- Min, Max -2.2, 1.3 -2.8, 1.2    
- 95% CI mea (-1.0; -0.6) -0.9; -0.5)    
- 95% CI med (-1.1; -0.5) -0.9; -0.4)    
- p-Value (1 <.0001 <.0001    
     
falciparum[/µl]      
52 51 51 46 49 
- Mean +/- S -39027.3+/-2 3+/-2 6+/-27261.1 -39357.6+/-2 1+/-33603.1 
- -23000.0 
- p5, p25, p 0, -5
.0, -
 -5
, -
 -5
, -
 -6
, -
 -54500.0,  
, 18000.0 
- Min, Max -99700.0, -2500.0 -100000, -2500.0 -100000, -2500.0 -100000, -3500.0 -100000, 82000.0 
- 95% CI mean (-46500.1; -31554.5) (-46855.9; -3 9; -31601.3) (-47406.2; -3 0; -23052.1) 
- 95% CI medi 6800.0; -2 0; - ; -2 0; - ; -19500.0) 
- p-Value (1 <.0001 <.0001 <.0001 <.0001 <.0001 
D 
75, p95 -2.0, -1 -0.3, 0.7 -2.2, -1.2 -0.2, 0.4 
n (  
ian (  
) 
 
P. 
- N 
D 6841.7 -39185. 7273.0 -39268.
-32650.0 -32000.0 -32000.0 -31350.0 
7103.0 -32704.
Median 
75, p95 -89750.
-17650
7750.0,  
4350.0 
-90000.0,
-17000.0
8000.0,  
4500.0 
-90000.0,
-17000.0
9750.0,  
4500.0 
-89800.0,
-17000.0
1000.0,  
9000.0 
-90000.0,
-15500.0
1514.6) (-46935.
21000.0) (-43500.0
1309.0) (-42356.
20000.0) (-40000.0an (-4
) 
0900.0) (-43500. 1000.0) (-46850.
(1) Wilcoxon Signed Rank Test 
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Table 12-24: Changes from baseline in lab-data by study day for level 1 (4x daily, FAS) 
Characteristic Day2-Baseline Day3-Baseline Day4-Baseline Day14-Baseline 
Haemoglobin[g/dl]     
- N 73 70 70 70 
Mean +/- SD -0.6+/-0.8 -0.9+/-0.9 -0.8+/-0.9 -0.2+/-1.3 
 Median -0.2 
5, p , -0.1, 0.3 -2.4, -1.3, , , 0.5, 1.6 
-5.2, 1.4 -5.7, 0.8 -5.3, 0.8 -4.9, 3.0 
95% CI mean (-0.8; -0.4) -1.1; -0.7) (-1.0; -0.6) (-0.5; 0.1) 
% CI median (-0.8; -0.3) -0.9; -0.6) (-0.9; -0.6) (-0.5; 0.2) 
Value (1) <.0001 <.0001 <.0001 0.1651 
 
 iparum[/µl] 
 N 73 70 70 
Mean +/- SD 0+/-31926.4 -32960.0+/-27673.9 -33634.9+/-2 6+/-2
- Median -9200.0 -26425.0 -27250.0 -23500.0 
5, p7  -2
 340
 -5
, -2
 -54100.0
, -2500.0 
0000.0, -5
-7200.0, -2
- Min, Max .0, 1375 -97230.0, 5500.0 0.0, -2 .0, 13
95% CI mean 0; -661.0) (-39558.6; -26361.4) (-40269.5; -27000.2) .5; -
% CI medi 0; - ; -17800.0) (-34000.0; - ; -
Value (1) 0.0005 <.0001 <.0001 <.0001 
 
ln(P. falciparum)[/µl]  
- N 73 70 70 70 
- Mean +/- SD -0.8+/-1.5 -5.1+/-2.6 -8.7+/-2.7 -8.2+/-3.4 
- Median -0.6 -4.6 -9.7 -9.6 
- p5, p25, p75, p95 -3.1, -1.3, 0.1, 1.0 -10.3, -6.6, -3.3, -1.8 -11.4, -10.7, -7.6, -2.5 -11.3, -10.7, -7.6, -0.6
- Min, Max -8.5, 2.6 -11.4, 0.9 -11.4, -1.9 -11.5, 0.5 
- 95% CI mean (-1.1; -0.4) (-5.7; -4.5) (-9.3; -8.0) (-9.0; -7.4) 
- 95% CI median (-1.0; -0.3) (-5.1; -4.2) (-10.2; -8.9) (-10.0; -8.8) 
- p-Value (1) <.0001 <.0001 <.0001 <.0001 
- 
- -0.6 -0.8 -0.7 
- p5, p2
- Min, Max 
75, p95 -1.5, -1.0 -0.4, 0.1 -2.4, -1.2 -0.2, 0.2 -2.5, -0.9
- (
- 95
 p-
(
-
    
P. falc
-
    
70 
- -8110. 7824.9 -32079. 8308.6 
- p5, p2 5, p95 -59000.0,
500.0,
2000.0, 
00.0 
-89750.0,
-9500.0
00.0 
2500.0,  
100.0 
-90500.0,
-9540.0
-9795
,  -9 4500.0,  
000.0 
-78000 000.0 -98000
(-38829
800.0 
-  (-15559. 25329.6) 
- 95
 p-
an (-13000.
 
3900.0) (-34000.0 18000.0) (-33000.0 16500.0) 
-
   
   
 
(1) Wilcoxon Signed Rank Test; Day14 is including Day 13-15 
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Tab : h AS) le 12-25  C anges from baseline in lab-data by study day for level 2 (4x daily, F
Characteristic Day2-Baseline Day3-Baseline Day4-Baseline Day14-Baseline 
Haemoglobin[g/dl]     
- N  7     
    -0.3 
-2.5, -1.1, 0.3, 1.3 
- 95% CI median 
    
P. falciparum[/µl]     
  77    
    
-86000.0, -45000.0,  
-10300.0, -2500.0 
    
     
    
 -0.8 -4.5 -9.6  
- p5, p25, p75, p95 
(-6.3; -4.8) (-9.2; -7.9) 
7 77 77 73
- Mean +/- SD 
 
-0.6+/-0.7 -0.9+/-0.8 -1.0+/-1.0 -0.5+/-1.2 
- Median -0.6 -0.9 -1.0
- p5, p25, p75, p95 -1.7, -1.1, -0.1, 0.3 -2.2, -1.5, -0.3, 0.2 -2.8, -1.6, -0.2, 0.5 
- Min, Max 
- 95% CI mean 
-2.2, 1.0 
(-0.8; -0.5) 
-2.8, 0.4 -3.4, 1.7 -4.4, 2.2 
(-1.1; -0.8) (-1.2; -0.7) (-0.7; -0.2) 
(-0.9; -0.4) (-1.2; -0.6) (-1.1; -0.7) (-0.7; 0.0) 
- p-Value (1) 
 
<.0001 <.0001 <.0001 0.0029 
- N 77 77 74
- Mean +/- SD 
 
-12550.6+/-26205.5 -30259.0+/-23479.0 -30571.3+/-24060.7 -29309.5+/-24410.5 
-23250.0 - Median -11500.0 -23500.0 -25000.0
- p5, p25, p75, p95 -53900.0, -25500.0,  
-500.0, 30500.0 
-85950.0, -45700.0,  
-12750.0, -3500.0 
-86000.0, -46500.0,  
-12800.0, -2500.0 
- Min, Max 
- 95% CI mean 
-92500.0, 82000.0 -96000.0, -1400.0 -96000.0, 14000.0 -96000.0, 14000.0 
(-18498.6; -6602.7) (-35588.1; -24929.9) 
(-31800.0; -17700.0) 
(-36032.4; -25110.2) (-34964.9; -23654.0) 
- 95% CI median (-14900.0; -3900.0) 
<.0001 
(-32500.0; -18000.0) (-30500.0; -16000.0) 
- p-Value (1) 
 
<.0001 <.0001 <.0001 
ln(P. falciparum)[/µl]
  - N 77 77 77 74
- Mean +/- SD 
 
-0.9+/-1.2 -5.6+/-3.2 -8.6+/-2.9 -8.0+/-3.6 
- Median -9.6
-3.5, -1.5, -0.1, 1.2 
-5.0, 1.5 
-10.8, -8.5, -3.2, -1.2 
-11.5, -0.4 
-11.4, -10.5, -8.2, -2.2
-11.5, 0.4 
-11.2, -10.4, -6.1, -0.3
- Min, Max -11.5, 1.6 
- 95% CI mean (-1.1; -0.6) (-8.8; -7.2) 
- 95% CI median (-0.9; -0.5) (-5.4; -3.9) (-10.0; -9.2) (-10.0; -9.2) 
- p-Value (1) <.0001 <.0001 <.0001 <.0001 
(1) Wilcoxon Signed Rank Test;    Day14 is including Day 13-15 
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Tab : h AS) le 12-26  C anges from baseline in lab-data by study day for level 3 (4x daily, F
Characteristic Day2 n-Baseli e Day3-Baseline Day4-Baseline Day14-Baseline Day28-Baseline 
Haemoglobin[g/dl]      
-  
- Mean +/- S -0.5+/-0.6 -0.6+/-0.7 -0.6+/-0.9 -0.4+/-.  
- -0.4 -0.5 -0.6 -0.4  
- p5, p25, p .6, , 1, , -  
- Min, Max -2.4, 1.0 -2.8, 1.0 -3.9, 1.1 -0.4, -0.4  
- 95% CI mea (-0.6; -0.3) -0.8; -0.4) -0.8; -0.4) (.; .)  
- 95% CI med (-0.5; -0.3) -0.7; -0.3) -0.8; -0.1) (.; .)  
- p-Value (1 <.0001 <.0001 <.0001 1.0000  
     
P.      
62 61 61 59 59 
- Mean +/- S -13184.5+/-2 0+/-2 5+/-2 8+/-2 6+/-24068.4 
- -16700.0 
- p5, p25, p75, p95 -61000.0, -2
-3000.0, 16
 -4
, -4
 -4
, -4
 -4
, 2
 -39300.0,  
, 4500.0 
- Min, Max -83500.0, 90 .0, -2 .0, -2 .0, 19 .0, 25500.0 
- 95% CI mea -19608.9; - 3; - ; -23 .7; - ; -18863.3) 
- 95% CI med 3000.0; - 0; - ; - ; - ; -12000.0) 
- p-Value (1 <.0001 <.0001 <.0001 <.0001 <.0001 
     
ln(P.      
62 61 61 59 59 
- Mean +/- SD -1.1+/-1.1 -6.0+/-2.7 -9.1+/-2.0 -8.2+/-3.3 -7.0+/-4.0 
- -1.1 -5.0 -9.6 -9.5 -8.9 
- p5, p25, p .7, , 4 3, -3.3, 0.6 
- Min, Max -4.0, 1.3 -11.2, -1.4 -11.3, 1.9 
- 95% CI mea (-1.4; -0.8) -6.7; -5.3) -9.7; -8.6) (-9.1; -7.4) (-8.0; -6.0) 
- 95% CI med (-1.4; -0.5) -6.3; -4.3) -9.9; -8.9) -9.7; -8.7) (-9.6; -4.4) 
- p-Value (1 <.0001 <.0001 <.0001 <.0001 <.0001 
N 62 61 61 1 
D 
Median 
75, p95 -1.7, -0 -0.1, 0.4 -1.7, -1.0 -0.1, 0.3 -1.8, -1. 0.1, 0.6 -0.4, -0.4 0.4, -0.4 
n (  (
ian (  (  
) 
 
 falciparum[/µl] 
- N 
D 5297.4 -29278. 5239.8 -29597. 5358.2 -26378. 5490.7 -25135.
Median -8250.0 -19000.0 -19500.0 -17000.0 
3000.0,  
500.0 
-76610.0,
-7900.0
6000.0,  
000.0 
-77000.0,
-8000.0
6000.0,  
000.0 
-81000.0,
-6000.0
0500.0,  
000.0 
-71000.0,
-6000.0
500.0 -89600 000.0 -90000 000.0 -90000
103.0) (-33021
000.0 -78000
n ( 6760.2) (-35742. 22813.8) (-36092.1 19735.9) (-31407.9
ian (-1 4500.0) (-29800. 13000.0) (-30000.0 13000.0) (-26500.0 12000.0) (-26000.0
) 
 
 falciparum)[/µl] 
- N 
Median 
75, p95 -3.3, -1 -0.3, 0.5 -10.8, -8.5  -4.1, -2.9 -11.2, -10.5, -8.6, -5.2 -11.3, -10.
-11.4, -1.2 
, -8.3, 0.3 -11.1, -10.
-11.4, 0.4 
n (  (
ian (  (  (  
) 
(1) Wilcoxon Signed Rank Test;   Day14 is including Day 13-15 / Day28 is including Day 25-30 
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Tabl : h AS) e 12-27 C anges from baseline in lab-data by WHO-Day for level 1 (4x daily, F
Characteristic D1-Baseline D2-Baseline D3-Baseline D14-Baseline 
Haemoglobin[g/dl]     
- N 70 70  69 
Mean +/- SD -0.9+/-0.9 -0.8+/-0.9  -0.2+/-1.3 
- Median -0.8 -0.7  -0.2 
5, p , , -  , 0.5, 1.6 
-5.7, 0.8 -5.3, 0.8  -4.9, 3.0 
95% CI mean (-1.1; -0.7) -1.0; -0.6)  (-0.5; 0.1) 
% CI median (-0.9; -0.6) -0.9; -0.6)  (-0.5; 0.2) 
- p-Value (1) <.0001 <.0001  0.1720 
 
P. 
- N 
Mean +/- SD 0+/-2 9+/-2 6+/-2 1+/-28483.9 
- Median 
5, p7  -5
, -2
 -5
, -2
 -5
, -2
 -5
, -2
- Min, Max 0.0, 55 .0, -2 .0, -2 .0, 138
95% CI mean ; - ; - ; - ; -253
 95% CI medi ; -1 0; - ; - ; -
p-Value (1) <.0001 <.0001 <.0001 <.0001 
- 
- p5, p2
- Min, Max 
75, p95 -2.4, -1.3 -0.4, 0.1 -2.4, -1.2 0.2, 0.2 -2.5, -0.9
- (  
- 95 (  
    
 falciparum[/µl]    
70 70 70 69 
- -32960. 7673.9 -33634. 7824.9 -33426. 7895.7 -32240.
-26425.0 -27250.0 -26000.0 -26000.0 
- p5, p2 5, p95 -89750.0,
-9500.0
2500.0,  
100.0 
-90500.0,
-9540.0
4100.0,  
500.0 
-90500.0,
-9700.0
0 0
5400.0,  
500.0 
-90000.0,
-7200.0
0 0
4500.0,  
000.0 
-9723 00.0 -97950 00.0 -9800 00.0 -9800 00.0 
97.6) - 
-
 (-39558.6
a 0
26361.4) (-40269.5
7800.0) (-34000.
27000.2) (-40078.1 26775.1) (-39082.7
n (-34000.
 
18000.0) (-34000.0 18000.0) (-33000.0 16000.0) 
- 
(1) Wilcoxon Signed Rank Test 
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Table 12-28: Changes from baseline in lab-data by WHO-Day for level 2 (4x daily, FAS) 
Characteristic D1-Baseline D2-Baseline D3-Baseline D14-Baseline 
Haemoglobin[g/dl]     
- N 77 77 1 71 
- Mean +/- SD 
 
-0.9+/-0.8 -1.0+/-1.0 -2.8+/-. -0.4+/-1.1 
- Median   -   
    
     
    
     
- 95% CI median (-31800.0; -17700.0) (-32500.0; -18000.0) (-32400.0; -18000.0) 
-0.9 -1.0 2.8 -0.3
- p5, p25, p75, p95 -2.2, -1.5, -0.3, 0.2 -2.8, -1.6, -0.2, 0.5 -2.8, -2.8, -2.8, -2.8 -2.4, -1.2, 0.3, 1.3 
- Min, Max -2.8, 0.4 -3.4, 1.7 -2.8, -2.8 -3.5, 2.2 
- 95% CI mean (-1.1; -0.8) (-1.2; -0.7) (.; .) (-0.7; -0.2) 
- 95% CI median (-1.2; -0.6) (-1.1; -0.7) (.; .) (-0.7; 0.0) 
- p-Value (1) 
 
<.0001 <.0001 1.0000 0.0028 
P. falciparum[/µl]
  - N 77 77 77 72
- Mean +/- SD 
 
-30259.0+/-23479.0 -30571.3+/-24060.7 -31145.5+/-23575.6 -30340.3+/-24477.7 
- Median -23500.0 -25000.0 -25500.0 -25750.0
- p5, p25, p75, p95 -85950.0, -45700.0,  
-12750.0, -3500.0 
-86000.0, -46500.0,  
-12800.0, -2500.0 
-86000.0, -46500.0,  
-13000.0, -3400.0 
-86000.0, -46550.0,  
-10500.0, -2500.0 
- Min, Max -96000.0, -1400.0 -96000.0, 14000.0 -96000.0, -1200.0 -96000.0, 14000.0 
- 95% CI mean (-35588.1; -24929.9) (-36032.4; -25110.2) (-36496.5; -25794.5) (-36092.3; -24588.3) 
(-32500.0; -17000.0) 
- p-Value (1) <.0001 <.0001 <.0001 <.0001 
(1) Wilcoxon Signed Rank Test 
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Tab 9: h AS) le 12-2  C anges from baseline in lab-data by WHO-Day for level 3 (4x daily, F
Characteristic D1-Baseline D2-Baseline D3-Baseline D14-Baseline D28-Baseline 
Haemoglobin[g/dl]      
- N 61 61 1 2  
- Mean +/- S -0.6+/-0.7 -0.6+/-0.9 -4.0+/-. -0.2+/-0.2  
- -0.5 -0.6 -4.0 -0.2  
- p5, p25, p .0, 1, 0.1, 0.6 -4.0, -4.0,  -  
- Min, Max -2.8, 1.0 -3.9, 1.1 -4.0, -4.0 -0.4, -0.1  
- 95% CI mea (-0.8; -0.4) -0.8; -0.4) (.; .) (-2.2; 1.7)  
- 95% CI med (-0.7; -0.3) -0.8; -0.1) (.; .) (-0.4; -0.1)  
- p-Value (1 <.0001 <.0001 1.0000 0.5000  
     
P.      
61 61 60 53 59 
- Mean +/- S -29278.0+/-2 5+/-2 2+/-2 4+/-2 6+/-24068.4 
- -16700.0 
- p5, p25, p 0, -4
.0, -4
 -4
, -4
 -4
, -4
 -3
, 2
 -39300.0,  
, 4500.0 
- Min, Max -89600.0, -2 .0, -2 .0, -2 .0, 19 .0, 25500.0 
- 95% CI mea -35742.3; - ; - ; - ; - ; -18863.3) 
- 95% CI med 9800.0; -1 (-30000.0; -13000.0) 0; - ; - ; -12000.0) 
- p-Value (1 <.0001 <.0001 <.0001 <.0001 <.0001 
D 
Median 
75, p95 -1.7, -1 -0.1, 0.3 -1.8, -1. -4.0, -4.0 -0.4, -0.4, 0.1, -0.1 
n (
ian (  
) 
 
 falciparum[/µl] 
- N 
D 5239.8 -29597. 5358.2 -28949.
-19000.0 -19500.0 -18250.0 -17000.0 
5008.4 -25793. 5052.9 -25135.
Median 
75, p95 -76610.
-7900
6000.0,  
000.0 
-77000.0,
-8000.0
6000.0,  
000.0 
-79000.0,
-7750.0
6000.0,  
000.0 
-81000.0,
-7500.0
5000.0,  
000.0 
-71000.0,
-6000.0
000.0 -90000 000.0 -90000 000.0 -90000 000.0 -78000
n ( 22813.8) (-36092.1
3000.0) 
23103.0) (-35409.5
(-34000.
22488.8) (-32698.8 18888.0) (-31407.9
ian (-2 14800.0) (-26500.0 13000.0) (-26000.0
) 
(1) Wilcoxon Signed Rank Test 
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Table 12-30: Changes from baseline in lab-data by study day for level 1 (FAS) 
Characteristic Day2-Baseline Day3-Baseline Day4-Baseline Day14-Baseline 
Haemoglobin[g/dl]     
- N  145 138 138 137 
Mean +/- SD -0.6+/-0.7 -0.8+/-0.8 -0.8+/-0.8 -0.2+/-1.1 
 Median -0.2 
5, p , - 2, , , 0.4, 1.6 
-5.2, 1.4 -5.7, 0.8 -5.3, 0.8 -4.9, 3.0 
95% CI mean (-0.7; -0.5) -1.0; -0.7) (-1.0; -0.7) (-0.4; -0.0) 
% CI median (-0.6; -0.3) -0.8; -0.7) (-0.8; -0.6) (-0.4; 0.0) 
Value (1) <.0001 <.0001 <.0001 0.0322 
 
 iparum[/µl] 
  
Mean +/- SD 3+/-39 7+/-2 5+/-2 3+/-2
- Median -9800.0 -26325.0 -26500.0 -25000.0 
5, p75, p95 8500.0, -2
-1000.0, 34
 -4
, -
 -5
, -
 -5
, 12
- Min, Max .0, 231 .0, 13 .0, -2 .0, 410
- 95% CI mean (-14445.7; -1618.8) 7.1; - ; - ; -
% CI medi 0; - ; - ; - ; -
Value (1) <.0001 <.0001 <.0001 <.0001 
falciparum)[/µl]     
- N 145 138 138 137 
- Mean +/- SD -0.8+/-1.4 -5.2+/-3.1 -8.5+/-2.9 -7.9+/-3.8 
- Median -0.7 -4.5 -9.8 -9.8 
- p5, p25, p75, p95 -2.7, -1.3, -0.2, 1.0 -10.7, -7.6, -3.1, -0.3 -11.3, -10.7, -7.6, -2.5 -11.3, -10.7, -5.6, 0.5 
- Min, Max -8.5, 2.9 -11.5, 1.2 -11.5, -1.2 -11.5, 1.8 
- 95% CI mean (-1.0; -0.5) (-5.7; -4.7) (-9.0; -8.0) (-8.6; -7.3) 
- 95% CI median (-0.9; -0.5) (-4.8; -4.2) (-10.0; -9.2) (-10.0; -9.0) 
- p-Value (1) <.0001 <.0001 <.0001 <.0001 
- 
- -0.5 -0.7 -0.7 
- p5, p2
- Min, Max 
75, p95 -1.5, -0.9 0.1, 0.1 -2.2, -1. -0.4, 0.1 -2.4, -1.2 -0.4, 0.3 -2.0, -0.9
- (
- 95
 p-
(
-
    
P. falc
- N
    
145 138 138 137 
- -8032. 071.8 -32825. 6207.3 -34247. 5780.6 -31544. 8854.7 
- p5, p2  -5 5500.0,  
000.0 
-88900.0,
-12400.0
6 0
9000.0,  
1500.0 
-89500.0,
-15000.0
0 0
2600.0,  
2800.0 
-83000.0,
-9500.0
0 0
4000.0,  
500.0 
-78000 00.0 -9723
(-3723
00.0 -9795 00.0 -9800 00.0 
28414.2) (-38587.1 29907.8) (-36419.4 26669.2) 
- 95
 p-
an (-12750.
 
7400.0) (-31000.0 20800.0) (-33500.0 21000.0) (-31500.0 20000.0) 
-
 
ln(P. 
    
(1) Wilcoxon Signed Rank Test;    Day14 is including Day 13-15 
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Table 12-31: Changes from baseline in lab-data by study day for level 2 (FAS) 
Characteristic Day2-Baseline Day3-Baseline Day4-Baseline Day14-Baseline 
Haemoglobin[g/dl      ]
- N 148 14   137 
 Mean +/- S -0.6 - .1 
- -0.6 -0.8 -0.7 -0.2 
- p5, p25, p75, p95 -1.7, -2.2  1.4
- Min, Max 
- 95% CI mean (-0.7; (- ) .1) 
- 95% CI median 
lue (1) <.0001 <.0001 <.0001 0.0041 
     
. falciparu     
- 1  1    
+/ 1336 -2  1.6 
 
- p5, p25, p7 -53900.0, -27250.0,  
-400.0, 23000.0 
-85950.0, -44800.0,  
-10320.0, -2400.0 
-86000.0, -43800.0,  
-9300.0, -1250.0 
, Max -92500.0, 92000.0 -96000.0, -1400.0 -96500.0, 14000.0 -96000.0, 42000.0 
- 95% CI mean (-17610.8; -9123.0) (-33719.0; -25599.0) (-31779.0; -22877.2) 
 95% CI med (-13500. (-28950.0; -16000.0) 
- p-Value (1) <.  
 
 
- 1     
 -9.3 
-11.3, -10.5, -7.7, -2.9 -11.3, -10.3, -3.9, -0.2
- Min, Max -5.0, 2.0 -11.5, 0.5 -11.5, 3.1 
- 95% CI mean (-1.0; -0.6) (-5.7; -4.8) (-8.9; -8.0) (-8.0; -6.7) 
- 95% CI median (-0.9; -0.6) (-5.2; -4.1) (-9.8; -9.2) (-9.7; -8.9) 
- p-Value (1) <.0001 <.0001 <.0001 <.0001 
5 144
- D 
Median 
+/-0.7 0.8+/-0.8 -0.8+/-0.9 -0.3+/-1
-1.0, -0.1, 0.5 
-2.2, 1.2 
, -1.4, -0.2, 0.3 
-2.8, 1.3 
-2.6, -1.5, -0.2, 0.5 
-3.4, 1.7 
-2.2, -1.0, 0.4,
-4.4, 2.2 
 
  -0.5) 
(-0.8; -0.5) 
0.9; -0.7) 
(-0.9; -0.6) 
(-1.0; -0.7
(-0.9; -0.5) 
(-0.5; -0
(-0.4; -0.1) 
- p-Va
P  m[/µl]
N 
 
48 45 144 138
- Mean 
-
- SD -
Median 
6.9+/-26125.1 9659.0+/-24734.0 
-10500.0 -21820.0 -23850.0 
-30443.1+/-25484.6 -27328.1+/-2644
-20500.0 
5, p95 -86000.0, -46700.0,  
-11000.0, -2500.0 
- Min
(-34641.1; -26245.2) 
- ian 0; -6000.0) 
<.0001 
(-30000.0; -17000.0) 
1 
(-27000.0; -15000.0) 
00010001 <.000 <.
 
ln(P. falciparum)[/µl] 
 
 
 
 
 
 
N 48 145 144 138
-7.4+/-4.0 - Mean +/- SD -0.8+/-1.2 -5.3+/-2.9 -8.5+/-2.8 
6 -9.5- Median -0.7 -4.
- p5, p25, p75, p95 -3.2, -1.4, -0.0, 1.1 -10.8, -7.1, -3.2, -1.3 
-11.5, -0.4 
(1) Wilcoxon Signed Rank Test;   Day14 is including Day 13-15 
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Table 12-32: Changes from baseline in lab-data by study day for level 3 (FAS) 
Characteristic Day2-Baseline Day3-Baseline Day4-Baseline Day14-Baseline Day28-Baseline 
Haemoglobin[g/dl]      
- N 115 113 112 1  
0.6 +/-0.7 0.7+/-0.9 -0.4+/-
 -0.5 -0.7 -0.6 -0.4 
, 0 0.3 1, 0 0.4,
-3.9, 1.2 
an 0.4) ; -0.5) 0.8; -0.5) (.; .) 
dian (-0.8; -0.5) (-0.8; -0.4) (.; .) 
<.0001 <.0001 <.0001 1.0000  
     
 /µl]
 115 113 112 109 
92.8 2632 +/-2 9.8+/-26864.9 -28569
.0 500. -23000.0 
p75, p95 28000.0,  , -53500.0,
-13000.0, -4000.0 
0.0, -55200
-13000.0, -4000.0 
9000.0, -48
12500.0, -3
-78000.0, 
-11750.0, 4500.0 
-83500.0, 90500.0 -99700.0, -2000.0 -100000, -2000.0 -100000, 19000.0 -100000, 82000.0 
(-22322.4; -13088.7) (-38671.8; -28857.1) 38937.2; -28989.5) (-37180.3; -26979 (-34081.2; -23057.7) 
- 95% CI median (-16000.0; -7000.0) (-33950.0; -19400.0 0.0; -19500.0) (-30700.0; -1 (-30000.0;
- p-Value (1) 0001 <.0001 <.0001 <.0001 
l]
  113 112 109
.4+/-3. -7.2+/-4.1 
-9.6 -9.5 
11.4, -10.6, -8.7, -5.0 -11.4, -10.4, -7.8, -1.4 -11.3, -10.4, -3.3, 0.3 
- Min, Max -9.3, 1.3 -11.2, -1.4 -11.5, -1.2 -11.5, 0.4 -11.5, 2.5 
- 95% CI mean (-1.4; -0.9) (-6.2; -5.3) (-9.7; -8.9) (-8.9; -7.8) (-8.0; -6.4) 
- 95% CI median (-1.2; -0.7) (-5.5; -4.5) (-10.0; -9.6) (-9.9; -9.0) (-9.7; -8.6) 
- p-Value (1) <.0001 <.0001 <.0001 <.0001 <.0001 
- Mean +/- SD 
 
-0.5+/- -0.7 - .  
 - Median
- p5, p25, p75, p95 
- Min, Max 
-1.7, -0.8, -0.1
-2.4, 1.0 
.5 -2.0, -1.2, -
-2.8, 1.3 
, 0.5 -2.2, -1. .0, 0.6 -0.4, -  -0.4, -0.4 
-0.4, -0.4 
 
 
- 95% CI me
 95% CI me
(-0.6; -
(-0.6; -0.4) 
(-0.8 (-   
 -
- p-Value (1) 
 
P. falciparum[
 
      
108 - N
- Mean +/- SD 
- Median 
-17705.6+/-249
-12350.0
 -33764.4+/-
 -24000
8.2 -33963.4
 -23
6564.0 -3207
0 
.4+/-28894.3 
-21150.0 
- p5, p25, -68500.0, -
-3000.0, 11500.0 
-88800.0   -8900 .0,  -8
-
000.0,  
500.0 
-47750.0,  
- Min, Max 
% CI mean - 95 (-  .3) 
) (-3400 7200.0)  -16700.0) 
<.0001 <.
 
ln(P. falciparum)[/µ
 
 
 
 
 
 
 
 
 
  
- N 115   
1 
108 
- Mean +/- SD -1.1+/-1.3 -5.8+/-2.5 -9.3+/-2.1 -8
-9.9 - Median -1.0 -5.0 
- p5, p25, p75, p95 -3.6, -1.7, -0.3, 0.5 -10.8, -7.6, -4.1, -2.9 -
(1) Wilcoxon Signed Rank Test;   Day14 is including Day 13-15 / Day28 is including Day 25-30 
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Table 12-33: Changes from baseline in lab-data by WHO-Day for level 1 (FAS) 
Characteristic D1-Baseline D2-Baseline D3-Baseline D14-Baseline 
Haemoglobin[g/     dl]  
- N 138 138 132 
 Mean +/-  .8+/- /-1.
- Median -0.7 -0.2 
25, -2 4, 0. .2, , 0.
 .3,  , 3.0
- 95% CI m 7) .0; - ; -0.0
- 95% CI median (-0.8; -0.6) (-0.4; 0.0) 
lue (1) <.0001 <.0001 0.0454 
    
. falciparum[/µl] 
138 138
+/- SD .5+/- /-28
 Median 26500 500.0
- p5, p25, -88900.0, -49000.0, 
-12400.0, -1500.0 
.0, -5
-15000.0, -2800.0 
 -54950.0,  
0, 7000.0 
, Max -97230.0, 13000.0 -97950.0, -2000.0 -98000.0, 41000.0 
- 95% CI mean (-37237.1; -28414.2) 8587.1; -2990 (-38804.7; -30063.6) ( 62.4; -27209.9
 95% CI median (- 00.0) .0; - (-33000.0; -20
- p-Value (1) <.0001 <.0001 
 
-  SD -0.8+/-0.8
7 
-0 0.8  -0.2+ 1 
-0.  
 - p5, p
- Min, Max 
 p75, p95 .2, -1.2, -0.
-5.7, 0.8
1 -2.4, -1
-5
-0.4, 0.3 
0.8 
-2.0, -0.9
-4.9
4, 1.6 
 
ean (-1.0; -0.
(-0.8; -0.7) 
(-1 0.7)  (-0.4 ) 
 
- p-Va  
 
P  
- N 
 
 
 
 
 
 
 
138 132 
- Mean 
-
-32825.7+/-26207.3 
-26325.0
-34247
 -
25780.6 
.0 
-34434.1+/-25964.1 
-26000.0
-32186.1+
 -26
900.7 
 
 p75, p95  -89500 2600.0,  -89500.0, -54000.0,  
-14000.0, -3300.0 
-83000.0,
8750.-
- Min -98000.0, -2000.0 
(-3 7.8) -371 ) 
- 31000.0; -208
01 
 (-33500 21000.0) (-33700.0; -21000.0) 350.0) 
<.00 <.0001 
(1) Wilcoxon Sig t 
 
ned Rank Tes
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Table 12-34: Changes from baseline in lab-data by WHO-Day for level 2 (FAS) 
Characteristic D1-Baseline D2-Baseline D3-Baseline D14-Baseline 
Haemoglobin[g/dl]     
- N 145 144 1 135 
- Mean +/- SD -0.8+/-0.8 -0.8+/-0.9 -2.8+/-. -0.3+/-1.
- Median 
25, p75, p95 2.2, -1.4, - - .
-2.8, 1.3 
- 95% CI mean (-0.9; -0.7) (-1.0; -0.7) (.; .) (-0.5; -0.1) 
CI median (-0.9; -0.6) (-0.9; -0.5) (.; .) (-0.4; -0.1) 
- p-Value (1) <.0001 <.0001 1.0000 0.0041 
 
P. 
  
629.4+/-2 - 7
- Median 
 p25, p75, p95 -85950.0, -44800.0,  
-10320.0, -2350.0 
-86000.0, -46500.0,  
-11000.0, -2500.0 
-86000.0, -46750.0,  
-11250.0, -2500.0 
-86000.0, -44750.0,
-9750.0, -1250.0 
 Min, Max -96000.0, -1400.0 00.0, 14000.0 500.0, -1200 6000.0, 420
- 95% CI mean -33694.5; -25564. 5.3; -26091. 21.1; -2681 347.0; -23
I med  -1 -1 ; 0
<.0001 
0 
-0.8 -0.7 -2.8 -0.2 
- p5, p
- Min, Max 
- 0.2, 0.3 -2.6, -1.5, 
-3.4, 1.7 
0.2, 0.5 -2.8, -2.8, -2.8, -2.8 -2.0, -1
-2.8, -2.8 
0, 0.4, 1.4 
-3.5, 2.2 
- 95% 
    
falciparum[/µl]     
- N
- Mean +/- SD 
145 145 144 
25478.3 970.5+
136 
+/-265-29 4765.3 73.2+/ -302  -30
-21820.0 -23500.0 -24000.0 
/-25197.3 -27844. 48.7 
-21250.0 
- p5,   
-  -965
2) (-3445
 -96
0) (-351
.0 -9
9.9) (-32
00.0 
342.4) (
(- 95% C
- p-Value (1) 
ian -28950.0; 6000.0) 30000.0; 
<.0001 
(- 6000.0) 30500.0(- -18000.0) (-27500.
<.0001 
 ; -15000.
<.0001 
0) 
(1) Wilcoxon Signed Rank Test 
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Table 12-35: Changes from baseline in lab-data by WHO-Day for level 3 (FAS) 
Characteristic D1-Baseline D2-Baseline D3-Baseline D14-Baseline D28-Baseline 
Haemoglobin[g/dl]      
- N 113 1  
      
 
an 
(-0.8; -0.4)  
 
     
 /µl]      
   
Median -21150.0 
5 -89800.0, -48000.0,  -78000.0, -47750.0,  
-11750.0, 4500.0 
00.0 
  
12 1 2 
- Mean +/- SD 
 
-0.7+/-0.7 -0.7+/-0.9 
-
-4.0+/-. 
-
-0.2+/-0.2  
- Median -0.7 0.6 4.0 -0.2
- p5, p25, p75, p95 -2.0, -1.2, -0.3, 0.5 -2.2, -1.1, 0.0, 0.6 
-
-4.0, -4.0, -4.0, -4.0 
-
-0.4, -0.4, -0.1, -0.1
 
 
- Min, Max 
 95% CI me
-2.8, 1.3 3.9, 1.2 
(-0.8; -0.5) 
4.0, -4.0 
(.; .) 
-0.4, -0.1
(-2.2; 1.7) 
 
 - (-0.8; -0.5) 
- 95% CI median 
Value (1) 
(-0.8; -0.5) (.; .) (-0.4; -0.1) 
- p- <.0001 <.0001 1.0000 0.5000 
 
arum[P. falcip  
- N 
SD 
113 112 111 99 108
- Mean +/- 
 
-33764.4+/-26328.2 -33963.4+/-26564.0 -33690.5+/-26456.5 
-24000.0 -23500.0 -23000.0 -23000.0 
-32096.0+/-26768.9 -28569.4+/-28894.3 
-
- p5, p25, p75, p9 -88800.0, -53500.0,  
-13000.0, -4000.0 
-89000.0, -55200.0,  
-13000.0, -4000.0 
-100000, -2000.0 
-89000.0, -54500.0,  
-13000.0, -4000.0 
-100000, -2000.0 
-13000.0, -3500.0 
-100000, 19000.0 - Min, Max 
- 95% CI mean 
-99700.0, -2000.0 -100  820
(-34081.2; -23057.7) 
000,
(-38671.8; -28857.1) (-38937.2; -28989.5) (-38667.0; -28714.1) (-37434.9; -26757.0) 
- 95% CI median (-33950.0; -19400.0) (-34000.0; -19500.0) (-33500.0; -19500.0) (-30000 17000.0)
<.0001 
.0; - (-300 -16700.0)
<.0001 
00.0; 
- p-Value (1) <.0001 <.0001 <.0001 
(1) Wilcoxon Signed Rank Test 
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Table 12-36: Feverflow by study day for Level 1 / 2x daily (FAS) 
Characteristic Day1 Day2 Day3 Day4 Day5 Day14 
min fever per day       
- N  72   9 9 68 
  5 .7 
       
 , , 1, 
 8 8 .6 
      
    
   9 9 68 
  5 .7 
       
 , , 1, 
 1 1 .6 
      
    
   69 9 68 
  5 .7 
       
 , , 1, 
9 9 .6 
72 69 6 6
- Mean +/- SD 
 
37.3+/- 1.0 36.2+/- 0.5 36.2+/- 0.5 36.0+/- 0.5
0
36.0+/- 0.
.0
36.8+/- 0
.7- Median 37.1 36.2 36.1 36. 36 36
- p5, p25, p75, p95 35.6, 36.6, 37.8, 
39.3 
35.5, 35.7, 36.6, 
37.2 
35.4, 35.9, 36.4,
37.3 
35.2, 35.8, 36.2
36.9 
35.2, 35.8, 36.2
36.9 
36.0, 36.4, 37.
38.4 
- Min, Max 
 
35.5, 39.7 35.2, 37.4 35.1, 37.5 35.0, 37. 35.0, 37. 35.6, 39
mean fever per day 
  
  
- N 72 72 69 6 6
- Mean +/- SD 
 
38.1+/- 0.8 37.0+/- 0.6 36.6+/- 0.5 36.4+/- 0.5
3
36.4+/- 0.
.3
36.8+/- 0
.7- Median 38.0 36.9 36.5 36. 36 36
- p5, p25, p75, p95 37.0, 37.4, 38.7, 
39.5 
36.1, 36.5, 37.5, 
38.0 
36.0, 36.3, 36.8,
37.6 
35.9, 36.1, 36.5
37.1 
35.9, 36.1, 36.5
37.1 
36.0, 36.4, 37.
38.4 
- Min, Max 
 
36.5, 39.9 36.0, 38.7 35.9, 38.2 35.8, 39. 35.8, 39. 35.6, 39
max fever per day 
  
  
- N 72 72 69 6
- Mean +/- SD 
 
38.9+/- 0.8 37.9+/- 1.1 37.1+/- 0.7 36.8+/- 0.5
7
36.8+/- 0.
.7
36.8+/- 0
.7- Median 39.0 37.8 36.9 36. 36 36
- p5, p25, p75, p95 37.6, 38.2, 39.5, 
40.3 
36.5, 37.0, 38.5, 
39.8 
36.4, 36.7, 37.2,
38.7 
36.2, 39.4 
36.2, 36.5, 37.0
37.5 
36.2, 36.5, 37.0
37.5 
36.0, 36.4, 37.
38.4 
- Min, Max 37.5, 41.0 36.3, 40.4 36.0, 39. 36.0, 39. 35.6, 39
min fever means the minimum of all fever measurements per calendar day of one patient; max, mean respectively 
D14 is the 14th day after first drug intake, but including of day 13 and 15 
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Table 12-37: Feverflow by study day for Level 2 / 2x daily (FAS) 
Characteristic Day1 Day2 Day3 Day4 Day5 Day14 
min fever per day       
- N  72      
       
      
      
       
      
      
       
71 68 68 68 64
- Mean +/- SD 
 
36.9+/- 0.8 36.3+/- 0.6 36.2+/- 0.5 36.1+/- 0.4 36.1+/- 0.4 36.5+/- 0.5 
- Median 36.9 36.1 36.2 36.1 36.1 36.5
- p5, p25, p75, p95 35.5, 36.4, 37.4, 
38.1 
35.5, 35.9, 36.6, 
37.5 
35.5, 35.8, 36.4, 
36.9 
35.4, 35.8, 36.3, 
36.7 
35.4, 35.8, 36.3, 
36.7 
35.7, 36.2, 36.8, 
37.1 
- Min, Max 
 
35.4, 38.7 35.0, 38.1 35.2, 37.7 35.0, 37.4 35.0, 37.4 35.2, 38.3 
mean fever per day 
  
      
- N 72 71 68 68 68 64
- Mean +/- SD 
 
37.8+/- 0.6 36.9+/- 0.7 36.7+/- 0.5 36.5+/- 0.3 36.5+/- 0.3 36.5+/- 0.5 
- Median 37.8 36.8 36.6 36.4 36.4 36.5
- p5, p25, p75, p95 36.8, 37.4, 38.2, 
38.8 
36.1, 36.5, 37.3, 
38.2 
36.1, 36.4, 36.9, 
38.0 
36.0, 36.2, 36.6, 
37.0 
36.0, 36.2, 36.6, 
37.0 
35.7, 36.2, 36.8, 
37.1 
- Min, Max 
 
36.7, 39.4 36.0, 38.8 36.0, 38.3 35.8, 37.5 35.8, 37.5 35.2, 38.3 
max fever per day 
- N 
      
72 71
37.7+/- 1.0 
68 68 68 64
- Mean +/- SD 
 
38.8+/- 0.8 37.2+/- 0.7 36.8+/- 0.4 36.8+/- 0.4 36.5+/- 0.5 
- Median 38.9 37.5 37.1 36.8 36.8 36.5
- p5, p25, p75, p95 37.5, 38.0, 39.4, 
40.1 
36.5, 36.9, 38.3, 
39.7 
36.4, 36.8, 37.4, 
38.7 
36.4, 36.5, 37.0, 
37.6 
36.4, 36.5, 37.0, 
37.6 
35.7, 36.2, 36.8, 
37.1 
- Min, Max 37.5, 40.4 36.2, 40.2 36.3, 39.8 36.3, 38.3 36.3, 38.3 35.2, 38.3 
min fever means the minimum of all fever measurements per calendar day of one patient; max, mean respectively 
D14 is the 14th day after first drug intake, but including of day 13 and 15 
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Table 12-38: Feverflow by study day for Level 3 / 2x daily (FAS) 
Characteristic Day1 Day2 Day3 Day4 Day5 Day14 Day28 
min fever per day        
- N  53 53 52 51 51 50 
36 36.1+/- .1+/- 0.4  0.4  36. 36.7+/- 
 36.8 36.1 36.1 36.2 36.2 
35.5
36.
 35
36.4, 36.8 
, 
8 36.5, 36.8 
5.9,
35 35.1, 3 35.2, 37.1  36.9  35. 35.6, 38
     
       
53 53 52 51 51 50 
37 36.7+/- .5+/- 0.3  0.4  36. 36.7+/- 
 37.6 36.7 36.5 36.5 36.5 
36.0
37.
 36
36.7, 37.0 
, 
1 
5.9,
36 35.9, 3 35.9, 37.5  37.4  35. 35.6, 38
     
       
53 53 52 51 51 50 
38 37.4+/- 0.7 36.9+/- 0.3  0.4  36. 36.7+/- 
 39.0 37.3 36.9 36.8 36.8 
39.4, 40.1 
36.3
37.
 36
37.1, 37.6 
, 
3 
5.9,
37 36.3, 3 36.3, 38.1  38.3  35. 35.6, 38
50 
- Mean +/- SD .7+/- 0.7  0.5 36  36.2+/- 36.2+/- 0.4 7+/- 0.6 
36.6 
0.6 
- Median 36.6 
- p5, p25, p75, p95 35.6, 36.2, 
37.2, 37.8 
, 35.8, 
3, 37.0 
35.4, .8, 35.5, 35.9
36.5, 36.
35.5, 35.9, 35.9, 36.3, 
36.9, 37.8 
3  36.3, 
36.9, 37.8 
- Min, Max 
 
.4, 38.2 7.2 35.0, 35.0, 36.9 6, 38.3 
 
.3 
 
mean fever per day 
  - N 50 
- Mean +/- SD .7+/- 0.5  0.5 36  36.5+/- 36.5+/- 0.4 7+/- 0.6 
36.6 
0.6 
- Median 36.6 
- p5, p25, p75, p95 37.0, 37.3, 
38.0, 38.5 
, 36.4, 
1, 37.6 
36.1, .3, 35.8, 36.3
36.7, 37.
35.8, 36.3, 
36.7, 37.1 
35.9, 36.3, 
36.9, 37.8 
3  36.3, 
36.9, 37.8 
- Min, Max 
 
.8, 38.8 7.9 35.7, 35.7, 37.4 6, 38.3 
 
.3 
 
max fever per day 
  - N 50 
- Mean +/- SD .9+/- 0.8 36.8+/- 36.8+/- 0.4 7+/- 0.6 
36.6 
0.6 
- Median 36.6 
- p5, p25, p75, p95 37.6, 38.2, , 36.8, 
8, 38.7 
36.5, .7, 36.1, 36.5
37.1, 37.
36.1, 36.5, 
37.1, 37.3 
35.9, 36.3, 
36.9, 37.8 
3  36.3, 
36.9, 37.8 
- Min, Max .5, 40.3 9.4 36.0, 36.0, 38.3 6, 38.3 .3 
min fever means the minimum of all fever measurements per calendar day of one patient; max, mean respectively 
D14 is the 14th day after first drug intake, but including of day 13 and 15 
D28 is the 28th day after first drug intake, but including of day 25, 26, 27, 29, 30 
 
 
 
Dose finding trial - BlueCQ-3-Report 
 
 Page 92 of 149   
Table 12-39: Feverflow by WHO-Day for Level 1 / 2x daily (FAS) 
Characteristic D0 D1 D2 D3 D14 
min fever per day      
- N 72 7 69 68 
/- 0. 3 36.0+/- 0.6 6.5+
36.2 35.9 
- p5, p25, p75, p95 35 5.8, 36. .5, .5 36.2, 36.2, 36.0, 36.4, 37.1, 38.2 
- Min, Max 35.2, 38. 39.4 35.2, 35.6, 39.0 
    
an fever per day   
72 72 69 68 
37.2+/- 0.8 .4+/- 0.5 36.7+/- 0.
37.1 3 36
, p95 36.2, 36.6, 37.7, 38.7 36.5, 36.5,  38.2 
- Min, Max 35.7, 39. 39.7 35.7, 35.6, 39.0 
    
r day   
- N 72 72 69 68 
38.2+/- 1.1 37.6+/- 1.0 6.9+/- 0.6 36.9+/- 0.4
38.2 36.8 36.9 36.7 
, p95  39. .6, 36.8, 38.1, 39.7 37.1, 36.6, 36.0, 38.2 
, 40.5 36.3  36 39.9 35.9,
2 64 
- Mean +/- SD 36.3+ 6 6.2+/- 0.6 
36.2 
3 /- 0.5 
36.4 
36.8+/- 0.6 
- Median 36.7 
.5, 3 7, 37.4 35
1 
35.9, 36.5, 37
35.1, 37.8 
35.2, 35.6, 
35.0, 
 36.9 35.8,  36.7, 37.3
 38.1 
 
 
 
me   
- N 
- Mean +/- SD 
 64 
36.8+/- 0.6 36 4 36.8+/- 0.6 
- Median 
, p75
36.7 36.
35. .2, 
.6 
 36. .4
36.7 
36.0, 36.4, 37.1,- p5, p25 36.1, 36.4, 37.3, 38.1 9, 36  37. .0, 2 36 9, 37
2 35.9, 38.7 35.8, 
 
 38.1 
 
max fever pe    
 64 
- Mean +/- SD 
- Median 
3  36.8+/- 0.6 
37.3 
- p5, p25, p75 36.9, 37.3,
6.5
3, 40.1 36
 
36.2, 36.5, 
.1, 
 37.5 36.2,  37.1, 37.6
 38.
 36.4, 37.1, 
- Min, Max 3 , 40.4 1 35.6, 39.0 
min fever means the mini ver per W  pati n res
D14 is the 14th day afte  intak tolera d +3 s 
 
mum of all fe
r first drug
measurements 
e, but with 
HO-Day of one
nce of -3 an
ent; max, mea
calendar day
pectively 
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Table 12-40: Feverflow by WHO-Day for Level 2 / 2x daily (FAS) 
Characteristic D0 D1 D2 D3 D14 
min fever per day      
- N 72 68 68 
- p5, p25, p75, p95 
- Min, Max 
    
- p5, p25, p75, p95 
  
- Mean +/- SD 
- Median 
- p5, p25, p75, p95 36.8, 37.3, 38.7, 39.9 
67 64 
- Mean +/- SD 36.2+/- 0.6 36.2+/- 0.5 36.0+/- 0.4 36.4+/- 0.4 36.5+/- 0.5 
- Median 36.1 
35.4, 35.9, 36.6, 37.5 
36.1 
35.5, 35.8, 36.5, 36.9 
36.0 36.4 36.5 
35.4, 35.7, 36.3, 36.7 35.7, 36.1, 36.6, 37.1 35.7, 36.2, 36.8, 37.1 
35.0, 37.5 35.2, 37.8 35.0, 37.2 35.5, 38.2 
 
35.2, 38.3 
 
mean fever per day 
- N 
     
72 
37.1+/- 0.7 
68 68 67 64 
- Mean +/- SD 36.8+/- 0.6 
36.7 
36.6+/- 0.4 36.6+/- 0.4 36.5+/- 0.5 
- Median 36.8 36.6 36.5 36.5 
36.2, 36.6, 37.4, 38.4 36.2, 36.4, 37.2, 38.0 36.0, 36.3, 36.8, 37.4 36.0, 36.3, 36.8, 37.2 35.7, 36.2, 36.8, 37.1 
- Min, Max 35.9, 38.8 
  
36.0, 38.4 35.7, 38.0 35.9, 38.3 
 
35.2, 38.3 
 
max fever per day   
68 
   
- N 72 68 67 64 
38.0+/- 1.0 
37.7 
37.5+/- 0.9 
37.2 
37.1+/- 0.7 36.8+/- 0.4 36.5+/- 0.5 
37.1 36.8 36.5 
36.4, 36.9, 37.9, 39.5 36.3, 36.7, 37.4, 38.4 36.3, 36.4, 37.0, 37.5 35.7, 36.2, 36.8, 37.1 
- Min, Max 36.5, 40.4 36.3, 40.2 36.1, 39.7 35.9, 38.3 35.2, 38.3 
min fever means the minimum of all fever measurements per WHO-Day of one patient; max, mean respectively 
D14 is the 14th day after first drug intake, but with tolerance of -3 and +3 calendar days 
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Table 12-41: Feverflow by WHO-Day for Level 3 / 2x daily (FAS) 
Characteristic D0 D1 D2 D3 D14 D28 
min fever per day       
- N  53 52 51 51 46 49 
36.1+ 36.1+/- 0.4 36.0+/- 0.4 +/- 0.5 - 0.5  0.4 
 36.0 36.1 .5 36.5 
35.4, 35.8, 36.4, 
36.9 
35.5, 35.8, 36.3, 
36.8 
35.4, 35.8, 36.3, 
36.8 
7, 36.0, 
37.0 
6 , 
35.1, 37.1 35.2, 37.0 35.0, 37.3 35.3, 38.3 35.6, 38.3 7.5 
      
      
53 52 51 51 6  
36.9+ 36.6+/- 0.4 36.5+/- 0.3 36.6+/- 0.4 - 0.5  0.4 
3 .5  36.5  
36
37
, 3
37.4 
3
37.1 
 36.8, 
37.1 
.2, 36
.3 
, 
 
- Min, Max 36.1, 38.3 36.1, 37.6 35.8, 37.6 35.9, 38.4 35.6, 38.3 35.9, 37.5 
      
max fever per day       
- N 53 52 51 51 46 49 
37.8+/- 0.7 37.3+/- 0.7 37.0+/- 0.4 36.8+/- 0.4 36.6+/- 0.5 36.6+/- 0.4 
37.1 37.0 36.8 36.5 36.5 
36.4, 36.8, 37.6, 36.4, 36.7, 37.1, 36.2, 36.5, 37.0, .2, 36.8, 
37.3 
, 36.8, 
37.3 
35.9, 38.4 35.6, 38.3 35.9, 37.5 
- Mean +/- SD 
 
/- 0.5 36.4
36.0 36.4 
36.6+/
36
36.6+/-
 - Median
- p5, p25, p75, p95 35. 36.6, 35.9, 36.2, 3
37.3 
.8, 36.0, 36.3, 36.8
37.3 
- Min, Max  35.9, 3
 
mean fever per day 
- N  
- Mean +/- SD 
  4
36.6+/
49
36.6+/-/- 0.4 
-  
- p5, p25, p75, p95 
Median 36.9 
.3, 36.7, 37.1, 36.1
6.6 36
6.3, 37.0, 36.0, 36.
  36.6
, 36.6, 36.0, 36.3,
 36.5
.8, 36.0, 36.3, 36.8
.8 
35.9, 36
37 37.3
 
 
- Mean +/- SD 
- Median 37.8 
- p5, p25, p75, p95 36.8, 37.3, 38.2, 
39.1 38.5 37.6 37.3 
35.9, 36 36.0, 36.3
- Min, Max 36.3, 39.4 36.3, 38.7 36.0, 38.1 
min fever means the minimum of all fever measurements per WHO-Day of one patient; max, mean respectively 
4 is the 14th day after first drug intake, but with tolerance of -3 and +3 calendar days 
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Table 12-42: Feverflow by study day for Level 1 / 4x daily (FAS) 
Characteristic Day1 Day2 Day3 Day4 Day5 Day14 
min fever per day       
- N  75
37.1+/- 0.8 
   0 70 70 
  5 .5 
 37.0      
- p5, p25, p75, p95  , 35.2, 35.7, 36.4, 
36.8 
9, 
 3 35.0, 37.3 35.6, 38.0 
   
    
   0 0 70 
  4 .5 
       
 , , 9, 
- Min, Max  7 35.8, 37.7 35.6, 38.0 
       
    
   0 0 70 
 5 .5 
       
40.2 38.7 
, , 9, 
 6 6 .0 
75 71 7
- Mean +/- SD 
 
36.2+/- 0.7 
36.1
36.2+/- 0.5 36.0+/- 0.5
1
36.0+/- 0.
.1
36.6+/- 0
.7- Median 36.2 36. 36 36
35.9, 36.5, 37.8, 
38.6 
35.4, 35.8, 36.4, 
37.7 
35.5, 35.9, 36.5,
37.1 
35.2, 35.7, 36.4
36.8 
35.6, 36.4, 36.
37.5 
- Min, Max 35.5, 39.3 35.1, 38.4 35.1, 37.7
    
35.0, 37.
mean fever per day 
  
  
- N 75
38.0+/- 0.8 
75 71 7 7
- Mean +/- SD 
 
37.0+/- 0.7 
36.8
36.7+/- 0.5 36.5+/- 0.4
5
36.5+/- 0.
.5
36.6+/- 0
.7- Median 37.9 36.7 36. 36 36
- p5, p25, p75, p95 37.1, 37.4, 38.5, 
39.5 
36.0, 36.5, 37.5, 
38.3 
36.0, 36.4, 37.0,
37.7 
35.9, 36.2, 36.6
37.3 
35.9, 36.2, 36.6
37.3 
35.6, 36.4, 36.
37.5 
35.5, 40.0 35.6, 38.9 35.9, 38.3 35.8, 37.
max fever per day 
  
  
- N 75 75 71
37.2+/- 0.6 
7 7
- Mean +/- SD 
 
38.9+/- 0.9 37.7+/- 0.9 36.9+/- 0.5
8
36.9+/- 0.
.8
36.6+/- 0
.7- Median 39.0
37.6, 38.2, 39.7, 
37.5 37.0
36.3, 36.8, 37.4, 
36. 36 36
- p5, p25, p75, p95 36.4, 36.9, 38.3, 
39.2 
36.4, 36.6, 37.0
38.1 
36.4, 36.6, 37.0
38.1 
35.6, 36.4, 36.
37.5 
- Min, Max 35.5, 40.7 35.8, 40.1 36.0, 39.0 36.3, 38. 36.3, 38. 35.6, 38
min fever means the minimum of all fever measurements per calendar day of one patient; max, mean respectively 
 
 
D14 is the 14th day after first drug intake, but including of day 13 and 15 
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Tabl : e AS) e 12-43 F verflow by study day for Level 2 / 4x daily (F
Characteristic Day1 Day2 Day3 Day4 Day5 Day14 
min fever per day       
- N  78     74 
  36.2     
      
mean fever per day 
       74 
       
- p5, p25, p75, p95 
37.7 
      
max fever per day 
     7    
       
77
36.3+/- 0.6 
77 77 77
- Mean +/- SD 
 
37.1+/- 0.8 36.3+/- 0.6 36.0+/- 0.5 36.0+/- 0.5 36.7+/- 0.6 
- Median 36.9 36.2 36.0 36.0 36.6
- p5, p25, p75, p95 35.8, 36.6, 37.5, 
38.6 
35.4, 35.9, 36.5, 
37.5 
35.5, 35.9, 36.8, 
37.4 
35.4, 35.7, 36.3, 
37.1 
35.1, 37.3 
35.4, 35.7, 36.3, 
37.1 
36.0, 36.3, 36.9, 
37.7 
- Min, Max 
 
35.6, 39.6 35.0, 37.7 35.4, 37.9 35.1, 37.3 35.0, 39.5 
      
- N 78 77 77 77 77
- Mean +/- SD 
 
38.0+/- 0.7 37.0+/- 0.7 36.8+/- 0.7 36.5+/- 0.5 36.5+/- 0.5 36.7+/- 0.6 
- Median 37.9 36.8 36.5 36.4 36.4 36.6
36.0, 36.3, 36.9, 37.1, 37.5, 38.3, 
39.2 
36.1, 36.5, 37.4, 
38.4 
36.1, 36.3, 37.2, 
38.2 
35.9, 36.1, 36.7, 
37.6 
35.9, 36.1, 36.7, 
37.6 
- Min, Max 
 
36.8, 39.6 35.7, 39.1 35.7, 38.8 35.7, 38.1 35.7, 38.1 35.0, 39.5 
    
7
  
- N 78 77
37.9+/- 1.2 
77 77 74
- Mean +/- SD 
 
39.1+/- 0.7 37.2+/- 0.8 36.9+/- 0.7 36.9+/- 0.7 36.7+/- 0.6 
- Median 39.1 37.6 37.0 36.8 36.8 36.6
- p5, p25, p75, p95 37.8, 38.5, 39.6, 
40.1 
36.5, 37.0, 38.8, 
40.0 
35.9, 40.4 
36.3, 36.7, 37.5, 
38.9 
36.1, 36.5, 37.2, 
38.2 
36.1, 36.5, 37.2, 
38.2 
36.0, 36.3, 36.9, 
37.7 
- Min, Max 37.5, 40.8 36.3, 39.9 35.8, 39.9 35.8, 39.9 35.0, 39.5 
min fever means the minimum of all fever measurements per calendar day of one patient; max, mean respectively 
D14 is the 14th day after first drug intake, but including of day 13 and 15 
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Tabl : e AS) e 12-44 F verflow by study day for Level 3 / 4x daily (F
Characteristic Day1 Day2 Day3 Day4 Day5 Day14 Day28 
min fever per day        
- N  62 62 61 61 61 60 
36 36.2+/- .1+/- 0.5  0.4  36. 36.6+/- 
36.8 36.1 36.0 36.1 36.1 
35.5
36.
 35
36.4, 36.9 
, 
8 36.3, 36.8 
5.9,
35 35.2, 37.7 35.2, 37.6  36.9  35. 35.6, 38
     
       
62 62 61 61 61 60 
37 36.8+/- .6+/- 0.4  0.3  36. 36.6+/- 
 37.5 36.7 36.6 36.4 36.4 
36.1
37.
 36
36.8, 37.2 
, 
0 
5.9,
36 36.0, 3 35.8, 38.1  37.1  35. 35.6, 38
     
       
62 62 61 61 61 60 
38 37.4+/- .0+/- 0.5  0.4  36. 36.6+/- 
 38.6 37.2 36.9 36.8 36.8 
36.5
38.
 36
37.2, 37.8 
, 
4 
5.9,
37 36.3, 3 36.2, 38.9  37.6  35. 35.6, 38
60 
- Mean +/- SD 
- Median 
.7+/- 0.7  0.5 36  36.2+/- 36.2+/- 0.4 6+/- 0.5 
36.6 
0.5 
36.6 
- p5, p25, p75, p95 35.6, 36.0, 
37.2, 37.6 
, 35.9, 
6, 37.1 
35.5, .8, 35.6, 35.9
36.3, 36.
35.6, 35.9, 35.9, 36.3, 
36.8, 37.5 
3  36.3, 
36.8, 37.5 
- Min, Max 
 
.5, 38.4 35.5, 35.5, 36.9 6, 38.7 
 
.7 
 
mean fever per day 
  - N 60 
- Mean +/- SD .5+/- 0.5  0.6 36  36.5+/- 36.5+/- 0.3 6+/- 0.5 
36.6 
0.5 
- Median 36.6 
- p5, p25, p75, p95 36.7, 37.2, 
37.8, 38.4 
, 36.4, 
0, 38.0 
36.1, .3, 36.0, 36.2
36.7, 37.
36.0, 36.2, 
36.7, 37.0 
35.9, 36.3, 
36.8, 37.5 
3  36.3, 
36.8, 37.5 
- Min, Max 
 
.6, 38.8 8.3 35.9, 35.9, 37.1 6, 38.7 
 
.7 
 
max fever per day 
- N 60 
- Mean +/- SD .6+/- 0.8  0.8 37  36.8+/- 36.8+/- 0.4 6+/- 0.5 
36.6 
0.5 
- Median 36.6 
- p5, p25, p75, p95 37.5, 38.0, 
39.4, 40.1 
, 36.8, 
0, 39.1 
36.4, .7, 36.2, 36.5
37.1, 37.
36.2, 36.5, 
37.1, 37.4 
35.9, 36.3, 
36.8, 37.5 
3  36.3, 
36.8, 37.5 
- Min, Max .5, 40.2 9.7 36.1, 36.1, 37.6 6, 38.7 .7 
min fever means the minimum of all fever measurements per calendar day of one patient; max, mean respectively 
D14 is the 14th day after first drug intake, but including of day 13 and 15 
28 is the 28th day after first drug intake, but including of day 25, 26, 27,D  29, 30 
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Tabl : ev AS) e 12-45 F erflow by WHO-Day for Level 1 / 4x daily (F
Characteristic D0 D1 D2 D3 D14 
min fever per day      
- N 75 72 70 70 
/- 0. 3  0.6 6.5+
36.1 
 36. .4, .2 36.3, 36.2, 35.6, 37.5 
 38. 37.7 35.4,
   
er day   
75 72 70 70 
7.1+/- 0.7 5+/- 0.5 36.7+/- 0.5 36.6+/- 0.5 
- Median .9 5 36
, p75, p95 , 37.8 36.7, 36.4,  37.5 
 38. 35.8, 38.4 38.0 35.8,
   
max fever per day   
- N 75 72 70 70 
38.0+/- 1.0 37.6+/- 0.9 37.0+/- 0.5 36.9+/- 0.6 
37.8 37.4 37.0 36.8 36.7 
- p5, p25, p75, p95  38. .4, .1 37.1, 36.6, 37.0, 37.5 35.6, 36.4, 36.9, 37.5 
, 40.4 3 38.6 35.8, 39
69 
- Mean +/- SD 36.3+ 7 6.3+/- 0.5 
3
36.0+/-
36.0 
 3 /- 0.5 
36.5 
36.6+/- 0.5 
- Median 6.2 36.7 
- p5, p25, p75, p95 
- Min, Max 
35.4, 35.8,
35.1,
7, 37.7 35
0 
35.9, 36.7, 37
35.1, 37.9 
35.1, 35.6, 
35.0, 
 37.2 35.7,  36.7, 37.0
 38.6 
 36.4, 36.9, 
35.6, 38.0 
 
 
  
mean fever p   
- N 
an +/- SD 
69 
- Me 3 36.9+/- 0.6 36.
36
36 6.5
36.8 36.
35. .2, 
.7 
 36. .3
36.7 
35.6, 36.4, 36.9,- p5, p25 .1, 3 , 38.5 36.0, 36.4, 37.3, 38.1 8, 36  37. .1, 4 36 9, 37
- Min, Max 35.9, 9 35.5, 
 
 39.2 35.6, 38.0 
  
   
 69 
- Mean +/- SD 
- Median 
36.6+/- 0.5 
36.6, 37.1,
6.2
7, 40.0 36
 
36.9, 38.3, 39
6.0  
36.3, 36.7, 
.9, 
 38.1 36.3, 
- Min, Max 3 , 39.2 35 .8 35.6, 38.0 
min fever means the mini ver per W  pati n res
D14 is the 14th day afte  intak tolera d +3 s 
 
mum of all fe
r first drug
measurements 
e, but with 
HO-Day of one
nce of -3 an
ent; max, mea
calendar day
pectively 
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Tab : e AS) le 12-46 F verflow by WHO-Day for Level 2 / 4x daily (F
Characteristic D0 D1 D2 D3 D14 
min fever per day      
- N 77 
36.3+/- 0.6 
77 77 
36.0+/- 0.5 
77 
36.4+/- 0.6 
72 
- Mean +/- SD 36.3+/- 0.6 36.6+/- 0.5 
- Median 36.2 36.2 36.0 36.3 
    
77 
    
36.6 
- p5, p25, p75, p95 35.4, 35.9, 36.6, 37.5 35.5, 35.9, 36.8, 37.5 35.4, 35.7, 36.3, 37.0 35.6, 36.1, 36.7, 37.7 36.0, 36.3, 36.9, 37.7 
- Min, Max 35.0, 37.9 35.4, 37.9 35.1, 37.3 35.6, 38.4 
 
35.0, 38.6 
 
mean fever per day      
- N 77 77 77 72 
- Mean +/- SD 37.2+/- 0.7 
37.1 
36.9+/- 0.7 36.6+/- 0.5 36.7+/- 0.6 36.6+/- 0.5 
- Median 36.7 36.5 36.6 36.6 
- p5, p25, p75, p95 36.2, 36.6, 37.7, 38.6 
35.9, 38.8 
36.0, 36.4, 37.5, 38.2 35.9, 36.3, 36.9, 37.5
35.8, 38.0 
36.0, 36.3, 36.9, 38.1 36.0, 36.3, 36.9, 37.7 
- Min, Max 35.7, 39.2 35.9, 39.2 
 
35.0, 38.6 
 
max fever per day      
- N 77 77 77 77 72 
- Mean +/- SD 38.2+/- 1.1 37.7+/- 1.1 37.2+/- 0.8 36.9+/- 0.6 36.6+/- 0.5 
- Median 38.2 37.4 37.0 36.8 36.6 
- p5, p25, p75, p95 36.7, 37.2, 39.2, 39.8 36.5, 36.9, 38.7, 40.0 36.4, 36.7, 37.4, 38.9 36.3, 36.5, 37.1, 38.2 36.0, 36.3, 36.9, 37.7 
- Min, Max 36.2, 40.3 35.9, 40.4 36.1, 39.9 36.0, 39.9 35.0, 38.6 
min fever means the minimum of all fever measurements per WHO-Day of one patient; max, mean respectively 
D14 is the 14th day after first drug intake, but with tolerance of -3 and +3 calendar days 
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Tab : e AS) le 12-47 F verflow by WHO-Day for Level 3 / 4x daily (F
Characteristic D0 D1 D2 D3 D14 D28 
min fever per day       
- N  62 61 61 60 53 59 
36.1+ 36.1+/- 0 36.1+/- 0.4 +/- 0.4 - 0.5  0.6 
 36.1 36.0 .5 36.5 
35 , 3 8  6.8, 35.9, 36.2, 36.8, 
5 
35.3, 35.2, 37.0 35.5, 37.1 35.5, 37.2 35.6, 38.7 40.0 
      
      
62 61 61 60 3 59 
36.9+ 36.7+/- 0.4 36.5+/- 0.4 36.5+/- 0.3 - 0.5 +/- 0.6 
3 .5  
36
37
, 3
37.4 
4
37.2 
 
37.1 
6
.8 
, 
5 
- Min, Max 36.0, 38.6 36.0, 37.8 35.8, 37.6 35.7, 37.3 35.6, 38.7 35.8, 40.0 
      
fever per day       
62 61 61 60 53 59 
37.7+/- 0.9 37.3+/- 0.7 37.0+/- 0.5 36.7+/- 0.4 .5+/- 0.5 36.6+/- 0.6 
- Median 3 9  36.5 
36.5, 36.8, 37.8, 36.3, 36.7, 37.2, 36.5, 37.0, .2, 36.8, 
37.8 
, 36.8, 
37.5 
35.8, 37.5 35.6, 38.7 35.8, 40.0 
- Mean +/- SD 
 
/- 0.5 .4 36.3
36.1 36.3 
36.5+/
36
36.6+/-
 - Median
- p5, p25, p75, p95 .5, 35.7, 36.5, 
37.1 
35.4 5.8, 36.3, 
36.7 
35.5, 35.
36.8 
, 36.3, 35.6, 36.1,
37.0 
36.5, 35.9, 36.2, 3
37.8 37.
35.8, - Min, Max  37.3 
 
mean fever per day 
- N  
- Mean +/- SD 
  5
36.5+//- 0.6 36.6
- Median 
- p5, p25, p75, p95 
36.8 
.2, 36.5, 37.2, 36.1
6.6 36
6.5, 36.9, 35.9, 36.
 36.5
, 36.8, 36.0, 36.3,
 36.5
36.7, 35.9, 36.2, 3
 36.5
.8, 35.9, 36.2, 36.8
.9 37 37.
 
 
max 
- N 
- Mean +/- SD 36
37.6 7.2 36.  36.8 36.5
- p5, p25, p75, p95 36.6, 37.1, 38.2, 
39.3 38.8 37.7 37.3 
36.2, 35.9, 36 35.9, 36.2
- Min, Max 36.2, 40.2 36.3, 39.1 35.8, 38.6 
min fever means the minimum of all fever measurements per WHO-Day of one patient; max, mean respectively 
D14 is the 14th day after first drug intake, but with tolerance of -3 and +3 calendar days 
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Table 12-48: Feverflow by study day for Level 1 (FAS) 
Characteristic Day1 Day2 Day3 Day4 Day5 Day14 
min fever per day       
- N  147    39 38 
- Mean +/- SD   5 .6 
        
 , , 35.8, 36.4, 37.0, 
37.9 
8 8 .6 
      
     
    39 38 
  4 36.7+/- 0.6 
      .7 
 , 35.9, 36.2, 36.6, 
37.3 
0, 
 1 1 .6 
      
    
    39 38 
  5 .6 
      
 , , 0, 
 9 9 .6 
147 140 139 1 1
37.2+/- 0.9 36.2+/- 0.6 36.2+/- 0.5 36.0+/- 0.5
36.0
36.0+/- 0.
.0
36.7+/- 0
.7- Median 37.0 36.2 36.2 36 36
- p5, p25, p75, p95 35.8, 36.6, 37.8, 
39.2 
35.4, 35.7, 36.6, 
37.3 
35.5, 35.9, 36.5,
37.2 
35.1, 37.7 
35.2, 35.7, 36.3
36.9 
35.2, 35.7, 36.3
36.9 
- Min, Max 
 
35.5, 39.7 35.1, 38.4 35.0, 37. 35.0, 37. 35.6, 39
mean fever per day 
  
 
- N 147
38.0+/- 0.8 
147 140 139 1 1
- Mean +/- SD 
 
37.0+/- 0.7 36.7+/- 0.5 36.4+/- 0.4
4
36.4+/- 0.
.4- Median 38.0 36.8 36.6 36. 36 36
- p5, p25, p75, p95 37.1, 37.4, 38.5, 
39.5 
36.1, 36.5, 37.5, 
38.1 
35.6, 38.9 
36.0, 36.3, 36.9,
37.6 
35.9, 36.2, 36.6
37.3 
35.8, 36.4, 37.
37.9 
- Min, Max 
 
35.5, 40.0 35.9, 38.3 35.8, 39. 35.8, 39. 35.6, 39
max fever per day 
  
  
- N 147 147 140 139 1 1
- Mean +/- SD 
- Median 
38.9+/- 0.9 37.8+/- 1.0 37.1+/- 0.7 36.8+/- 0.5
7
36.8+/- 0.
.7
36.7+/- 0
.739.0 37.6 37.0 36. 36 36
- p5, p25, p75, p95 37.6, 38.2, 39.6, 
40.2 
36.5, 36.9, 38.5, 
39.6 
36.3, 36.7, 37.3,
38.7 
36.3, 36.5, 37.0
37.8 
36.3, 36.5, 37.0
37.8 
35.8, 36.4, 37.
37.9 
- Min, Max 35.5, 41.0 35.8, 40.4 36.0, 39.4 36.0, 39. 36.0, 39. 35.6, 39
min fever means the minimum of all fever measurements per calendar day of one patient; max, mean respectively 
D14 is the 14th day after first drug intake, but including of day 13 and 15 
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Table 12-49: Fever  by study day for Level 2 (FAS) flow
Characteristic Day1 Day2 Day3 Day4 Day5 Day14 
min fever per day       
- N 150 148 138 
- Mean +/- SD 37.0+/- 0.8 36.3+/- 0.6  36.6+/- 0.6 
- Median 36.9 36.2 36.5 
- p5, p25, p75, p95 35.6, 36.5, 37.4, 
38.4 
35.5, 35.9, 36.5, 
37.5 
. .9, 36.2, 36.9, 
37.6 
- Min, Max 35.4, 39.6 35.0, 38.1  35.0, 39.5 
    
mean fever per day     
- N 150 148 145 145 145 138 
- Mean +/- SD 37.9+/- 0.6 37.0+/- 0.7 6.7+/- 0.6 36.5+/- 0.4 36.6+/- 0.6 
- Median 37.9 36.8 36.6 36.4 36.4 36.5 
- p5, p25, p75, p95 36.9, 37.4, 38.3, 
39.1 
36.1, 36.5, 37.3, 
38.4 
, 36.4, 37.0, 
38.0 37.4 
35.9, 36.2, 36.6, 
37.4 
.9, 36.2, 36.9, 
37.6 
- Min, Max 36.7, 39.6 35.7, 39.1 35.7, 38.8 35.7, 38.1 35.7, 38.1 35.0, 39.5 
       
max fever per day       
- N 150 148 145 145 145 138 
- Mean +/- SD 38.9+/- 0.8 37.8+/- 1.1  .9 36.6+/- 0.6 
- Median 36.5 
- p5, p25, p75, p95 37.5, 38.4, 39.5, 
40.1 
36.5, 36.9, 38.7, 
39.9 
 3 .9, 36.2, 36.9, 
37.6 
- Min, Max 37.5, 40.8 35.9, 40.4 5  . 35.0, 39.5 
1
2+
36
35
37
2,
45
/- 
.2
.8,
.3
 3
 
 
, 
 
14
.1+/
36
 35.
36
35.0, 37.4 
 
36.5+/- 0.4 
35.9, 36.2, 36.6, 
5
- 
.0
7,
.9 
 
 
 
14
+/
6.
5.
6.
, 
 
5
- 0
0
7, 
9 
37
 
 
, 
 
3
35.5
3
36.1
3
36.4
6.
, 
35.
0.
 3
 
7.9
5 
6.6
36
.4,
0.4
 36
36
.4,
3
.1
3
 3
3
5.0
.4
36
.4
 
.3
 
35 3, 35 35
35
35
7.
, 
36.
2+
39.0 37.5 37.1 36.8 
36
38
3,
/- 
.7,
.8
 3
0.
 3
 
9.
7 
7.
9 
36
.3
3
.9+/
36.
37
.8,
- 
5,
.7 
 39
0.6
 3
.9
36
.3,
35
+/
6.
37.
8, 
- 0
5, 
7 
39
.6
37
.9
 
.1
 
36.8 
, 5, 36 , 7.1, 36
min fever means the minimum of all fever measurements per calendar day of one patient; max, mean respectively 
D14 is the 14th day after first drug intake, but including of day 13  15 
 
 and
Dose finding trial - BlueCQ-3-Report 
 
 Page 103 of 149   
Table 12-50: Feverflow by study day for Level 3 (FAS) 
Characteristic Day1 Day2 Day3 Day4 Day5 Day14 Day28 
min fever per day        
- N 115 115 110 
- Mean +/- SD 36.7+/- 0.7 36.2+/- 0.5 . /  0.5 
- Median 36.8 36.1 6 36.6 
- p5, p25, p75, p95 35.6, 36.1, 
37.2, 37.6 
35.5, 35.8, 
36.5, 37.1 
.
36
 
,
6.3, 
7.8 
- Min, Max 35.4, 38.4 35.1, 37.7 3 , 8.7 
    
mean fever per day     
- N 115 115 113 112 112 110  
- Mean +/- SD 37.6+/- 0.5 36.8+/- 0.5 +/- 0.4 36.5+/- 0.3 36.5+/- 0.3 36.6+/- 0.5 
- Median 37.6 36.7 36.5 36.4 36.4 36.6  
- p5, p25, p75, p95 36.8, 37.2, 
38.0, 38.5 
36.1, 36.4, 
37.1, 37.9 
, 36.3, 
8, 37.1 
35.9, 36.2, 
36.7, 37.1 
35.9, 36.2, 
36.7, 37.1 
35.9, 36.3, 
36.8, 37.8 
- Min, Max 36.6, 38.8 35.9, 38.3 8, 38.1 35.7, 37.4 35.7, 37.4 35.6, 38.7 
        
max fever per day       
- N 115 115 113 112 112 110  
- Mean +/- SD 38.7+/- 0.8 37.4+/- 0.8 . /  0.5 
- Median 38.7 37.2 6  
- p5, p25, p75, p95 37.5, 38.0, 
39.4, 40.1 
36.3, 36.8, 
37.8, 39.1 ,
6.3, 
7.8 
- Min, Max 37.5, 40.3 36.3, 39.7 
1
1+
36
4,
4,
2,
13
/- 
.0
 35
 36
 37
 
 
 
11
2+/
36.
6, 
.5, 
35.0, 36.9 
2
- 
2
35
36
 112 
 
 
1
6+
36
9,
.8,
.6,
10
/- 
.6
 36
 3
 3
 
 
 
 
36.
35.
36.
35.
36.6
36.1
36.
35.
37.
36.
37.
36.
0.
.8
4 
, 
.8 
.6 
36
35
0.4
.9,
.8
 
 
 
36
35
36
.2+
3
.6,
.5
5.0
- 0
.2
35.
 36.
 36.
.4 
9, 
8 
9 
3
3
6.
5.
36
35
0.
.3
7.
8.
5 
, 
8 
7 
36.
35.
36.
35.
6+/-
9, 3
8, 3
6, 3
 
110
36.6+/- 0.5 
36.6
35.9, 36.3, 
36.8, 37.8 
35.6, 38.7 
 
110
6+/-
36.6
9, 3
8, 3
35.6, 38.7 
 
  
0+
36
4,
1,
2,
/- 
.9
 36
 3
 3
0.
.7
7.7
8.9
4 
, 
 
 
36
36
37
36
8+/
36.
, 
.1, 
.0, 
- 
8
36
37
38
0.4
.5,
.4
.3
 
 
 
 
36
36
37
.8+
3
.1
.1
- 0
.8
6.
 37.
36.0, 38.3 
.4 
5, 
4 
3
3
6.
5.
36
6+
36
9,
.8,
/- 
.6
 36
 3
35.6, 38.7 
0.
.3
7.
5 
, 
8 
36.
35.
36.
    
.1 , 3
min fever means the minimum of all fever measurements per calendar day of one patient; max, mean respectively 
D14 is the 14th day after first drug intake, but including ay 13 and 15 
D28 is the 28th day after first drug intake, but including 9
 
of d
of day 25, 26, 27, 2 , 30 
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Table 12-51: Fever y WHO-Day for Level 1 (FAS) flow b
Characteristic D0 D1 D2 D3 D14 
min fever per day      
- N 147 144  
- Mean +/- SD 36.3+/- 0.6 36.2+/- 0. 0  0.6 
- Median 36.2 36.2 6  
- p5, p25, p75, p95 35.5, 35.8, 36.7, 37.5 35.5, 35.9, 36.6, 37.3 3 8 , 7.0, 37.7 
- Min, Max 35.1, 38.1 35.1, 37.9 35. , 9.0 
   
mean fever per day   
- N 147 144 139 138  
- Mean +/- SD 37.2+/- 0.8 36.9+/- 0. 36.5+/- 0.5 36.7+/- 0.5 
- Median 37.0 36.8 36.4 36.7  
- p5, p25, p75, p95 36.2, 36.6, 37.8, 38.5 36.1, 36.4, 37.3, 38.1 35.9, 36.2, 36.7, 3 36.0, 36.5, 36.9, 37.4  37.7 
- Min, Max 35.7, 39.2 35.8, 38.7 35.5, 39.7 35.7, 39.2 
      
max fever per day     
- N 147 144 139 138  
- Mean +/- SD 38.1+/- 1.0 37.6+/- 0. 36.9+/- 0.5 36.9+/- 0.5 
- Median 37.9 37.4 36.9 36.8  
- p5, p25, p75, p95 36.8, 37.2, 39.0, 40.0 36.5, 36.8, 38.2 3 2 , 7.0, 37.7 
- Min, Max 36.2, 40.5 36.0, 40.4 , 9.0 
139
+/-
35.9
6, 3
0, 3
 
 
 0.
 
6.
9.
138 
/- 0
.5 
 36
 38
 
133
7+/-
36.7
4, 3
6, 3
 
133
36.7+/- 0.6 
36.7
35.8, 36.4, 37.0,
35.6, 39.0 
 
133
36.7+/- 0.6 
36.7
4, 3
6, 3
6 
 
6 
 
9 
, 3
 
36.
35.
6 
2, 
4 
36
, 36
35
 
.5+
3
.2
.2
.5
.7,
.6 
 
 3
36.
 36.
35.
 
35.1, 
 
7.1
7.4
35. 7.1 35.8,
9.2 36.2, 36.
35.
6, 3
9, 3
7.
9.
1, 
9 
8.0 36. , 36
35
.6
.8
 37
 39
.0,
.8 
 37.6 35.8, 36.
35.
min fever means the minimum of all fever measurements per WHO-Day of one patient; max, mean respectively 
D14 is the 14th day after first drug intake, but with tolerance of - d
 
3 and +3 calendar ays 
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Table 12-52: Feverflow by WHO-Day for Level 2 (FAS) 
Characteristic D0 D1 D2 D3 D14 
min fever per day      
- N 149 
- Mean +/- SD 36.3+/- 0.6 3 +/- 0.5 
- Median 36.2  36.5 
- p5, p25, p75, p95 35.4, 35.9, 36.6, 37.5 35 .4, 6 6.9, 37.5 
- Min, Max 35.0, 37.9 7 7 8.6 
    
mean fever per day   
- N 149 145 45 144  
- Mean +/- SD 37.1+/- 0.7 36.9+/- 0.7 3 /- 36.6+/- 0.5 
- Median 36.9 36.7 .5 36.6  
- p5, p25, p75, p95 36.2, 36.6, 37.6, 38.4 36.1, 36.4, 37.2, 38.2 36.0, 36.3, 36.8, 37.5 36.0, 36.3, 36.9, 37.4  37.5 
- Min, Max 35.9, 38.8 35.7, 39.2 35.7, 38.0 35.9, 39.2 
      
max fever per day     
- N 149 145 145 144  
- Mean +/- SD 38.1+/- 1.0 37.6+/- 1.0 37.2+/- 0.7 36.9+/- 0.5 
- Median 37.8 37.3 37.0 36.8  
- p5, p25, p75, p95 36.7, 37.2, 39.0, 39.8 36 7 6.9, 37.5 
- Min, Max 36.2, 40.4 9 8.6 
1
.3+
3
.8
.2
45
/-
6.
, 
, 3
 
 
 0
1 
36.
1
0+
3
.7
.0
1
6.6+
36
45
/- 
6.0
, 3
, 3
 144
+/-
6.
, 
, 
 
 0
4 
36
38
 
136 
2, 3
0, 3
 
136
36.6+/- 0.5 
36.5
35.9, 36.2, 36.9,
35.0, 38.6 
 
136
36.6+/- 0.5 
36.5
2, 3
0, 3
36
 35
35
.6 
6,
.9 
36.
 35
35
0.4 
.3,
.3 
0.5 
6.4
3
36.1
35.5
.5
.7,
.4 
 
 3
36.6
 36.
35.
 
.5,
.5,
 37.3 35  37.0 35.6, 
 
7.2 35.9,
 36
35
.9
.9
, 
, 
38.
40.
2,
4 
 39.9 36.3, 36
36
.7
.1
, 3
, 3
.4,
.9 
 38.4 36.3, 36.5
35.9
, 
, 
37
39
.1,
.9 
 37.7 35.9, 36.
35.
min fever means the minimum of all fever measurements p
D14 is the 14th day after first drug intake, but with tolerance of -3 and +3 calendar days 
 
er WHO-Day of one patient; max, mean respectively 
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Table 12-53: Feverflow by WHO-Day for Le 3 (FASvel ) 
Characteristic D0 D1 D2 D3 D14 D28 
min fever per day       
- N 115 113 112 111 99 108 
- Mean +/- SD 36.1+/- 0.5 36.1+/- 0.4 36.1+/- 0.4 36.3+/- 0.4 36.6+/- 0.5 .6+/- 0.5 
- Median 36.0 36.1 36.1 36.3 36.5 36.5 
- p5, p25, p75, p95 35.4, 35.7, 36.4, 
37.1 
35.5, 35.8, 36.3, 
36.8 
35.5, 35 36.3, 
36
.6, 36. 6.6, 9, 36.2 .8,  36.2, 36.8, 
37.4 
- Min, Max 35.1, 37.3 35.2, 37.0 35.3, 38.3 35.6, 38.7 .8, 40.0 
       
mean fever per day       
- N 115 113 1  1 99 108 
- Mean +/- SD 36.9+/- 0.5 36.7+/- 0.4 / .6+/- 0.5 
- Median 36.8 36.6  . 5 36.5 
- p5, p25, p75, p95 36.2, 36.5, 37.2, 
37.9 
36.1, 36.4, 36.9, 
37.4 
35.9, .7
.
5
8
 36.2, 36.8, 
37.4 
- Min, Max 36.0, 38.6 36.0, 37.8  3 .8, 40.0 
     
max fever per day      
- N 115 113  111 99 108 
- Mean +/- SD 37.8+/- 0.8 37.3+/- 0.7 36.8+/- 0.4 36.6+/- 0.5 .6+/- 0.5 
- Median 37.7 37.2  . 5 36.5 
- p5, p25, p75, p95 36.6, 37.2, 38.2, 
39.3 
36.4, 36.8, 37.8, 
38.7 
36.4, .
.
35
8
 36.2, 36.8, 
37.4 
- Min, Max 36.2, 40.2 36.3, 39.1 35.8, .8, 40.0 
36
6.0,
35
36
6.0,
35
36
6.0,
35
.8, 
.8 
35.0, 37.3 
35 0, 3
 37.0
35. , 36
37.8 
3
12
36.5+/- 0.3 
5
3, 
1 
1
5+
36
36
37
.7,
1
- 0.
5
, 3
1 
38.
 
 
 
 
 
 
 
36.
0, 
35
4 
6.
4 
36
.9,
3
.6
 3
5.
+/-
36.
6.
37.
6, 
 0.5
36
 
8.7
 
.8
 
36.
36.
37.
35.8, 37.6 
 
112
37.0+/- 0.4 
36.
36.
37.
36 , 36. .3 8, 3 2, , 3
9
7, 
7 
 38
36
36
37
.8,
8
5, 3
3 
8.
 
 
36.
6.2
37.
6, 
 
37
.6
.1
 
, 36.2, 
35
7.
4 
0, .9,
3
 3
5.
, 36
 
.7
.8
 
, 3
 3 38
min fever means the minimum of all fever measurements per WHO-Day of one pa  c
D14 is the 14th day after first drug intake, but with tolerance of -3 and + d
 
tien
3 ca
t;
le
 m
nd
ax,
ar 
mea
ays
n 
 
respe tively 
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Table  C n AS)  12-54: o comitant medication by generic name for Level 1 (F
Medication group 
- generic name 
2x daily 
(N=125) 
4x daily 
(N=114) 
Antibiotic 33( 26.4%) 27( 23.7%) 
- Amoxicillin 9( 3( 11.1%) 
- Cefadroxil 3( 6( 22.2%) 
- Ciprofloxacin 1(  3.0%) 0(  0.0%) 
- Cotrimoxazol 14( 42.4%) 9( 33.3%) 
- Erythromycin 2(  6.1%) 4( 14.8%) 
- Metronidazol 4( 5( 18.5%) 
   
histaminic 3(  2.4%) 1(  0.9%) 
- Mequitazin 3(100.0%) 1(100.0%) 
   
Antimalarial (1) 33( 26 32( 28.1%) 
- Quinine 3( 4( 12.5%) 
 Sulfad .5%) 
   
Antipyretic 39( 31.2%) 36( 31.6%) 
- Ibu ) 
- Paracetamol 29( 80.6%) 
   
Others 17( 13.6%) 18( 15.8%) 
- Albendazol 0(  0.0%) 1(  5.6%) 
- Debridat 0(  0.0%) 1(  5.6%) 
27.3%) 
  9.1%) 
  12.1%) 
Anti
.4%) 
  9.1%) 
- oxa/Pyrimethamin 30( 90.9%) 28( 87
- Acetylsalicylicacid 3(  7.7%) 0(  0.0%) 
profen 5( 12.8%) 7( 19.4%
31( 79.5%) 
- Metopimazine 16( 94.1%) 15( 83.3%) 
- Trimebutine 1(  5.9%) 1(  5.6%) 
Number of medications taken, rather than number of 
from CQ or MB
patients with that specific medica part 
 
 
tion, (1) a
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Table 12-55: Concomitant medication AS) by generic name for Level 2 (F
Medication group 
- generic name 
2x daily 
(N=116) 
4x daily 
(N=131) 
Antibiotic 24( 2 32( 24.4%) 0.7%) 
- Amoxicillin 9( 37.5%) 9( 28.1%) 
- Cefadroxil 9( 10( 31.3%) 
- Ceftriaxon 1( 0(  0.0%) 
- Ciprofloxacin 1(  4.2%) 1(  3.1%) 
- Cotrimoxazol 1(  4.2%) 1(  3.1%) 
- Erythromycin 2( 7( 21.9%) 
- Gentamycin 1(  4.2%) 0(  0.0%) 
- Metronidazo 0 4( 12.5%) 
   
Antihistaminic 1(  0.9%) 3(  2.3%) 
quitazin 1(100.0%) 3(100.0%) 
   
Antimalarial (1) 35 28( 21.4%) 
- Quinine 5( 14 0(  0.0%) 
- Sulfadoxa/Py 30( 28(100.0%) 
Antipyretic 26( 22.4%) 47( 35.9%) 
- Acetylsalicylicacid 1(  3.8%) 1(  2.1%) 
- Par ) 
   
Others 9%) 21( 16.0%) 
- Albendazol 3( 10.0%) 1(  4.8%) 
- Debridat 0(  0.0%) 1(  4.8%) 
- Diazepam 1(  3.3%) 0(  0.0%) 
n 
- Phenobarbital 1( 0(  0.0%) 
37.5%) 
  4.2%) 
 8.3%) 
l (  0.0%) 
- Me
( 30.2%) 
.3%) 
rimethamin  85.7%) 
   
- Ibuprofen 19( 73.1%) 34( 72.3%) 
acetamol 6( 23.1%) 12( 25.5%
30( 25.
- Iro 2(  6.7%) 1(  4.8%) 
- Metopimazine 23( 76.7%) 18( 85.7%) 
  3.3%) 
Number of medications taken, rath umber of patients with that specific medication, (1) apart 
from CQ or MB 
er than n
 
Dose finding trial - BlueCQ-3-Report 
 
 Page 109 of 149   
Table 12-56: Concomitant medication AS) by generic name for Level 3 (F
Medication group 
- generic name 
2x daily 
(N=80) 
4x daily 
(N=117) 
Antibiotic 16( 2 33( 28.2%) 0.0%) 
- Amoxicillin 8( 50.0%) 13( 39.4%) 
- Cefadroxil 2( 3(  9.1%) 
- Ceftriaxon 0( 1(  3.0%) 
- Ciprofloxacin 2( 12.5%) 5( 15.2%) 
- Erythromycin 2( 12.5%) 8( 24.2%) 
- Metronidazol 2( 3(  9.1%) 
   
Antihistaminic 1(  1.3%) 2(  1.7%) 
quitazin 1(100.0%) 2(100.0%) 
   
Antimalarial 29 39( 33.3%) 
- Quinine 3( 10 3(  7.7%) 
- Sulfadoxa/Py 26( 36( 92.3%) 
Antipyretic 10( 12.5%) 21( 17.9%) 
- Ibuprofen 8( 80.0%) 17( 81.0%) 
  
Others  22( 18.8%) 
- Albendazol 5%) 2(  9.1%) 
- Diazepam 0(  0.0%) 1(  4.5%) 
- Hydrocortisone 0(  0.0%) 1(  4.5%) 
- Iron 2(  8.3%) 1(  4.5%) 
12.5%) 
  0.0%) 
 12.5%) 
- Me
(1) ( 36.3%) 
.3%) 
rimethamin  89.7%) 
   
- Paracetamol 2( 20.0%) 4( 19.0%) 
 
24( 30.0%)
3( 12.
- Metopimazine 19( 79.2%) 17( 77.3%) 
Number of medicat ke  ions ta n, rather than number of patients with that specific medication, (1) apart 
from CQ or MB 
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Table 12-57: Concomitant medication by generic name and group (FAS) 
Medication group 
- generic name 
2x daily 
(N=321) 
4x daily 
(N=362) 
Antibiotic 73( 2 92( 25.4%) 2.7%) 
- Amoxicillin 26( 35.6%) 25( 27.2%) 
- Cefadroxil 14( 19( 20.7%) 
- Ceftriaxon 1( 1(  1.1%) 
- Ciprofloxacin 4(  5.5%) 6(  6.5%) 
- Cotrimoxazol 15( 20.5%) 10( 10.9%) 
- Erythromycin 6( 19( 20.7%) 
- Gentamycin 1( 0(  0.0%) 
- Metronidazo 6
   
Antihistaminic 5(  1.6%) 6(  1.7%) 
quitazin 5(100.0%) 6(100.0%) 
   
Antimalarial 97 99( 27.3%) 
- Quinine 11( 11 7(  7.1%) 
- Sulfadoxa/Pyrimethamin 86( 88.7%) 92( 92.9%) 
  
Antipyretic 75( 23.4%) 104( 28.7%) 
- Acetylsalicylicacid 4(  5.3%) 1(  1.0%) 
- Par ) 
   
Others 1%) 61( 16.9%) 
- Albendazol 6(  8.5%) 4(  6.6%) 
- Debridat 0(  0.0%) 2(  3.3%) 
- Diazepam 1(  1.4%) 1(  1.6%) 
n 
- Metopimazine 58( 50( 82.0%) 
- Phenobarbital 1(  0(  0.0%) 
- Trimebutine 1(  1.4%) 1(  1.6%) 
 19.2%) 
  1.4%) 
  8.2%) 
  1.4%) 
l (  8.2%) 12( 13.0%) 
- Me
(1) ( 30.2%) 
.3%) 
 
- Ibuprofen 32( 42.7%) 58( 55.8%) 
acetamol 39( 52.0%) 45( 43.3%
71( 22.
- Hydrocortisone 0(  0.0%) 1(  1.6%) 
- Iro 4(  5.6%) 2(  3.3%) 
81.7%) 
1.4%) 
Number of medications taken, rat mber of patients with that specific medication, (1) apart 
m CQ or MB 
her than nu
fro
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Table 12-58: Number of patients with concomitant medication by group and level (FAS) 
Medication level 2x daily 4x daily Total 
Antibiotic 1 8.9%) 75 ( 30.7%) 4.7%) 28/72 ( 3  23/  51/147 ( 3
 2 0.7%) 
3 15/53 ( 28.3%) 25/62 ( 40.3%) 40/115 ( 34.8%) 
 Total 63/197 ( 32.0%) 74/215 ( 34.4%)  33.3%) 
  
nic 1 .8%) 75 ( 1.3%)  2.0%) 
2 4% 8 ( 3.8%)  2.7%) 
3  2.6%) 
Total 4/197 ( 2.0%) 6/215 ( 2.8%) 10/412 ( 2.4%) 
   
l 1 0.3% 5 ( 37.3%)  38.8%) 
2 3.1 8 ( 35.9%)  39.3%) 
 3 .1 2 ( 58.1%)  53.9%) 
 Total 1 3.7 5 ( 42.8%)  43.2%) 
    
1 1.7% 75 ( 36.0%) 147 ( 38.8%) 
2 0.6% 78 ( 51.3%)  41.3%) 
3 8.9% 62 ( 30.6%) 29/115 ( 25.2%) 
Total 1.5 5 ( 40.0%)  35.9%) 
 
1 31/72 ( 43.1%) 36/75 ( 48.0%) /147 ( 45.6%) 
2 8.3% 78
3 8.5% 62
Total 52.8 21
20/72 ( 27.8%) 26/78 ( 33.3%) 46/150 ( 3
 
137/412 (
 
i
  
Antihistam 2/72 ( 2  1/ 3/147 (
 1/72 ( 1.
1/53 ( 1.9%) 
) 3/7
2/62 ( 3.2%) 
4/150 (
/115 ( 3
 
  
Antimalaria 29/72 ( 4 ) 28/7 57/147 (
 31/72 ( 4 %) 28/7 59/150 (
26/53 ( 49
86/ 97 ( 4
%) 36/6
%) 92/21
62/115 (
1 8/412 (7
 
ic Antipyret 30/72 ( 4 ) 27/ 57/
 22/72 ( 3 ) 40/ 62/150 (
 10/53 ( 1 ) 19/
 62/197 ( 3
   
%) 86/21 148/412 (
 
Other 67
 42/72 ( 5 ) 36/  ( 46.2%) 78/150 ( 52.0%) 
 31/53 ( 5 ) 29/  ( 46.8%) 60/115 ( 52.2%) 
 104/197 ( %) 101/ 5 ( 47.0%) 205/412 ( 49.8%) 
created by t_report.sas 
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T - :  able 12 59  Primary analysis by study day for Level 1 (FAS)
Characteristic 
2x daily 
(N=72) 
4x daily 
(N=75) 
Comparison 
(N=147) 
RAE    
- Yes 0(  0. 0(  0.
- No 72(100 75(100  
   
SAE   
- Yes 0(  0. 0(  0.
- No 72(100 75(100
   
Changes in HB[g/dl] (3)   
- N 68 70
- Mean -0.8+/- -0.8+/- -0.0+/-  0.8 
- Median -0. -0.
- Min, -3.5, -5.3, 
-  p5, p25, p75, p95 -1.7, -1.3, -0.5,  0.3 -2.4, -1.2, -0.2,  0.2 
-  95% CI mean   [-0.29; 0.26] 
- p-Value (4)   
0%) 0%)  
.0%) .0%) 
 
 
0%) 0%)  
.0%) .0%)  
 
 
   
 +/- SD  0.7  0.9 
8 7  
 Max  0.8  0.8  
 
0.4071 
(1) CI=95% confidence in e rates or rela f SAE rat
(2) Chi-Square-test for differences of incidence rates 
(3) change Day4(Study day)-Baseline 
 = WMW-Test 
 
 
terval of th tive risk o es 
(4) U-Test
 
Table 12-60: Primary analysis by study day for Level 2 (FAS) 
Characteristic 
2x daily 
(N=72) 
4x daily 
(N=78) 
Comparison 
(N=150) 
RAE    
-   1.4%) 1(  1.3%)  
-  
 
SAE  
- 
- No 71( 98.6%) 77( 98.7%)  
- 95% CI (1) [0.00; 0.07] [0.00; 0.07] [0.069; 17.00] 
p-Value (2)   0.9545 
    
Changes in HB[g/dl] (3)    
- N 67 77  
- Mean +/- SD -0.7+/- 0.9 -1.0+/- 1.0 0.3+/-  0.9 
- Median -0.5 -1.0  
- Min, Max -2.7,  1.2 -3.4,  1.7  
-  p5, p25, p75, p95 -2.6, -1.3, -0.2,  0.5 -2.8, -1.6, -0.2,  0.5  
-  95% CI mean   [-0.01; 0.61] 
- p-Value (4)   0.0465 
Yes 1(
No 71( 98.6%) 77( 98.7%) 
   
  
Yes 1(  1.4%) 1(  1.3%)  
(1) CI=95% confidence interval of the rates or relative risk of SAE rates 
(2) Chi-Square-test for differences of incidence rates 
(3) change Day4(Study day)-Baseline 
(4) U-Test = WMW-Test 
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Table 12-61: Primary analysis by study day for Level 3 (FAS) 
Characteristic 
2x daily 
(N=53) 
4x daily 
(N=62) 
Comparison 
(N=115) 
RAE    
- Yes 0(  0. 1(  1.
- No 53(100.0%) 61( 98
   
SAE    
- Yes 0(  0. 1(  1.
- No 53(100 61( 98
- 95% CI (1) [0.00; 0.10] [0.00; 0.09] [0.016; 9.351] 
p-Valu   
   
Changes in HB[g/dl] (3)   
- N 51 61
- Mean +/- SD -0.7+/- 0.8 -0.6+/- 0.9 -0.1+/-  0.9 
- Medi -0. -0.
- Min, -2.8, -3.9, 
-  p5, p25, p75, p95 -2.2, -1.2, -1.8, -1.1, 
-  95% CI mean   [-0.44; 0.23] 
- p-Value (4)   0.3050 
0%) 6%)  
.4%)  
 
0%) 6%)  
.0%) .4%)  
  
e (2) 0.353 
 
 
   
  
an 7 6  
 Max  1.2  1.1  
-0.2,  0.4  0.1,  0.6  
(1) CI=95% confidence in e rates or rel  SAE rat
(2) Chi-Square-test for differences of incidence rates 
= WMW-Test 
 (FAS) 
terval of th ative risk of es 
(3) change Day4(Study day)-Baseline 
(4) U-Test 
 
 
 
Table 12-62: Primary analysis by study day for all Levels
Characteristic 
2x daily 
(N=197) 
4x daily 
(N=215) 
Comparison 
(N=412) 
RAE    
- Yes 1(  0.5%) 2(  0.9%)  
- No 196( 99.5%) 213( 99.1%)  
    
SAE    
- Yes 1(  0.5%) 2(  0.9%)  
- No 196( 99.5%) 213( 99.1%)  
- 95% CI (1) [0.00; 0.03] [0.00; 0.03] [0.050; 5.971] 
p-Value (2)   0.6142 
    
Changes in HB[g/dl] (3)    
- N 186 208  
- Mean +/- SD -0.7+/- 0.8 -0.8+/- 0.9 0.1+/-  0.9 
- Median -0.7 -0.7  
- Min, Max -3.5,  1.2 -5.3,  1.7  
-  p5, p25, p75, p95 -2.2, -1.2, -0.3,  0.4 -2.4, -1.3, -0.1,  0.5  
-  95% CI mean   [-0.10; 0.25] 
- p-Value (4)   0.7186 
 (1) CI=95% confidence interval of the rates or relative risk of SAE rates 
(2) Chi-Square-test for differences of incidence rates 
(3) change Day4(Study day)-Baseline 
(4) U-Test = WMW-Test 
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Table 12-63: Primary analysis by WHO Day for Level 1 (FAS) 
Characteristic 
2x daily 
(N=72) 
4x daily 
(N=75) 
Comparison 
(N=147) 
RAE    
- Yes 0(  0. 0(  0.
- No 72(100. 75(100.  
   
SAE   
- Yes 0(  0. 0(  0.0%) 
- No 72(100. 75(100.  
   
Changes in HB[g/dl] (3)   
- N 68 70 
- Mean -0.8+/- -0.8+/- -0.0+/-  0.8 
- Medi -0.8 -0.7
- Min, Max -3.5,  0.8 -5.3,  0.8 
-  p5, p25, p75, p95 -1.7, -1.3, -2.4, -1.2, -
-  95% CI mean   [-0.29; 0.26] 
- p-Va   
0%) 0%)  
0%) 0%) 
 
 
0%)  
0%) 0%) 
 
 
 
 +/- SD  0.7  0.9 
an    
 
-0.5,  0.3 0.2,  0.2  
lue (4) 0.4071 
(1) CI=95% confidence interval of the rates or relative risk of SAE rates 
(2) Chi-Square-test for differences of incidence rates 
(3) change D2(WHO)-Baseline 
 = WMW-Test 
 
 
 
Table 12-64: Primary analysis by WHO Day for Level 2 (FAS) 
(4) U-Test
Characteristic 
2x daily 
(N=72) 
4x daily 
(N=78) 
Comparison 
(N=150) 
RAE    
- Yes 1(  1. 1(  1.3%) 
- No 71( 98.6%) 77( 98.7%) 
   
SAE   
- Yes 1(  1.4%) 1(  1.3%)  
- No 71( 98.6%) 77( 98.7%)  
- 95% CI (1) [0.00; 0.07] [0.00; 0.07] [0.069; 17.00] 
p-Value (2)   0.9545 
    
Changes in HB[g/dl] (3)    
- N 67 77  
- Mean +/- SD -0.7+/- 0.9 -1.0+/- 1.0 0.3+/-  0.9 
- Median 
- 
- 
-  [-0.01; 0.61] 
-  0.0465 
4%)  
 
 
 
-0.5 -1.0  
Min, Max -2.7,  1.2 -3.4,  1.7  
 p5, p25, p75, p95 -2.6, -1.3, -0.2,  0.5 -2.8, -1.6, -0.2,  0.5  
 95% CI mean  
p-Value (4)  
(1) CI=95% confidence interval of the rates or relative risk of SAE rates 
(2) Chi-Square-test for differences of incidence rates 
(3) change D2(WHO)-Baseline 
(4) U-Test = WMW-Test 
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Table 12-65: Primary analysis by WHO Day for Level 3 (FAS) 
Characteristic 
2x daily 
(N=53) 
4x daily 
(N=62) 
Comparison 
(N=115) 
RAE    
- Yes 0(  0. 1(  1.
- No 53(100 61( 98
   
SAE   
- Yes 0(  0. 1(  1.
- No 53(100.0%) 61( 98
- 95% CI (1) [0.00; 0.10] [0.00; 0.09] [0.016; 9.351] 
p-Valu   
    
Changes in HB[g/dl] (3)   
- N 51 61
- Mean +/- SD -0.7+/- 0.8 -0.6+/- 0.9 -0.1+/-  0.9 
- Medi -0. -0.
- Min, -2.8, -3.9, 
-  p5, p25, p75, p95 -2.2, -1.2, -1.8, -1.1, 
-  95% CI mean   [-0.44; 0.23] 
- p-Value (4)   
0%) 6%)  
.0%) .4%)  
 
 
0%) 6%)  
.4%)  
  
e (2) 0.353 
 
   
  
an 7 6  
 Max  1.2  1.1  
-0.2,  0.4  0.1,  0.6  
0.3050 
(1) CI=95% confidence in e rates or rel  SAE rat
(2) Chi-Square-test for differences of incidence rates 
= WMW-Test 
s (FAS) 
terval of th ative risk of es 
(3) change D2(WHO)-Baseline 
(4) U-Test 
 
 
 
Table 12-66: Primary analysis by WHO Day for all Level
Characteristic 
2x daily 
(N=197) 
4x daily 
(N=215) 
Comparison 
(N=412) 
RAE    
- Yes 1(  0.5%) 2(  0.9%)  
- No 196( 99.5%) 213( 99.1%)  
    
SAE    
- Yes 1(  0.5%) 2(  0.9%)  
- No 196( 99.5%) 213( 99.1%)  
- 95% CI (1) [0.00; 0.03] [0.00; 0.03] [0.050; 5.971] 
p-Value (2)   0.6142 
    
Changes in HB[g/dl] (3)    
- N 186 208  
- Mean +/- SD -0.7+/- 0.8 -0.8+/- 0.9 0.1+/-  0.9 
- Median -0.7 -0.7  
- Min, Max -3.5,  1.2 -5.3,  1.7  
-  p5, p25, p75, p95 -2.2, -1.2, -0.3,  0.4 -2.4, -1.3, -0.1,  0.5  
-  95% CI mean   [-0.10; 0.25] 
- p-Value (4)   0.7186 
(1) CI=95% confidence interval of the rates or relative risk of SAE rates 
(2) Chi-Square-test for differences of incidence rates 
(3) change D2(WHO)-Baseline 
(4) U-Test = WMW-Test 
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Table 12-67: Efficacy results by group and dose level (PP) 
 2x daily  4x daily  Group comparison 
    
Level1 MB 36 mg/kg    
- ETF/N 1.6%, 1/62 3.0%, 2/66 p=0.5923 (1) 
- LCF14/N 8.1%, 5/62 3.0%, 2/66 p=0.2047 (1) 
- TF14/N 9.7%, 6/62 6.1%, 4/66 p=0.4452 (1) 
- LPF14/N 24.2%, 15/62 22.7%, 15/66 p=0.8449 (1) 
    
Level2 MB 54 mg/kg    
- ETF/N 3.1%, 2/64 6.9%, 5/73 p=0.3140 (1) 
- LCF14/N 4.7%, 3/64 11.0%, 8/73 p=0.1688 (1) 
- TF14/N 7.8%, 5/64 17.8%, 13/73 p=0.0783 (1) 
- LPF14/N 35.9%, 23/64 17.8%, 13/73 p=0.0159 (1) 
    
Level3 MB 72 mg/kg    
- ETF/N 0.0%, 0/47 0.0%, 0/52 - 
- LCF14/N 10.6%, 5/47 9.6%, 5/52 p=0.8661 (1) 
- TF14/N 10.6%, 5/47 9.6%, 5/52 p=0.8661 (1) 
- LPF14/N 21.3%, 10/47 19.2%, 10/52 p=0.8002 (1) 
    
Level comparison    
- p-value (ETF) 0.3266 (2) 0.0595 (2) 0.7290 (3), 0.0960 (4), 0.9930 (5)
- p-value (LCF14) 0.4824 (2) 0.1492 (2) 0.3168 (3), 0.2613 (4), 0.1722 (5)
- p-value (LF14) 0.8684 (2) 0.0838 (2) 0.2944 (3), 0.2634 (4), 0.1984 (5)
- p-value (LPF14) 0.1764 (2) 0.7631 (2) 0.1155 (3), 0.4045 (4), 0.2486 (5)
    
ETF=early treatment failure, LCF14=late clinical failure (day 14),  
LPF14=late parasitological failure (day 14), 
(1) group comparisons within level, (2) level comparison within group,  
(3) test of overall group comparison, (4) test of overall level comparison,  
(5) test of group*level interaction, Likelihood ratio tests were used 
(3) and (4) also used the model with interaction term (!) and therefore a bit different from the 
results given in the report,  
table created by t_paper_resi.sas for the publication 
 
 
TF14=treatment failure (ETF or LCF14),  
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Table 12-68: Treatment failure by group for Level 1 (FAS) 
 
2x daily 
(N=72) 
4x daily 
(N=75) 
Total 
(N=147) 
ETF 5(  6.9%) 7(  9.3%) 12(  8.2%) 
- reason1 0(  0.0%) 0(  0.0%) 0(  0.0%) 
- reason2 0(  0.0%) 0(  0.0%) 0(  0.0%) 
- reason2+3 0(  0.0%) 0(  0.0%) 0(  0.0%) 
- reason3 1( 20.0%) 1( 14.3%) 2( 16.7%) 
- reason3+4 1( 14.3%) 
0(  0.0%) 
 
1
5( 50.0%) 
3( 30.0%) 1( 16.7%) 4( 25.0%) 
1 1
5( 33.3%) 
10( 66.7%) 6( 46.2%) 16( 57.1%) 
1
0(  0.0%) 1(  3.2%) 
0(  0.0%) 1(  8.3%) 
- reason4 0(  0.0%) 0(  0.0%) 
- reason5 4( 80.0%) 5( 71.4%) 9( 75.0%) 
   
LCF_14 0( 13.9%) 6(  8.0%) 16( 10.9%) 
- reason1 2( 33.3%) 7( 43.8%) 
- reason2 2( 20.0%) 3( 50.0%) 5( 31.3%) 
- reason3 
    
TF_14 5( 20.8%) 3( 17.3%) 28( 19.0%) 
- ETF 7( 53.8%) 12( 42.9%) 
- LCF_14 
    
LPF_14 16( 22.2%) 5( 20.0%) 31( 21.1%) 
- reason1 15( 93.8%) 15(100.0%) 30( 96.8%) 
- reason2 1(  6.3%) 
 
 
percentages of ETF, LCF_14, TF_14 and LPF_14 are based on the number of pat. by group, otherwise 
Parasitaemia on D3(WHO)>= 25% 
F_14-reason1: reason1: Fever(>=37,5°C) and parasitaemia >0 on D4-D14(WHO) 
F_14-reason2: treated (D4-D13) with antimalarials although no fever and/or no parasites; reason3: 
Missing Information 
LPF_14-reason1: Temperature < 37,5°C on D14(WHO) and parasitaemia > 0; reason2: Missing Information 
 
 
 
(for subreasons) based on the number of failures. 
ETF-reason1: Severe malaria on D1-D3(WHO); reason2: Parasitaemia on D2(WHO)> baseline count 
ETF-reason3: Fever(>=37,5°C)on D3(WHO) and parasitaemia > 0; reason4: 
of baseline count 
ETF-reason5: Missing information 
LC
LC
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Table 12-69: Treatment failure by group for Level 2 (FAS) 
 
2x daily 
(N=72) 
4x daily 
(N=78) 
Total 
(N=150) 
ETF 7(  9.7%) 6(  7.7%) 13(  8.7%) 
- reason1 1( 14.3%) 0(  0.0%) 1(  7.7%) 
2 1(  7.7%) 
 
- reason3+4 0(  0.0%) 0(  0.0%) 0(  0.0%) 
n4 
- reason5 
  
F_14 6(  8.3%) 12( 15.4%) 18( 12.0%) 
1 
- reason2 
- reason3 3( 50.0%) 4( 33.3%) 7( 38.9%) 
TF_14 
- ETF 
LCF_14 6( 46.2%) 12( 66.7%) 18( 58.1%) 
LPF_14 
- reason1 
- reason2 0(  0.0%) 0(  0.0%) 0(  0.0%) 
- reason 0(  0.0%) 1( 16.7%) 
- reason2+3 1( 14.3%) 0(  0.0%) 1(  7.7%) 
- reason3 1( 14.3%) 2( 33.3%) 3( 23.1%) 
- reaso 0(  0.0%) 2( 33.3%) 2( 15.4%) 
4( 57.1%) 1( 16.7%) 5( 38.5%) 
  
LC
- reason 3( 50.0%) 8( 66.7%) 11( 61.1%) 
0(  0.0%) 0(  0.0%) 0(  0.0%) 
    
13( 18.1%) 18( 23.1%) 31( 20.7%) 
7( 53.8%) 6( 33.3%) 13( 41.9%) 
- 
    
23( 31.9%) 13( 16.7%) 36( 24.0%) 
23(100.0%) 13(100.0%) 36(100.0%) 
percentages of ETF, LCF_14, TF_14 an  based on the at. by g ise 
(for subreasons) based on the number of failures. 
ith antimalarials although no fever and/or no parasites; reason3: 
d LPF_14 are  number of p roup, otherw
ETF-reason1: Severe malaria on D1-D3(WHO); reason2: Parasitaemia on D2(WHO)> baseline count 
ETF-reason3: Fever(>=37,5°C)on D3(WHO) and parasitaemia > 0; reason4: Parasitaemia on D3(WHO)>= 25% 
of baseline count 
ETF-reason5: Missing information 
LCF_14-reason1: reason1: Fever(>=37,5°C) and parasitaemia >0 on D4-D14(WHO) 
LCF_14-reason2: treated (D4-D13) w
Missing Information 
LPF_14-reason1: Temperature < 37,5°C on D14(WHO) and parasitaemia > 0; reason2: Missing Information 
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Table 12-70: Treatment failure by group for Level 3 (FAS) 
 
2x daily 
(N=53) 
4x daily 
(N=62) 
Total 
(N=115) 
ETF 2(  3.8%) 2(  3.2%) 4(  3.5%) 
- reason1 0(  0.0%) 0(  0.0%) 0(  0.0%) 
- reason2 0(  0.0%) 0(  0.0%) 0(  0.0%) 
- reason2+3 0(  0.0%) 0(  0.0%) 0(  0.0%) 
- reason3 0(  0.0%) 0(  0.0%) 0(  0.0%) 
- reason3+4 0(  0.0%) 0(  0.0%) 0(  0.0%) 
- reason4 0(  0.0%) 0(  0.0%) 0(  0.0%) 
- reason5 2(100.0%) 
5( 55.6%) 
reason3 4( 44.4%) 7( 58.3%) 11( 52.4%) 
LCF_14 9( 81.8%) 12( 85.7%) 21( 84.0%) 
0(  0.0%) 0(  0.0%) 
9( 90.0%) 12( 66.7%) 21( 75.0%) 
  
TF_28 12( 22.6%) 20( 32.3%) 32( 27.8%) 
- TF_14 11( 91.7%) 14( 70.0%) 25( 78.1%) 
- LCF_28 (1) 1(  8.3%) 6( 30.0%) 7( 21.9%) 
    
LPF_28 21( 39.6%) 23( 37.1%) 44( 38.3%) 
- reason1 21(100.0%) 23(100.0%) 44(100.0%) 
2(100.0%) 4(100.0%) 
    
LCF_14 9( 17.0%) 12( 19.4%) 21( 18.3%) 
- reason1 5( 41.7%) 10( 47.6%) 
- reason2 0(  0.0%) 0(  0.0%) 0(  0.0%) 
- 
    
TF_14 11( 20.8%) 14( 22.6%) 25( 21.7%) 
- ETF 2( 18.2%) 2( 14.3%) 4( 16.0%) 
- 
    
LPF_14 10( 18.9%) 10( 16.1%) 20( 17.4%) 
- reason1 10(100.0%) 10(100.0%) 20(100.0%) 
- reason2 0(  0.0%) 
    
LCF_28 10( 18.9%) 18( 29.0%) 28( 24.3%) 
- reason1 
- reason2 1( 10.0%) 5( 27.8%) 6( 21.4%) 
- reason3 0(  0.0%) 1(  5.6%) 1(  3.6%) 
  
percentages of ETF, LCF_14, TF_14 and LPF_14 are based on the number of pat. by group, otherwise 
(for subreasons) based on the number of failures. 
ETF-reason1: Severe malaria on D1-D3(WHO); reason2: Parasitaemia on D2(WHO)> baseline count 
ETF-reason3: Fever(>=37,5°C)on D3(WHO) and parasitaemia > 0; reason4: Parasitaemia on D3(WHO)>= 25% 
of baseline count 
ETF-reason5: Missing information 
LCF_14-reason1: reason1: Fever(>=37,5°C) and parasitaemia >0 on D4-D14(WHO) 
LCF_14-reason2: treated (D4-D13) with antimalarials although no fever and/or no parasites; reason3: 
Missing Information 
LPF_14-reason1: Temperature < 37,5°C on D14(WHO) and parasitaemia > 0; reason2: Missing Information 
LCF_28-reason1: LCF_14; reason2:Fever(>=37,5°C) and parasitaemia >0 on D18-D28(WHO); reason3: Missin 
information 
(1) without previously meeting any of the criteria of LCF_14 
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Table 12-71: Treatment failure by group for all Levels (FAS) 
 
2x daily 
(N=197) 
4x daily 
(N=215) 
Total 
(N=412) 
ETF 14 15(  7.1%) (  7.0%) 29(  7.0%) 
- 1 0
- 0 1
- 1 0
- 2 3
- reason3+4 0 1
- 0 2
- 10 8
   
L 25 30
- 13 15
- 2 3
- 10 12
   
T 39 45
- 14 15
- 25 30
   
L 49 38
- 48 38
- 1 0
 reason1 (  7.1%) (  0.0%) 1(  3.4%) 
 reason2 (  0.0%) (  6.7%) 1(  3.4%) 
 reason2+3 (  7.1%) (  0.0%) 1(  3.4%) 
 reason3 ( 14.3%) ( 20.0%) 5( 17.2%) 
(  0.0%) (  6.7%) 1(  3.4%) 
 reason4 (  0.0%) ( 13.3%) 2(  6.9%) 
 reason5 ( 71.4%) ( 53.3%) 18( 62.1%) 
 
CF_14 ( 12.7%) ( 14.0%) 55( 13.3%) 
 reason1 ( 52.0%) ( 50.0%) 28( 50.9%) 
 reason2 (  8.0%) ( 10.0%) 5(  9.1%) 
 reason3 ( 40.0%) ( 40.0%) 22( 40.0%) 
 
F_14 ( 19.8%) ( 20.9%) 84( 20.4%) 
 ETF ( 35.9%) ( 33.3%) 29( 34.5%) 
 LCF_14 ( 64.1%) ( 66.7%) 55( 65.5%) 
 
PF_14 ( 24.9%) ( 17.7%) 87( 21.1%) 
 reason1 ( 98.0%) (100.0%) 86( 98.9%) 
 reason2 (  2.0%) (  0.0%) 1(  1.1%) 
percentages of ETF, LCF_14, TF_14 and LPF_14 are based on the number of pat. by group, otherwise 
(for subreasons) based on the number of failures. 
ETF-reason1: Severe malaria on D1-D3(WHO); reason2: Parasitaemia on D2(WHO)> baseline count 
ETF-reason3: Fever(>=37,5°C)on D3(WHO) and parasitaemia > 0; reason4: Parasitaemia on D3(WHO)>= 25% 
of baseline count 
ETF-reason5: Missing information 
LCF_14-reason1: reason1: Fever(>=37,5°C) and parasitaemia >0 on D4-D14(WHO) 
LCF_14-reason2: treated (D4-D13) with antimalarials although no fever and/or no parasites; reason3: 
Missing Information 
LPF_14-reason1: Temperature < 37,5°C on D14(WHO) and parasitaemia > 0; reason2: Missing Information 
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Table 12-72: Treatment failure by group for Level 1 (PP) 
 
2x daily 
(N=62) 
4x daily 
(N=66) 
Total 
(N=128) 
ETF 1(  1.6%) 2(  3.0%) 3(  2.3%) 
- reason1 0(  0.0%) 0(  0.0%) 0(  0.0%) 
- reason2 0(  0.0%) 0(  0.0%) 0(  0.0%) 
- reason2+3 0(  0.0%) 0(  0.0%) 0(  0.0%) 
- reason3 1(100.0%) 1( 50.0%) 2( 66.7%) 
- reason3+4 0(  0.0%) 1( 50.0%) 1( 33.3%) 
- reason4 0(  0.0%) 0(  0.0%) 0(  0.0%) 
- reason5 0(  0.0%) 0(  0.0%) 0(  0.0%) 
    
LCF_14 5(  8.1%) 2(  3.0%) 7(  5.5%) 
- reason1 5(100.0%) 2(100.0%) 7(100.0%) 
- reason3 0(  0.0%) 0(  0.0%) 0(  0.0%) 
    
TF_14 6(  9.7%) 4(  6.1%) 10(  7.8%) 
4 
F_14 15( 24.2%) 15( 22.7%) 30( 23.4%) 
1 
- ETF 1( 16.7%) 2( 50.0%) 3( 30.0%) 
- LCF_1 5( 83.3%) 2( 50.0%) 7( 70.0%) 
    
LP
- reason 15(100.0%) 15(100.0%) 30(100.0%) 
per  ETF, LCF_14, TF_14 and LPF_14 are based on the pat. by g ise 
(for subreasons) based on the number of failures. 
aemia > 0; reason4: Parasitaemia on D3(WHO)>= 25% 
centages of number of roup, otherw
ETF-reason1: Severe malaria on D1-D3(WHO); reason2: Parasitaemia on D2(WHO)> baseline count 
ETF-reason3: Fever(>=37,5°C)on D3(WHO) and parasit
of baseline count 
ETF-reason5: Missing information 
LCF_14-reason1: reason1: Fever(>=37,5°C) and parasitaemia >0 on D4-D14(WHO); reason3: Missing 
Information 
LPF_14-reason1: Temperature < 37,5°C on D14(WHO) and parasitaemia > 0 
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Table 12-73: Treatment failure by group for Level 2 (PP) 
 
2x daily 
(N=64) 
4x daily 
(N=73) 
Total 
(N=137) 
ETF   2(  3.1%) 5(  6.8%) 7(  5.1%) 
- reason1   
   
   
   
   
  2( 40.0%) 
   
   
   
   
   
TF_14 5(  7.8%) 13( 17.8%) 18( 13.1%) 
   
_14   
LPF_14 23( 35.9%) 13( 17.8%) 36( 26.3%) 
on1 ) ) 
0(  0.0%) 0(  0.0%) 0(  0.0%) 
- reason2 0(  0.0%) 1( 20.0%) 1( 14.3%) 
- reason2+3 1( 50.0%) 0(  0.0%) 1( 14.3%) 
- reason3 1( 50.0%) 2( 40.0%) 3( 42.9%) 
- reason3+4 0(  0.0%) 0(  0.0%) 0(  0.0%) 
- reason4 0(  0.0%) 2( 28.6%) 
- reason5 0(  0.0%) 0(  0.0%) 0(  0.0%) 
 
LCF_14 3(  4.7%) 8( 11.0%) 11(  8.0%) 
- reason1 3(100.0%) 8(100.0%) 11(100.0%) 
- reason3 0(  0.0%) 0(  0.0%) 0(  0.0%) 
    
- ETF 2( 40.0%) 5( 38.5%) 7( 38.9%) 
- LCF 3( 60.0%) 8( 61.5%) 11( 61.1%) 
    
- reas 23(100.0% 13(100.0% 36(100.0%) 
pe of ETF, LCF_14, TF_14 a re based on the number of pat. by g wise 
(for subreasons) based on the number of failures. 
ETF-reason1: Severe malaria on D1-D3(WHO); reason2: Parasitaemia on D2(WHO)> baseline count 
ETF-reason3: Fever(>=37,5°C)on D3(WH itaemia > 0; r asitaemia o  25% 
of baseline count 
ETF-reason5: Missing information 
LCF_14-reason1: reason1: Fever(>=37,5°C) and parasitaemia >0 on D4-D14(WHO); reason3: Missing 
In
LP eason1: Temperature < 37,5°C  and parasitaem
 
 
 
rcentages nd LPF_14 a roup, other
O) and paras eason4: Par n D3(WHO)>=
formation 
F_14-r on D14(WHO) ia > 0 
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Table 12-74: Treatment failure by group for Level 3 (PP) 
 
2x daily 
(N=47) 
4x daily 
(N=52) 
Total 
(N=99) 
ETF 0(  0.0%) 0(  0.0%) 0(  0.0%) 
    
LCF_14 5( 10.6%) 5(  9.6%) 10( 10.1%) 
- reason1 5(100.0%) 5(100.0%) 10(100.0%) 
- reason3 0(  0.0%) 0(  0.0%) 
LCF_14 5(100.0%) 5(100.0%) 10(100.0%) 
F_28 6( 12.8%) 10( 19.2%) 16( 16.2%) 
n1 
n2 
_28 6( 12.8%) 10( 19.2%) 16( 16.2%) 
) 6( 37.5%) 
23(100.0%) 44(100.0%) 
0(  0.0%) 
    
TF_14 5( 10.6%) 5(  9.6%) 10( 10.1%) 
- ETF 0(  0.0%) 0(  0.0%) 0(  0.0%) 
- 
    
LPF_14 10( 21.3%) 10( 19.2%) 20( 20.2%) 
- reason1 10(100.0%) 10(100.0%) 20(100.0%) 
    
LC
- reaso 5( 83.3%) 5( 50.0%) 10( 62.5%) 
- reaso 1( 16.7%) 5( 50.0%) 6( 37.5%) 
    
TF
- TF_14 5( 83.3%) 5( 50.0%) 10( 62.5%) 
- LCF_28 (1 1( 16.7%) 5( 50.0%) 
    
LPF_28 21( 44.7%) 23( 44.2%) 44( 44.4%) 
- reason1 21(100.0%) 
percentages of ETF, LCF_14, TF_14 and LPF_14 are based on the number of pat. by group, otherwise 
(for subreasons) based on the number of failures. 
ETF-reason1: Severe malaria on D1
ETF-reason3: Fever(>=37,5°C)on D3(
-D3(WHO); reason2: Parasitaemia on D2(WHO)> baseline count 
n D3(WHO)>= 25% 
 
LPF_14-reason1: Temperature < 37,5°C on D14(WHO) and parasitaemia > 0 
F_28-reason1: LCF_14; reason2:Fever(>=37,5°C) and parasitaemia >0 on D18-D28(WHO); reason3: Missin 
formation 
) without previously meeting any of the criteria of LCF_14 
 
 
 
WHO) and parasitaemia > 0; reason4: Parasitaemia o
of baseline count 
ETF-reason5: Missing information 
LCF_14-reason1: reason1: Fever(>=37,5°C) and parasitaemia >0 on D4-D14(WHO); reason3: Missing
Information 
LC
in
(1
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Table 12-75: Treatment failure by group for all Levels (PP) 
 
2x daily 
(N=173) 
4x daily 
(N=191) 
Total 
(N=364) 
ETF 3(  1.7%)  7(  3.7%) 10(  2.7%) 
- reason1   
   
   
  3( 42.9%) 
   
- reason4 0(  0.0%)  
   
   
   
   
  0(  0.0%) 
TF_14 16(  9.2%) 22( 11.5%) 38( 10.4%) 
   
- LCF_14   
LPF_14 48( 27.7%) 38( 19.9%) 86( 23.6%) 
on1  38(100.0%) 
0(  0.0%) 0(  0.0%) 0(  0.0%) 
- reason2 0(  0.0%) 1( 14.3%) 1( 10.0%) 
- reason2+3 1( 33.3%) 0(  0.0%) 1( 10.0%) 
- reason3 2( 66.7%) 5( 50.0%) 
- reason3+4 0(  0.0%) 1( 14.3%) 1( 10.0%) 
2( 28.6%) 2( 20.0%) 
- reason5 0(  0.0%) 0(  0.0%) 0(  0.0%) 
 
LCF_14 13(  7.5%) 15(  7.9%) 28(  7.7%) 
- reason1 13(100.0%) 15(100.0%) 28(100.0%) 
- reason3 0(  0.0%) 0(  0.0%) 
    
- ETF 3( 18.8%) 7( 31.8%) 10( 26.3%) 
13( 81.3%) 15( 68.2%) 28( 73.7%) 
    
- reas 48(100.0%) 86(100.0%) 
percentages of ETF, LCF_14, TF_14 an e based on the pat. by g ise 
(for subreasons) based on the number of failures. 
aemia > 0; reason4: Parasitaemia on D3(WHO)>= 25% 
d LPF_14 ar  number of roup, otherw
ETF-reason1: Severe malaria on D1-D3(WHO); reason2: Parasitaemia on D2(WHO)> baseline count 
ETF-reason3: Fever(>=37,5°C)on D3(WHO) and parasit
of baseline count 
ETF-reason5: Missing information 
LCF_14-reason1: reason1: Fever(>=37,5°C) and parasitaemia >0 on D4-D14(WHO); reason3: Missing 
Information 
LPF_14-reason1: Temperature < 37,5°C on D14(WHO) and parasitaemia > 0 
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Table 12-76: Treatment failure by group for children < 2 years / Level 1 (FAS) 
 
2x daily 
(N=24) 
4x daily 
(N=30) 
Total 
(N=54) 
ETF   1(  4.2%) 3( 10.0%) 4(  7.4%) 
- reason1   
   
   
   
- reason3+4   
- reason4   
- reason5   
   
LCF_14   
   
   
- reason3 1( 20.0%) 0(  0.0%) 1( 16.7%) 
    
TF_14  
   
   
   
  
 5(100.0%) 
   
0(  0.0%) 0(  0.0%) 0(  0.0%) 
- reason2 0(  0.0%) 0(  0.0%) 0(  0.0%) 
- reason2+3 0(  0.0%) 0(  0.0%) 0(  0.0%) 
- reason3 1(100.0%) 0(  0.0%) 1( 25.0%) 
0(  0.0%) 0(  0.0%) 0(  0.0%) 
0(  0.0%) 0(  0.0%) 0(  0.0%) 
0(  0.0%) 3(100.0%) 3( 75.0%) 
 
5( 20.8%) 1(  3.3%) 6( 11.1%) 
- reason1 3( 60.0%) 0(  0.0%) 3( 50.0%) 
- reason2 1( 20.0%) 1(100.0%) 2( 33.3%) 
6( 25.0%) 4( 13.3%) 10( 18.5%)
- ETF 1( 16.7%) 3( 75.0%) 4( 40.0%) 
- LCF_14 5( 83.3%) 1( 25.0%) 6( 60.0%) 
 
LPF_14 4( 16.7%) 5( 16.7%) 9( 16.7%) 
- reason1 3( 75.0%) 8( 88.9%) 
- reason2 1( 25.0%) 0(  0.0%) 1( 11.1%) 
percentages of ETF, LCF_14, TF_14 and LPF_14 are based on the number of pat. by group, otherwise 
(for subreasons) based on the number of failures. 
LPF_14-reason1: Temperature < 37,5°C on D14(WHO) and parasitaemia > 0; reason2: Missing Information 
 
ETF-reason1: Severe malaria on D1-D3(WHO); reason2: Parasitaemia on D2(WHO)> baseline count 
ETF-reason3: Fever(>=37,5°C)on D3(WHO) and parasitaemia > 0; reason4: Parasitaemia on D3(WHO)>= 25% 
of baseline count 
ETF-reason5: Missing information 
LCF_14-reason1: reason1: Fever(>=37,5°C) and parasitaemia >0 on D4-D14(WHO) 
LCF_14-reason2: treated (D4-D13) with antimalarials although no fever and/or no parasites; reason3: 
Missing Information 
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Table 12-77: Treatment failure by group for children < 2 years / Level 2 (FAS) 
 
2x daily 
(N=18) 
4x daily 
(N=24) 
Total 
(N=42) 
ETF 3( 16.7%) 3( 12.5%) 6( 14.3%) 
- reason1 0(  0.0%) 0(  0.0%) 0(  0.0%) 
- reason2 0(  0.0%) 0(  0.0%) 0(  0.0%) 
- reason2+3 0(  0.0%) 0(  0.0%) 0(  0.0%) 
- reason3 1( 33.3%) 1( 33.3%) 2( 33.3%) 
- reason3+4 0(  0.0%) 
2( 66.7%) 
3( 16.7%) 
4( 57.1%) 
- reason3 1( 33.3%) 
3( 50.0%) 
3( 50.0%) 4( 57.1%) 
 
LPF_14 
6(100.0%) 
0(  0.0%) 
0(  0.0%) 0(  0.0%) 
- reason4 0(  0.0%) 1( 33.3%) 1( 16.7%) 
- reason5 1( 33.3%) 3( 50.0%) 
    
LCF_14 4( 16.7%) 7( 16.7%) 
- reason1 2( 66.7%) 2( 50.0%) 
- reason2 0(  0.0%) 0(  0.0%) 0(  0.0%) 
2( 50.0%) 3( 42.9%) 
    
TF_14 6( 33.3%) 7( 29.2%) 13( 31.0%) 
- ETF 3( 42.9%) 6( 46.2%) 
- LCF_14 7( 53.8%) 
   
6( 33.3%) 4( 16.7%) 10( 23.8%) 
- reason1 4(100.0%) 10(100.0%) 
- reason2 0(  0.0%) 0(  0.0%) 
percentages of ETF, LCF_14, TF_14 and LPF_14 are based on the number of pat. by group, otherwise 
(for subreasons) based on the number of failures. 
ETF evere malaria on D1-D3(W 2: Parasitaemia  baseline
ETF-reason3: Fever(>=37,5°C)on D3(WHO)  rea itaemia on D3(WHO)>= 25% 
of baseline count 
ETF-reason5: Missing information 
LCF_14-reason1: reason1: Fever(>=37,5°C) and parasitaemia >0 on D4-D14(WHO) 
LCF_14-reason2: treated (D4-D13) with  no r no para n3: 
Missing Information 
LPF_14-reason1: Temperature < 37,5°C on D14(WHO) and parasitaemia > 0; reason2: Missing Information 
 
 
-reason1: S HO); reason  on D2(WHO)>  count 
 and parasitaemia > 0; son4: Paras
 antimalarials although  fever and/o sites; reaso
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Table 12-78: Treatment failure by group for children < 2 years / Level 3 (FAS) 
 
2x daily 
(N=6) 
4x daily 
(N=16) 
Total 
(N=22) 
ETF 0 1(  0.0%) (  6.3%) 1(  4.5%) 
- 0 0
- 0 0
- reason2+3 0 0
- 0(  0.0%) 0
- 0 0
- 0 0
- 0 1(100.0%) 
   
L 1 2
- 1 1
- 0(  0.0%) 0(  0.0%) 
- 0 1
   
T 1 3( 18.8%) 
- 0 1( 33.3%) 
- 1 2
   
L 2( 33.3%) 1(  6.3%) 
- 2 1
- 0 0
4( 25.0%) 5( 22.7%) 
%) 
- reason2 0(  0.0%) 1( 25.0%) 1( 20.0%) 
0(  0.0%) 1( 25.0%) 1( 20.0%) 
 
LPF_28 2( 33.3%) 6( 37.5%) 8( 36.4%) 
- reason1 2(100.0%) 6(100.0%) 8(100.0%) 
 reason1 (  0.0%) (  0.0%) 0(  0.0%) 
 reason2 (  0.0%) (  0.0%) 0(  0.0%) 
(  0.0%) (  0.0%) 0(  0.0%) 
 reason3 (  0.0%) 0(  0.0%) 
 reason3+4 (  0.0%) (  0.0%) 0(  0.0%) 
 reason4 (  0.0%) (  0.0%) 0(  0.0%) 
 reason5 (  0.0%) 1(100.0%) 
 
CF_14 ( 16.7%) ( 12.5%) 3( 13.6%) 
 reason1 (100.0%) ( 50.0%) 2( 66.7%) 
 reason2 0(  0.0%) 
 reason3 (  0.0%) ( 50.0%) 1( 33.3%) 
 
F_14 ( 16.7%) 4( 18.2%) 
 ETF (  0.0%) 1( 25.0%) 
 LCF_14 (100.0%) ( 66.7%) 3( 75.0%) 
 
PF_14 3( 13.6%) 
 reason1 (100.0%) (100.0%) 3(100.0%) 
 reason2 (  0.0%) (  0.0%) 0(  0.0%) 
    
LCF_28 1( 16.7%) 
- reason1 1(100.0%) 2( 50.0%) 3( 60.0
- reason3 
   
TF_28 1( 16.7%) 5( 31.3%) 6( 27.3%) 
- TF_14 1(100.0%) 3( 60.0%) 4( 66.7%) 
- LCF_28 (1) 2( 40.0%) 2( 33.3%)  
    
percentages of ETF, LCF_14, TF_14 and LPF_14 are based on the number of pat. by group, otherwise 
(for subreasons) based on the number of failures. 
ETF-reason1: Severe malaria on D1-D3(WHO); reason2: Parasitaemia on D2(WHO)> baseline count 
ETF-reason3: Fever(>=37,5°C)on D3(WHO) and parasitaemia > 0; reason4: Parasitaemia on D3(WHO)>= 25% 
of baseline count 
ETF-reason5: Missing information 
LCF_14-reason1: reason1: Fever(>=37,5°C) and parasitaemia >0 on D4-D14(WHO) 
LCF_14-reason2: treated (D4-D13) with antimalarials although no fever and/or no parasites; reason3: 
Missing Information 
LPF_14-reason1: Temperature < 37,5°C on D14(WHO) and parasitaemia > 0; reason2: Missing Information 
LCF_28-reason1: LCF_14; reason2:Fever(>=37,5°C) and parasitaemia >0 on D18-D28(WHO); reason3: Missin 
information 
(1) without previously meeting any of the criteria of LCF_14 
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Table 12-79: Treatment failure by group for children < 2 years / all Levels (FAS) 
 
2x daily 
(N=48) 
4x daily 
(N=70) 
Total 
(N=118) 
ETF 4(  8.3%) 7( 10.0%) 11(  9.3%) 
- reason1 .0
- reason2 0(  0.0%) 
- reason2+3 . 0(  0.0%) 
- reason3 
- reason3+4 .
- reason4 
- reason5 
  
LCF_14 
- reason1 .
- reason2 
- reason3 2( 22.
  
TF_14 13( 27.1%) 14( 20.0%) 
- ETF 11( 40.7%) 
- LCF_14 9( 69.2%) 7( 50.0%) 16( 59.3%) 
  
LPF_14 5
- reason1 1  
- reason2 
0(  0 %) 0(  0.0%) 0(  0.0%) 
0(  0.0%) 
0
0(  0.0%) 
0(  0 %) 0(  0.0%) 
2( 50.0%) 1( 14.3%) 3( 27.3%) 
0(  0 0%) 0(  0.0%) 0(  0.0%) 
0(  0
2( 50.0%) 
.0%) 1( 14.3%) 
5( 71.4%) 
1(  9.1%) 
7( 63.6%) 
  
9( 18.8%) 
7
7( 10.0%) 16( 13.6%) 
6( 66 %) 3( 42.9%) 9( 56.3%) 
1( 11.1%) 
2
1( 14.3%) 2( 12.5%) 
 %) 3( 42.9%) 5( 31.3%)
  
27( 22.9%) 
4( 30.8%) 7( 50.0%) 
  
12( 2 .0%) 
.7
10( 14.3%) 22( 18.6%) 
11( 9 %) 10(100.0%) 21( 95.5%)
1(  8.3%) 0(  0.0%) 1(  4.5%) 
percentages of ETF, LC 4, _14  th t. rwise 
(for subreasons) based on the number of failures. 
ETF-reason1: Severe m o re em
ETF-reason3: Fever(>=37,5°C)on D3(WHO) and  25% 
of baseline count 
ETF-reason5: Missing information 
LCF_14-reason1: reason1: Fever(>=37,5°C) and parasitaemia >0 on D4-D14(WHO) 
LCF_14-reason2: treated (D4-D13) with antimalarials although no fever and/or no parasites; reason3: 
Missing Information 
LPF_14-reason1: Temperature < 37,5°C on D14(WHO) and parasitaemia > 0; reason2: Missing Information 
 
 
 
F_1 TF_14 and LPF  are based on e number of pa by group, othe
alaria n D1-D3(WHO); ason2: Parasita i aa on D2(WHO)> b seline count 
parasitaemia > 0; reason4: Parasitaemia on D3(WHO)>=
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Table 12-80: Treatment failure by group for children >= 2 years / Level 1 (FAS) 
 
2x daily 
(N=48) 
4x daily 
(N=45) 
Total 
(N=93) 
ETF 4(  8.3%) 4(  8.9%) 8(  8.6%) 
- reason1 0
- reason2 
- reason2+3 0(  0.0%) 
- reason3 
- reason3+4 
- reason4 0(  0.0%) 
- reason5 6( 75.0%) 
 
LCF_14 5( 11.1%) 10( 10.8%) 
- reason1 
- reason2 
- reason3 
  
TF_14 
- ETF 
- LCF_14 5( 55.6%) 5( 55.6%) 10( 55.6%) 
  
LPF_14 
- reason1 . 22(100.0%) 
- reason2 0(  0.
0(  0. %) 0(  0.0%) 0(  0.0%) 
0(  0.0%) 
0
0(  0.0%) 0(  0.0%) 
0(  0. %) 0(  0.0%) 
0(  0.0%) 
0
1( 25.0%) 1( 12.5%) 
0(  0. %) 1( 25.0%) 1( 12.5%) 
0(  0.
4(100.0%) 
0%) 0(  0.0%) 
2( 50.0%) 
   
5( 10.4%) 
0%2( 40. ) 2( 40.0%) 4( 40.0%) 
1( 20.0%) 
0%
2( 40.0%) 3( 30.0%) 
2( 40. ) 1( 20.0%) 3( 30.0%) 
  
9( 18.8%) 9( 20.0%) 18( 19.4%) 
4( 44.4%) 4( 44.4%) 8( 44.4%) 
  
12( 25.0%) 
0
10( 22.2%) 22( 23.7%) 
12(100 %) 10(100.0%) 
0%) 0(  0.0%) 0(  0.0%) 
percentages of ETF, LC 4, _14 are based on th t. rwise 
(for ubreasons) based  the
ETF- ason1: Severe m o r em
ETF-reason3: Fever(>= )o  25% 
of baseline count 
ETF-reason5: Missing 
LCF_14-reason1: reason1: Fever(>=37,5°C) and parasitaemia >0 on D4-D14(WHO) 
LCF_14-reason2: treated (D4-D13) with antimalarials although no fever and/or no parasites; reason3: 
Missing Information 
LPF_14-reason1: Temperature < 37,5°C on D14(WHO) and parasitaemia > 0; reason2: Missing Information 
 
 
 
F_1 TF_14 and LPF e number of pa by group, othe
 s on  number of failures. 
re alaria 
37 °C
n D1-D3(WHO); eason2: Parasita ia on D2(WHO)> baseline count 
,5 n D3(WHO) and parasitaemia > 0; reason4: Parasitaemia on D3(WHO)>=
information 
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Table 12-81: Treatment failure by group for children >= 2 years / Level 2 (FAS) 
 
2x daily 
(N=54) 
4x daily 
(N=54) 
Total 
(N=108) 
ETF .4%) 4(  7 3(  5.6%) 7(  6.5%) 
- reason1 .0
- reason2 
- reason2+3 .
- reason3 
- reason3+4 .
- reason4 .0%) 
- reason5 
  
LCF_14 
- reason1 .
- reason2 
- reason3 . %) 
  
TF_14 7( 13.0%) 11( 20.4%) 18( 16.7%) 
- ETF 
- LCF_14 3( 42.9%) 8( 72.7%) 11( 61.1%) 
  
LPF_14 1.5%) 
- reason1 0.
- reason2 
1( 25 %) 0(  0.0%) 1( 14.3%) 
0(  0.0%) 
0
1( 33.3%) 1( 14.3%) 
1( 25 %) 0(  0.0%) 1( 14.3%) 
0(  0.0%) 1( 33.3%) 1( 14.3%) 
0(  0 0%) 0(  0.0%) 0(  0.0%) 
0(  0
2( 50.0%) 
1( 33.3%) 
0(  0.0%) 
1( 14.3%) 
2( 28.6%) 
  
3(  5.6%) 
3
8( 14.8%) 11( 10.2%) 
1( 33 %) 6( 75.0%) 7( 63.6%) 
0(  0.0%) 
7
0(  0.0%) 0(  0.0%) 
2( 66 2( 25.0%) 4( 36.4%) 
  
4( 57.1%) 3( 27.3%) 7( 38.9%) 
  
17( 3 9( 16.7%) 26( 24.1%) 
17(10 0%) 9(100.0%) 26(100.0%) 
0(  0.0%) 0(  0.0%) 0(  0.0%) 
percentages of ETF, LC 4, _1 h t. rwise 
(for ubreasons) based  the
ETF- ason1: Severe m o r em s
ETF- ason3: Fever(>= )o parasitaemia > 0;  25% 
of 
ETF
LCF_14-reason1: reason1: Fever(>=37,5°C) and parasitaemia >0 on D4-D14(WHO) 
LCF_14-reason2: treated (D4-D13) with antimalarials although no fever and/or no parasites; reason3: 
Missing Information 
LPF_14-reason1: Temperature < 37,5°C on D14(WHO) and parasitaemia > 0; reason2: Missing Information 
 
 
 
F_1 TF_14 and LPF 4 are based on t e number of pa by group, othe
 s on  number of failures. 
re alaria 
37 °C
n D1-D3(WHO); eason2: Parasita ia on D2(WHO)> ba eline count 
re ,5 n D3(WHO) and  reason4: Parasitaemia on D3(WHO)>=
baseline count 
-reason5: Missing information 
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Ta 82  T ) ble 12- : reatment failure by group for children >= 2 years / Level 3 (FAS
 
2x daily 
(N=47) 
4x daily 
(N=46) 
Total 
(N=93) 
ETF 2(  4.3%) 1(  2.2%) 3(  3.2%) 
- reason1 .0
- reason2 
- reason2+3 .
- reason3 0(  0.0%) 
- reason5 2(100.0%) 1(100.0%) 3(100.0%) 
- reason1 50.0%) 4%) 
- reason2 .0
- reason3 
  
TF_14 1
- .0 3( 14.3%) 
- LCF_14 
- reason1 8(100.0%) 9(100.0%) 17(100.0%) 
- reason2 0(  0.0%) 0(  0.0%) 0(  0.0%) 
    
LCF_28 9( 19.1%) 14( 30.4%) 23( 24.7%) 
- reason1 8( 88.9%) 10( 71.4%) 18( 78.3%) 
- reason2 1( 11.1%) 4( 28.6%) 5( 21.7%) 
- reason3 0(  0.0%) 0(  0.0%) 0(  0.0%) 
    
TF_28 11( 23.4%) 15( 32.6%) 26( 28.0%) 
- TF_14 10( 90.9%) 11( 73.3%) 21( 80.8%) 
- LCF_28 (1) 1(  9.1%) 4( 26.7%) 5( 19.2%) 
    
LPF_28 19( 40.4%) 17( 37.0%) 36( 38.7%) 
- reason1 19(100.0%) 17(100.0%) 36(100.0%) 
0(  0 %) 0(  0.0%) 0(  0.0%) 
0(  0.0%) 
0
0(  0.0%) 0(  0.0%) 
0(  0 %) 0(  0.0%) 0(  0.0%) 
0(  0.0%) 0(  0.0%) 
- reason3+4 0(  0.0%) 0(  0.0%) 0(  0.0%) 
- reason4 0(  0.0%) 0(  0.0%) 0(  0.0%) 
    
LCF_14 8( 17.0%) 10( 21.7%) 18( 19.4%) 
4(  4( 40.0%) 8( 44.
0(  0 %) 0(  0.0%) 0(  0.0%) 
4( 50.0%) 6( 60.0%) 10( 55.6%) 
  
10( 2 .3%) 11( 23.9%) 21( 22.6%) 
 ETF 2( 20 %) 1(  9.1%) 
8( 80.0%) 10( 90.9%) 18( 85.7%) 
    
LPF_14 8( 17.0%) 9( 19.6%) 17( 18.3%) 
percentages of ETF, LCF_14, TF_14 and LPF_14 are based on the number of pat. by group, otherwise 
(for subreasons) based on the number of failures. 
ETF-reason1: Severe malaria on D1-D3(WHO); reason2: Parasitaemia on D2(WHO)> baseline count 
ETF-reason3: Fever(>=37,5°C)on D3(WHO) and parasitaemia > 0; reason4: Parasitaemia on D3(WHO)>= 25% 
of baseline count 
ETF-reason5: Missing information 
LCF_14-reason1: reason1: Fever(>=37,5°C) and parasitaemia >0 on D4-D14(WHO) 
LCF_14-reason2: treated (D4-D13) with antimalarials although no fever and/or no parasites; reason3: 
Missing Information 
LPF_14-reason1: Temperature < 37,5°C on D14(WHO) and parasitaemia > 0; reason2: Missing Information 
LCF_28-reason1: LCF_14; reason2:Fever(>=37,5°C) and parasitaemia >0 on D18-D28(WHO); reason3: Missin 
information 
(1) without previously meeting any of the criteria of LCF_14 
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Table 12-8 tm n els (FAS) 3: Trea e t failure by group for children >= 2 years / all Lev
 
2x daily 
(N=149) 
4x daily 
(N=145) 
Total 
(N=294) 
E 10(  6.7%) 8(  5.5%) 18(  6.1%) TF 
- 1(  5.6%) 
- 0( 1(  5.6%) 
- 1( 10.0%) ) 
- 0(  0.0%) 2( 25.0%) ) 
- 0(  0.0%) 1( 12.5%) ) 
- reason4 0(  0.0%) 1( 12.5%) 
- reason5 8( 80.0%) 3( 37.5%) 11( 61.1%) 
   
L 39( 13.3%) 
- 19( 48.7%) 
- 1(  6.3%) ) 
- 8( 50.0%) 9( 39.1%) 17( 43.6%) 
  
TF_14 26( 17.4%) 31( 21.4%) 57( 19.4%) 
- 10( 38.5%) 8( 25.8%) 18( 31.6%) 
- LCF_14 16( 61.5%) 23( 74.2%) 39( 68.4%) 
    
L 37( 65( 22.1%) 
- 37(100.0%) %) 
- 0(  0.0%) 0(  0.0%) ) 
 reason1 1( 10.0%) 0(  0.0%) 
 reason2   0.0%) 1( 12.5%) 
0(  0.0%)  reason2+3 1(  5.6%
 reason3 2( 11.1%
 reason3+4 1(  5.6%
1(  5.6%) 
 
CF_14 16( 10.7%) 
7( 43.8%) 
23( 15.9%) 
 reason1 12( 52.2%) 
2(  8.7%)  reason2 3(  7.7%
 reason3 
  
 ETF 
PF_14  24.8%) 28( 19.3%) 
28(100.0%)  reason1 65(100.0
 reason2 0(  0.0%
perce  TF_14 and LPF_14 are based on the number of pat. by g herwise 
(for subreasons) based on the number of failures. 
ETF-reason1: Severe malaria on D1-D3(WHO); reason2: Parasitaemia on D2(WHO)> baseline count 
ETF-reason3: Fever(>=37,5°C)on D3(WHO) and itaemia > 0; reason4: Parasitaemia on D3(WHO)>= 25% 
of baseline count 
ETF-reason5: Missing information 
LCF_14-reason1: reason1: Fever(>=37,5°C) and parasitaemia >0 on D4-D14(WHO) 
LCF_1 4-D13) with antimalarials although no fever and/or no para eason3: 
Missi
LPF_14-reason1: Temperature < 37,5°C on D14(WHO) and parasitaemia > 0; reason2: Missing Information  
 
ntages of ETF, LCF_14, roup, ot
paras
4-reason2: treated (D
ng Information 
sites; r
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Table 12-8 y e  and level 4: Earl tr atment failures with two-sided 95% CI by group
Analysis set Level Statistic 2x daily 4x daily Total 
FAS 1 events/N (%) 72 ( 6.9%) 7/75 ( 9.3%) 12/147 ( 8.2%) 5/
  exact 95% CI [ 2.29%, 15.47%] [ 3.84%, 18.29%] [ 4.29%, 13.83%]
2 events/N (%) 7/72 ( 9.7%) 13/150 ( 8.7%) 
 exact 95% C 19.01%] [ 2.88%, 15.99%] [ 4.70%, 14.36%]
events/N (%) 53 ( 3.8%) 2/62 ( 3.2%) 4/115 ( 3.5%) 
exact 95% CI [ 0.46%, 12.98%] [ 0.39%, 11.17%] [ 0.96%,  8.67%]
events/N (%) 14/197 ( 7.1%) 15/215 ( 7.0%) 29/412 ( 7.0%) 
  exact 95% CI [ 3.94%, 11.64%] [ 3.96%, 11.25%] [ 4.76%,  9.95%]
     
1 events/N (%) 2 ( 1.6%) 2/66 ( 3.0%) 3/128 ( 2.3%) 
 exact 95 66%] [ 0.49%,  6.70%]
2 events/N (% 3.1%) 5/73 ( 6.8%) 7/137 ( 5.1%) 
exact 95% CI [ 0.38%, 10.84%] [ 2.26%, 15.26%] [ 2.08%, 10.24%]
events/N (%) 47 ( 0.0%) 0/52 ( 0.0%) 0/99 ( 0.0%) 
exact 95% CI [ 0.00%,  7.55%] [ 0.00%,  6.85%] [ 0.00%,  3.66%]
Total events/N (%) 173 ( 1.7%) 7/191 ( 3.7%) 10/364 ( 2.7%) 
 exact 95% CI [ 0.36%,  4.98%] [ 1.49%,  7.41%] [ 1.33%,  4.99%]
    
1 events/N %) 2/92 ( 2.2%) 
 exact 95% C 11.77%] [ 0.05%, 11.29%] [ 0.26%,  7.63%]
events/N (%) 64 ( 3.1%) 5/73 ( 6.8%) 7/137 ( 5.1%) 
exact 95% CI [ 0.38%, 10.84%] [ 2.26%, 15.26%] [ 2.08%, 10.24%]
events/N (%) 47 ( 0.0%) 0/52 ( 0.0%) 0/99 ( 0.0%) 
 exact 95% CI [ 0.00%,  7.55%] [ 0.00%,  6.85%] [ 0.00%,  3.66%]
Total events/N (%) 3/156 ( 1.9%) 6/172 ( 3.5%) 9/328 ( 2.7%) 
 exact 95% CI 0%,  5.52%] [ 1.29%,  7.44%] [ 1.26%,  5.14%]
 6/78 ( 7.7%) 
 I [ 4.00%, 
 3 2/
  
 Total 
 
PP 1/6
 % CI [ 0.04%,  8. [ 0.37%, 10.52%] 
 ) 2/64 ( 
  
 3 0/
  
 3/
 
  
PP *  (%) 1/45 ( 2.2 1/47 ( 2.1%) 
 I [ 0.06%, 
 2 2/
  
 3 0/
 
 
 [ 0.4
PP *: PP set in the strong sense, created by: t_report.sas 
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Table 12-8 t en  and level 5: Trea m t failures (day 14) with two-sided 95% CI by group
Analysis set Level Statistic 2x daily 4x daily Total 
FAS 1 events/N (%) /72 (20.8%) 13/75 (17.3%) 28/147 (19.0%) 15
  exact 95% CI [12.16%, 32.02%] [ 9.57%, 27.81%] [13.05%, 26.34%]
2 events/N %) 18/78 (23.1%) 31/150 (20.7%) 
 exact 95% C 28.89%] [14.29%, 34.00%] [14.49%, 28.03%]
events/N (%) /53 (20.8%) 14/62 (22.6%) 25/115 (21.7%) 
exact 95% CI [10.84%, 34.11%] [12.93%, 34.97%] [14.59%, 30.40%]
events/N (%) 39/197 (19.8%) 45/215 (20.9%) 84/412 (20.4%) 
 exact 95% CI [14.47%, 26.05%] [15.70%, 26.99%] [16.60%, 24.61%]
    
1 events/N (%) 2 ( 9.7%) 4/66 ( 6.1%) 10/128 ( 7.8%) 
 exact 95 88%]
2 events/N (% 7.8%) 13/73 (17.8%) 18/137 (13.1%) 
exact 95% CI [ 2.59%, 17.30%] [ 9.84%, 28.53%] [ 7.98%, 19.97%]
events/N (%) 47 (10.6%) 5/52 ( 9.6%) 10/99 (10.1%) 
exact 95% CI [ 3.55%, 23.10%] [ 3.20%, 21.03%] [ 4.95%, 17.79%]
Total events/N (%) 16/173 ( 9.2%) 22/191 (11.5%) 38/364 (10.4%) 
  exact 95% CI [ 5.38%, 14.58%] [ 7.36%, 16.92%] [ 7.49%, 14.05%]
    
1 events/N %) 7/92 ( 7.6%) 
 exact 95% C 21.22%] [ 1.34%, 17.54%] [ 3.11%, 15.05%]
 2 events/N (%) 64 ( 7.8%) 13/73 (17.8%) 18/137 (13.1%) 
exact 95% CI [ 2.59%, 17.30%] [ 9.84%, 28.53%] [ 7.98%, 19.97%]
 3 events/N (%) 47 (10.6%) 5/52 ( 9.6%) 10/99 (10.1%) 
 exact 95% CI [ 3.55%, 23.10%] [ 3.20%, 21.03%] [ 4.95%, 17.79%]
Total events/N (%) 14/156 ( 9.0%) 21/172 (12.2%) 35/328 (10.7%) 
  exact 95% CI 9%, 14.60%] [ 7.72%, 18.06%] [ 7.55%, 14.53%]
  (%) 13/72 (18.1
 I [ 9.98%, 
 3 11
  
 Total 
 
  
PP 6/6
 % CI [ 3.63%, 19. [ 1.68%, 14.80%] [ 3.81%, 13.90%]
 ) 5/64 ( 
  
 3 5/
  
 
  
PP *  (%) 4/45 ( 8.9 3/47 ( 6.4%) 
 I [ 2.48%, 
5/
  
5/
 
 
[ 4.9
PP *: PP set in the strong sense, created by: t_report.sas 
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Table 12-86: C  or p up and level linical arasitological failures (day 14) with 95% CI by gro
Analysis set Level Statistic 2x daily 4x daily Total 
FAS 1 events/N (%) /72 (40.3%) 25/75 (33.3%) 54/147 (36.7%) 29
  exact 95% CI [28.88%, 52.50%] [22.86%, 45.17%] [28.94%, 45.07%]
 2 events/N (%) 72 (50.0%) 31/78 (39.7%) 67/150 (44.7%) 
 exact 95% C 62.02%] [28.83%, 51.46%] [36.55%, 52.99%]
3 events/N %) 24/62 (38.7%) 45/115 (39.1%) 
exact 95% CI [26.45%, 54.00%] [26.60%, 51.93%] [30.16%, 48.67%]
 events/N (%) 86/197 (43.7%) 80/215 (37.2%) 166/412 (40.3%) 
exact 95% CI [36.62%, 50.89%] [30.73%, 44.04%] [35.52%, 45.20%]
    
1 events/N (%) /62 (33.9%) 19/66 (28.8%) 40/128 (31.3%) 
 exact 95% CI [22.33%, 47.01%] [18.30%, 41.25%] [23.35%, 40.04%]
2 events/N (% 3.8%) 26/73 (35.6%) 54/137 (39.4%) 
 exact 95 72%]
events/N (%) /47 (31.9%) 15/52 (28.8%) 30/99 (30.3%) 
exact 95% CI [19.09%, 47.12%] [17.13%, 43.08%] [21.47%, 40.35%]
events/N (%) 64/173 (37.0%) 60/191 (31.4%) 124/364 (34.1%) 
 exact 95% CI [29.79%, 44.65%] [24.90%, 38.51%] [29.21%, 39.19%]
     
1 events/N (%) 45 (33.3%) 15/47 (31.9%) 30/92 (32.6%) 
 exact 95% C 48.95%] [19.09%, 47.12%] [23.20%, 43.18%]
2 events/N %) 26/73 (35.6%) 54/137 (39.4%) 
exact 95% CI [31.37%, 56.72%] [24.75%, 47.69%] [31.18%, 48.12%]
events/N (%) /47 (31.9%) 15/52 (28.8%) 30/99 (30.3%) 
exact 95% CI [19.09%, 47.12%] [17.13%, 43.08%] [21.47%, 40.35%]
Total events/N (%) 58/156 (37.2%) 56/172 (32.6%) 114/328 (34.8%) 
 exact 95% CI [29.59%, 45.27%] [25.62%, 40.11%] [29.61%, 40.18%]
36/
 I [37.98%, 
  (%) 21/53 (39.6
  
 Total
  
  
PP 21
 
 ) 28/64 (4
 % CI [31.37%, 56. [24.75%, 47.69%] [31.18%, 48.12%]
 3 15
  
 Total 
 
 
PP * 15/
 I [20.00%, 
  (%) 28/64 (43.8
  
 3 15
  
 
 
PP *: PP set in the strong sense, two-sided 95% confidence intervals, created by: t_report.sas 
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Table 12-87: Treatment failures (day 28) with 95% CI by group for level 3 
Analysis set Level Statistic 2x daily 4x daily Total 
FAS 3 events/N (%) /53 (22.6%) 20/62 (32.3%) 32/115 (27.8%) 12
  exact 95% CI [12.28%, 36.21%] [20.94%, 45.34%] [19.87%, 36.95%]
3 events/N %) 10/52 (19.2%) 16/99 (16.2%) 
 exact 95% C 25.74%] [ 9.63%, 32.53%] [ 9.53%, 24.91%]
events/N (%) 47 (12.8%) 10/52 (19.2%) 16/99 (16.2%) 
exact 95% CI [ 4.83%, 25.74%] [ 9.63%, 32.53%] [ 9.53%, 24.91%]
PP  (%) 6/47 (12.8
 I [ 4.83%, 
PP * 3 6/
  
PP *: PP set in the strong sense, two-sided 95% confidence intervals, created by: t_report.sas 
 
 
Table 12-88: Clinical or parasito ay 28  group f  level 3 logical failures (d ) with 95% CI by or
Analysis set Level Statistic 2x daily 4x daily Total 
FAS 3 events/N (%) 33/53 (62.3%) 43/62 (69.4%) 76/115 (66.1%) 
  exact 95% CI [47.89%, 75.21%] [56.35%, 80.44%] [56.67%, 74.65%]
events/N (%) 27/47 (57.4%) 33/52 (63.5%) 60/99 (60.6%) 
 exact 95% CI [42.18%, 71.74%] [48.96%, 76.38%] [50.28%, 70.28%]
3 events/N (%) /47 (57.4%) 33/52 (63.5%) 60/99 (60.6%) 
 exact 95% CI [42.18%, 71.74%] [48.96%, 76.38%] [50.28%, 70.28%]
PP 3 
 
PP * 27
 
PP *: PP set in the strong sense, two-sided 95% confidence intervals, created by: t_report.sas 
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Tab S) le 12-89: Fever clearance time by group and level (FA
 2x daily 4x daily Comparison 
Level   1   
- N 72 75  
Med 6.0 [ 5.5; 10  [ 5
Min 0.0,  28.6 0.1,  47.  
p-v  
p-v n)   0.5422
v  
   
vel  
N 72 77  
Med 5.3 [ 4.1;  5  [ 2
Min 0.0,  35.4 0.1,  37.6  
p-v  
p-v )   0.6975
v  
   
vel  
N 53 62  
Med 4.4 [ 1.6;  6  [ 1
Min 0.0,  19.6 0.0,  17.4  
p-v  
p-v )   0.3522
v  
   
l l  
N 197 214  
Med  [ 5.3;  5  [ 5
Min 0.0,  35.4 0.0,  47.  
p-v  
p-v   0.3336
value (-2Log(LR))  
- ian [CI] .5] 5.8 .3;  6.6]  
- , Max 4 
- alue (Log-Rank)  0.9880 
- alue (Wilcoxo  
- p- alue (-2Log(LR))  0.9598 
 
Le  2   
- 
- ian [CI] .9] 5.4 .2;  6.2]  
- , Max  
- alue (Log-Rank)  0.9423 
- alue (Wilcoxon  
- p- alue (-2Log(LR))  0.8368 
 
Le  3   
- 
- ian [CI] .0] 1.9 .4;  5.7]  
- , Max  
- alue (Log-Rank)  0.4508 
- alue (Wilcoxon  
- p- alue (-2Log(LR))  0.5210 
 
Al evels   
- 
- ian [CI] 5.6 .9] 5.6 .1;  5.9]  
- , Max 4 
- alue (Log-Rank)  0.7360 
- alue (Wilcoxon)  
- p-  0.6174 
The median is based on survival techniques. LR=Likelihood Ratio Test. CI=95% confidence interval 
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Table 12-90: Fever clearance time by group and level (PP) 
 2x daily 4x daily Comparison 
Level 1    
- N 
- Median [CI]  [ 5 5.6 [ 4.9;  6.8] 
- Min, Max 0.0
- p-value (Log-Rank) 
- p-value (Wilcoxon) 
- p-value (-2Log(LR)) 
 
Level 2  
N 
- Median [CI]  [ 5.3 [ 1.5;  6.2] 
- Min, Max 0.0,
- p-value (Log-Rank) 
- p-value (Wilcoxon) 
- p-value (-2Log(LR)) 
 
Level 3 
- N 47 52 
dian [CI]  [ 1 1.6 [ 1.2;  5.7] 
- Min, Max 0.0
- p-value (Log-Rank) 
- p-value (Wilcoxon)   0.5134 
- p-value (-2Log(LR)) 
 
All levels 
- N 
- Medi
- Min, Max 0.0,  35. 0.0,  37.6  
- p-value (Log-Rank)   0.8054 
- p-value (Wilcoxon)   0.5734 
- p-value (-2Log(LR))   0.9565 
45 47  
5.8 .4; 10.4]  
,  28.6 0.1,  36.8  
  0.6742 
  0.7910 
  0.7911 
   
  
- 64 73  
5.3 4.1;  5.8]  
  35.4 0.1,  37.6  
  0.9497 
  0.6748 
  0.8562 
   
   
 
- Me 1.9 .5;  5.7]  
,  19.4 0.0,  17.4  
  0.8292 
  0.8404 
   
   
156 172  
an [CI] 5.4 [ 4.6;  5.8] 5.4 [ 4.4;  5.8]  
4 
The median is based on survival techniques. LR=Likelihood Ratio Test. CI=95% confidence interval 
 
T 
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T  able 12-91: Parasite clearance time by group and level (FAS)
 2x daily 4x daily Comparison 
Level 1    
- N 72 
 [CI] 67.6 [66.6; 68.4] 68.1 [67.7; 68.4] 
20.5,  95.0 
  
lcoxon)  
2Log(LR))  
 
 
71 7
68.1 [67.7; 69.0] [67
19.9,  93.9 .9,
 (Log-Rank)  
Wilcoxon)  
(LR))  
 
 
- N  
- Median [CI] 69.0 [68.3; 69.4] 68.1 [67.5; 68.7]  
- Min, Max 21.5,  94.0 19.4,  94.2  
- p-value (Log-Rank)   0.3392 
- p-value (Wil 0.0835 
- p-value (-2Log(LR)) 0.7574 
 
 
N 196 2
[CI] 68.3 [67.8; 68.8] 68.0 [67.7; 68.3] 
19.9,  95.0 .8,
  
  
Log(LR))  
73  
- Median
- Min, Ma
 
x 
- p-value (Log-Rank)
18.8,  92.9  
 0.5022 
- p-value (Wi  0.5937 
- p-value (-  0.9912 
   
Level 2   
- N 7  
- Median [CI]  67.8 .3; 68.7]  
- Min, Max 42   94.9  
- p-value  0.7201 
- p-value (  0.3870 
- p-value (-2Log  0.7067 
   
Level 3   
53 62 
coxon)   
  
 
All levels 
  
 
12 
 
-  
- Median  
- Min, Max 18   94.9  
- p-value (Log-Rank)
ilcoxon)
 0.3196 
- p-value (W
-2
 0.2928 
- p-value (  0.6962 
The median is based on survival techniques. LR=Likelihood Ratio Test. CI=95% confidence interval 
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T 2- 2:able 1 9  Parasite clearance time by group and level (PP) 
 2x daily 4x daily Comparison 
    
Level 1    
62 66 
42.5,  95.0 
 67.5 [66.6; 68.3] [67
og-Rank)  
lcoxon)  
- p-value (-2Log(LR))  
  
Level 2  
- N 64 7
- Min, Max 42.1,  93.9 .9,
I] 68.2 [67.7; 69.0] [67
og-Rank)  
- p-value (Wilcoxon)   0.4233 
- p-value (-2Log(LR))   0.8107 
    
Level 3    
- N 47 52  
- Min, Max 44.0,  94.0 43.6,  94.2  
- Median [CI]  
- p-value (Log-Rank) 0.4679 
p-value (Wilcoxon)  
 
 
ls   
173 191 
42.1,  95.0 .8,
 68.3 [67.8; 68.8] [67
 
ilcoxon)   
Log(LR))   
- N 
- Min, Ma
 
x 
- Median [CI]
18.8,  92.9 
 68.0 
 
.0; 68.4]  
- p-value (L  0.2990 
- p-value (Wi  0.7093 
 0.8430 
  
  
3  
42   94.9  
- Median [C  67.8 .3; 68.7]  
- p-value (L  0.7559 
 69.0 [68.4; 69.4] 68.1 [67.5; 68.9] 
  
-  0.1228 
- p-value (-2Log(LR))  
 
0.7736 
 
Al
 
 l leve
- N  
- Min, Max 18   94.9 
.6; 68.3] 
 
- Median [CI]  68.0  
- p-value (Log-Rank) 
- p-value (W
 0.2735 
0.2698 
- p-value (-2 0.6864 
The median is based on survival techniques. LR=Likelihood Ratio Test. CI=95% confidence interval 
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Table 12-93: Parasite clearance time by group and level (PP in the strong sense) 
 2x daily 4x daily Comparison 
Level 1    
- N 
- Median [CI] 
45 47
67.0 [66.2; 68.3] [67.0; 68.6] 
x 42.5,  94.5 18.8,  92.9 
 
 
7
9.0] [67
.1,  93.9 .9,
 
 
 
- Median [CI]   
- Min, Max 44.0,  94.0 43.6,  94.2  
- p-value (Log-Rank)   0.4679 
- p-value (Wilcoxon)   0.1228 
- p-value (- ) 0.7736 
   
l levels    
156 1
68.3 [67.8; 68.9] [67
 42.1,  94.5 18.8,  94.9 
ank)  
 
- p-value (-2Log(LR))  
  
 68.0  
- Min, Ma
- p-value 
 
(Log-Rank)  
- p-value (Wilcoxon)  
0.5432 
0.4979  
 - p-value (-2Log(LR)) 0.8904 
  
Level 2  
  
  
- N 64 
- Median [CI] 68.2 [67.7; 6
3  
 67.8 .3; 68.7]  
- Min, Max 42 42   94.9  
- p-value (Log-Rank) 
- p-value (Wilcoxon) 
 0.7416 
 
 
0.3928 
0.7901 - p-value (-2Log(LR))  
    
Level 3 
- N 
  
 47 52 
69.0 [68.4; 69.4] 68.1 [67.5; 68.9]
2Log(LR)    
 
Al
- N 
 Median [CI] 
72 
.6; 6 .4] 
 
-  68.0 8  
- Min, Max  
- p-value (Log-R  0.4661 
- p-value (Wilcoxon)  0.2939 
 0.6953 
The median is based on survival techniques. LR=Likelihood Ratio Test. CI=95% confidence interval 
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Table 12-94: AE overview by group and level (FAS) 
Dose level txt 2x daily 4x daily Total 
1 25/72 (34.7%) 23/75 (30.7%) 32.7%)  Num. of Pat. with >=1 AE 48/147 (
 Num. of AEs 30 27 57 
2 Num. of Pat. with >=1 AE 9/72 (12.5%) 12/78 (15.4%) 21/150 (14.0%) 
 
3 5/5 10/62 (16.1%) 3.0%) 
Tot 39/197 (19.8%) 45/215 (20.9%) 0.4%) 
1 t. with >=1 RAE ./7
 
2 1/7 .3%) 
2 
3 ./5 .9%) 
Tot RAE 1/197 ( 0.5%) 2/215 ( 0.9%) 3/412 ( 0.7%) 
 Num. of RAEs 3 
1 Num. of Pat. with >=1 SAE ./75 (  . %) ./147 (  . %) 
 Num. of SAEs . . . 
2 Num. of Pat. with >=1 SAE 1/72 ( 1.4%) 1/78 ( 1.3%) 2/150 ( 1.3%) 
 Num. of SAEs 2 
3 Num. wi h >
Num. of SAEs 
Tot >=1 SAE 1/1 ) .7%) 
1  of Pat. with >=1 non-SAE 25/72 (34.7%) 23/75 (30.7%) 48/147 (32.7%) 
2 8/7 11/78 (14.1%) .7%) 
3 5/5 10/62 (16.1%) .0%) 
Tot 38/1 44/215 (20.5%) 
Num. of AEs 
 Num. of Pat. with >=1 AE 
9 
3 ( 9.4%) 
12 21 
15/115 (1
 Num. of AEs 
al Num. of Pat. with >=1 AE 
7 11 18 
84/412 (2
 Num. of AEs 46 
2 (  . %) 
50 96 
 Num. of Pa ./75 (  . %) ./147 (  . %) 
. Num. of RAEs 
 Num. of Pat. with >=1
. . 
 RAE 
 Num. of RAEs 
2 ( 1.4%) 1/78 ( 1.3%) 2/150 ( 1
1 1 
 Num. of Pat. with >=1 RAE 3 (  . %) 1/62 ( 1.6%) 1/115 ( 0
 Num. of RAEs . 1 1 
al Num. of Pat. with >=1 
1 2 
./72 (  . %) 
1 1 
of Pat. t =1 SAE ./53 (  . %) 1/62 ( 1.6%) 1/115 ( 0.9%) 
1  . 1 
al Num. of Pat. with 
Num. of SAEs 
97 ( 0.5%) 
1 
2/215 ( 0.9%
 
3/412 ( 0
3  2
 Num.
 Num. of non-SAEs 
 Num. of Pat. with >=1 non-SAE 
30 
2 (11.1%) 
27 57 
19/150 (12
 Num. of non-SAEs 8 11 19 
 Num. of Pat. with >=1 non-SAE 
 Num. of non-SAEs 
3 ( 9.4%) 15/115 (13
7 10 17 
al Num. of Pat. with >=1 non-SAE 
 Num. of non-SAEs 
97 (19.3%) 82/412 (19.9%) 
93 45 48 
created by t_rep
 
ort.sas 
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Table 12-95 er of S p, and level 
Analysis set level statistic 2x daily 4x d Total 
: Numb  AEs with two-sided CI by analysis population, grou
 aily 
FAS 1 events/N (%) 0/72 (0.0% 0/75 ( 0/147 (0.0%) ) 0.0%) 
 xact 95% CI [0.00%, 4. 0% 0.00%, 2.48%] 
 2 events/N (%) 1/72 (1.4%) 1/78 (1.3%) 2/150 (1.3%) 
 0.16%, 4.73%] 
 62 1/115 (0.9%) 
 72%] 0.04%, 8.66%] 0.02%, 4.75%] 
 1/197 (0.5 215 (0.9%) 3/412 (0.7%) 
 [0.01%, 2.8 11%, 0.15%, 2.11%] 
   
PP ) 0/62 (0.0%) 0/128 (0.0%) 
 [0.00%, 5.7 00% 0.00%, 2.84%] 
 0/64 (0.0 /73 0/137 (0.0%) 
 0.00%, 2.66%] 
 3 1/99 (1.0%) 
  exact 95% CI [0.00%, 7.55%] 0.05%,10.26%] 0.03%, 5.50%] 
 Total events/N (%) 0/173 (0.0%) 1/191 (0.5%) 1/364 (0.3%) 
  exact 95% CI [0.00%, 2.11%] 0.01%, 2.88%] 0.01%,1.52%] 
  
PP * events/N (%) 
  exact 95% CI [0.00%, 7.8 00%, 0.00%, 3.93%] 
 vents/N (%) 0/64 (0.0 /73 0/137 (0.0%) 
 xact 95% CI [0.00%, 5.6 00% 0.00%, 2.66%] 
 3 events/N (%) 0/47 (0.0%) 1/52 (1.9%) 1/99 (1.0%) 
 0%, 7.5 05%, 0.03%, 5.50%] 
 56 (0.0 172 1/328 (0.3%) 
 3 0.01%, 1.69%] 
 e 99%] 0.0 , 4.80%] 
 exact 95% CI [0.04%, 7.50%] 
3 events/N (%) 0/
0.03%, 6.94%] 
0%) 1/53 (0.
 exact 95% CI [0.00%, 6.
 (1.6%) 
Total events/N (%) 
 
%) 2/
 exact 95% CI 0%] 0.  3.32%] 
 
vents/N (%
  
 1 e
 exact 95% CI 
0/66 (0.0%) 
8%] 0.
%) 0
,5.44%] 
(0.0%) 2 events/N (%) 
 exact 95% CI [0.00%, 5.6 00%
events/N (%) 0/47 (0.0%) 1/52 (1.9%) 
0%] 0. ,4.93%] 
    
1 0/45 (0.0 /47 0/92 (0.0%) %) 0
7%] 0.
(0.0%) 
 7.55%] 
2 e
 e
%) 0
0%] 0.
 (0.0%) 
, 4.93 ] %
 exact 95% CI [0.0
 0/1
5%] 0. 10.26%] 
Total events/N (%) %) 1/
4%] 0.01%,3.20%] 
 (0.6%) 
 exact 95% CI [0.00%, 2.
* PP in the strong sense; if 0 events occured the CI is automatically one
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Table 12-96: Adverse events by PT Term for Level 1 (FAS) 
 
2x daily 
(N=72) 
4x daily 
(N=75) 
Total 
(N=147) 
Number of AE's (=100%) 30(100.0%) 27(100.0%) 57(100.0%) 
    
13( 22.8%) 
7( 12.3%) 
1(  3.7%) 
0(  0.0%) 
- Dysuria  1(  1.8%) 
- Folliculitis 0(  0.0%) 1(  3.7%) 1(  1.8%) 
- Nausea 1(  3.3%) 0(  0.0%) 1(  1.8%) 
- Strongyloidiasis 0(  0.0%) 1(  3.7%) 1(  1.8%) 
PT Term    
- Bronchitis acute 11( 36.7%) 6( 22.2%) 17( 29.8%) 
- Diarrhoea 6( 20.0%) 7( 25.9%) 
- Vomiting 
- Dysentery 
5( 16.7%) 2(  7.4%) 
3( 10.0%) 
2(  6.7%) 
3( 11.1%) 
1(  3.7%) 
6( 10.5%) 
3(  5.3%) - Pruritus 
- Skin infection 0(  0.0%) 3( 11.1%) 3(  5.3%) 
- Nasopharyngitis 1(  3.3%) 1(  3.7%) 2(  3.5%) 
- Abdominal pain 0(  0.0%) 1(  1.8%) 
- Cough 1(  3.7%) 1(  1.8%) 
1(  3.3%) 0(  0.0%)
percentages are based on the number of AE's by group 
 
 
 
Table 12-97: Adverse events by PT Term for Level 2 (FAS) 
 
2x daily 
(N=72) 
4x daily 
(N=78) 
Total 
(N=150) 
Number of AE's (=100%) 12(100.0%) 21(100.0%) 9(100.0%) 
   
- Otitis media acut  1(  4.8%) 
- Trichomoniasis intestinal 0(  0.0%) 1(  8.3%) 1(  4.8%) 
 
 PT Term 
- Pruritus 
 
1( 11.1%) 
 
3( 25.0%) 4( 19.0%) 
- Bronchitis acute 1( 11.1%) 2( 16.7%) 3( 14.3%) 
3( 14.3%) - Diarrhoea 0(  0.0%) 3( 25.0%) 
- Vomiting 2( 22.2%) 1(  8.3%) 3( 14.3%) 
- Aphthous stomatitis 0(  0.0%) 1(  8.3%) 1(  4.8%) 
- Cerebral malaria 1( 11.1%) 
1( 11.1%) 
0(  0.0%) 1(  4.8%) 
- Dysuria 0(  0.0%) 
1(  8.3%) 
1(  4.8%) 
- Gastroenteritis 0(  0.0%) 1(  4.8%) 
- Hookworm infection 
- Nasopharyngitis 
1( 11.1%) 0(  0.0%) 
) 
1(  4.8%) 
1(  4.8%) 1( 11.1%) 0(  0.0%
e 1( 11.1%) 0(  0.0%)
percentages are based on the number of AE's by group 
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Table 12-98: Adverse events by PT Term for Level 3 (FAS) 
 
2x daily 
(N=53) 
4x daily 
(N=62) 
Total 
(N=115) 
Number of AE's (=100%) 7(100.0%) 11(100.0%) 18(100.0%) 
    
PT Term    
- Dysentery 1( 14.3%) 2( 18.2%) 3( 16.7%) 
- Pruritus 1( 14.3%) 2( 18.2%) 3( 16.7%) 
- Diarrhoea 0(  0.0%) 2( 18.2%) 2( 11.1%) 
- Nasopharyngitis 2( 28.6%) 0(  0.0%) 2( 11.1%) 
- Anaemia 0(  0.0%) 1(  9.1%) 1(  5.6%) 
- Bronchitis acute 0(  0.0%) 1(  9.1%) 1(  5.6%) 
- Cough 0(  0.0%) 1(  9.1%) 1(  5.6%) 
- Dyspnoea 0(  0.0%) 1(  9.1%) 1(  5.6%) 
- Dysuria 1( 14.3%) 0(  0.0%) 1(  5.6%) 
- Rhinitis 0(  0.0%) 1(  9.1%) 1(  5.6%) 
- Strongyloidiasis 1( 14.3%) 0(  0.0%) 1(  5.6%) 
- Trichomoniasis intestinal 1( 14.3%) 0(  0.0%) 1(  5.6%) 
percentages are based on the number of AE's by group 
 
 
 
Table 12-99: Adverse events by PT Term for all Levels (FAS) 
 
2x daily 
(N=197) 
4x daily 
(N=215) 
Total 
(N=412) 
Number of AE's (=100%) 46(100.0%) 50(100.0%) 96(100.0%) 
    
PT Term    
- Bronchitis acute 12( 26.1%) 9( 18.0%) 21( 21.9%) 
- Diarrhoea 6( 13.0%) 12( 24.0%) 18( 18.8%) 
- Pruritus 4(  8.7%) 6( 12.0%) 10( 10.4%) 
- Vomiting 7( 15.2%) 3(  6.0%) 10( 10.4%) 
- Dysentery 4(  8.7%) 5( 10.0%) 9(  9.4%) 
- Nasopharyngitis 4(  8.7%) 1(  2.0%) 5(  5.2%) 
- Dysuria 3(  6.5%) 0(  0.0%) 3(  3.1%) 
- Skin infection 0(  0.0%) 3(  6.0%) 3(  3.1%) 
- Cough 0(  0.0%) 2(  4.0%) 2(  2.1%) 
- Strongyloidiasis 1(  2.2%) 1(  2.0%) 2(  2.1%) 
- Trichomoniasis intestinal 1(  2.2%) 1(  2.0%) 2(  2.1%) 
- Abdominal pain 0(  0.0%) 1(  2.0%) 1(  1.0%) 
- Anaemia 0(  0.0%) 1(  2.0%) 1(  1.0%) 
- Aphthous stomatitis 0(  0.0%) 1(  2.0%) 1(  1.0%) 
- Cerebral malaria 1(  2.2%) 0(  0.0%) 1(  1.0%) 
- Dyspnoea 0(  0.0%) 1(  2.0%) 1(  1.0%) 
- Folliculitis 0(  0.0%) 1(  2.0%) 1(  1.0%) 
- Gastroenteritis 0(  0.0%) 1(  2.0%) 1(  1.0%) 
- Hookworm infection 1(  2.2%) 0(  0.0%) 1(  1.0%) 
- Nausea 1(  2.2%) 0(  0.0%) 1(  1.0%) 
- Otitis media acute 1(  2.2%) 0(  0.0%) 1(  1.0%) 
- Rhinitis 0(  0.0%) 1(  2.0%) 1(  1.0%) 
percentages are based on the number of AE's by group 
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Table 12-100: Adverse events by HLT Term for Level 1 (FAS) 
 
2x daily 
(N=72) 
4x daily 
(N=75) 
Total 
(N=147) 
Number of AE's (=100%) 30(100.0%) 27(100.0%) 57(100.0%) 
    
HLT Term    
- Lower respiratory tract and lung infections 11( 36.7%) 6( 22.2%) 17( 29.8%) 
- Diarrhoea (excl infective) 6( 20.0%) 7( 25.9%) 13( 22.8%) 
- Nausea and vomiting symptoms 6( 20.0%) 2(  7.4%) 8( 14.0%) 
- Abdominal and gastrointestinal infections 3( 10.0%) 3( 11.1%) 6( 10.5%) 
- Pruritus NEC 2(  6.7%) 1(  3.7%) 3(  5.3%) 
- Skin structures and soft tissue infections 0(  0.0%) 3( 11.1%) 3(  5.3%) 
- Upper respiratory tract infections 1(  3.3%) 1(  3.7%) 2(  3.5%) 
- Bacterial infections NEC 0(  0.0%) 1(  3.7%) 1(  1.8%) 
- Bladder and urethral symptoms 1(  3.3%) 0(  0.0%) 1(  1.8%) 
- Coughing and associated symptoms 0(  0.0%) 1(  3.7%) 1(  1.8%) 
- Gastrointestinal and abdominal pains (excl 
oral and throat) 
0(  0.0%) 1(  3.7%) 1(  1.8%) 
- Nematode infections 0(  0.0%) 1(  3.7%) 1(  1.8%) 
percentages are based on the number of AE's by group 
 
 
 
Table 12-101: Adverse events by HLT Term for Level 2 (FAS) 
 
2x daily 
(N=72) 
4x daily 
(N=78) 
Total 
(N=150) 
Number of AE's (=100%) 9(100.0%) 12(100.0%) 21(100.0%) 
    
HLT Term    
- Pruritus NEC 1( 11.1%) 3( 25.0%) 4( 19.0%) 
- Diarrhoea (excl infective) 0(  0.0%) 3( 25.0%) 3( 14.3%) 
- Lower respiratory tract and lung infections 1( 11.1%) 2( 16.7%) 3( 14.3%) 
- Nausea and vomiting symptoms 2( 22.2%) 1(  8.3%) 3( 14.3%) 
- Abdominal and gastrointestinal infections 0(  0.0%) 1(  8.3%) 1(  4.8%) 
- Bladder and urethral symptoms 1( 11.1%) 0(  0.0%) 1(  4.8%) 
- Ear infections 1( 11.1%) 0(  0.0%) 1(  4.8%) 
- Encephalitis nonviral infectious 1( 11.1%) 0(  0.0%) 1(  4.8%) 
- Nematode infections 1( 11.1%) 0(  0.0%) 1(  4.8%) 
- Protozoal infections NEC 0(  0.0%) 1(  8.3%) 1(  4.8%) 
- Stomatitis and ulceration 0(  0.0%) 1(  8.3%) 1(  4.8%) 
- Upper respiratory tract infections 1( 11.1%) 0(  0.0%) 1(  4.8%) 
percentages are based on the number of AE's by group 
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Table 12-102: Adverse events by HLT Term for Level 3 (FAS) 
 
2x daily 
(N=53) 
4x daily 
(N=62) 
Total 
(N=115) 
Number of AE's (=100%) 7(100.0%) 11(100.0%) 18(100.0%) 
    
HLT Term    
- Abdominal and gastrointestinal infections 1( 14.3%) 2( 18.2%) 3( 16.7%) 
- Pruritus NEC 1( 14.3%) 2( 18.2%) 3( 16.7%) 
- Upper respiratory tract infections 2( 28.6%) 1(  9.1%) 3( 16.7%) 
- Diarrhoea (excl infective) 0(  0.0%) 2( 18.2%) 2( 11.1%) 
- Anaemias NEC 0(  0.0%) 1(  9.1%) 1(  5.6%) 
- Bladder and urethral symptoms 1( 14.3%) 0(  0.0%) 1(  5.6%) 
- Breathing abnormalities 0(  0.0%) 1(  9.1%) 1(  5.6%) 
- Coughing and associated symptoms 0(  0.0%) 1(  9.1%) 1(  5.6%) 
- Lower respiratory tract and lung infections 0(  0.0%) 1(  9.1%) 1(  5.6%) 
- Nematode infections 1( 14.3%) 0(  0.0%) 1(  5.6%) 
- Protozoal infections NEC 1( 14.3%) 0(  0.0%) 1(  5.6%) 
percentages are based on the number of AE's by group 
 
 
 
Table 12-103: Adverse events by HLT Term for all Levels (FAS) 
 
2x daily 
(N=197) 
4x daily 
(N=215) 
Total 
(N=412) 
Number of AE's (=100%) 46(100.0%) 50(100.0%) 96(100.0%) 
    
HLT Term    
- Lower respiratory tract and lung infections 12( 26.1%) 9( 18.0%) 21( 21.9%) 
- Diarrhoea (excl infective) 6( 13.0%) 12( 24.0%) 18( 18.8%) 
- Nausea and vomiting symptoms 8( 17.4%) 3(  6.0%) 11( 11.5%) 
- Abdominal and gastrointestinal infections 4(  8.7%) 6( 12.0%) 10( 10.4%) 
- Pruritus NEC 4(  8.7%) 6( 12.0%) 10( 10.4%) 
- Upper respiratory tract infections 4(  8.7%) 2(  4.0%) 6(  6.3%) 
- Bladder and urethral symptoms 3(  6.5%) 0(  0.0%) 3(  3.1%) 
- Nematode infections 2(  4.3%) 1(  2.0%) 3(  3.1%) 
- Skin structures and soft tissue infections 0(  0.0%) 3(  6.0%) 3(  3.1%) 
- Coughing and associated symptoms 0(  0.0%) 2(  4.0%) 2(  2.1%) 
- Protozoal infections NEC 1(  2.2%) 1(  2.0%) 2(  2.1%) 
- Anaemias NEC 0(  0.0%) 1(  2.0%) 1(  1.0%) 
- Bacterial infections NEC 0(  0.0%) 1(  2.0%) 1(  1.0%) 
- Breathing abnormalities 0(  0.0%) 1(  2.0%) 1(  1.0%) 
- Ear infections 1(  2.2%) 0(  0.0%) 1(  1.0%) 
- Encephalitis nonviral infectious 1(  2.2%) 0(  0.0%) 1(  1.0%) 
- Gastrointestinal and abdominal pains (excl 
oral and throat) 
0(  0.0%) 1(  2.0%) 1(  1.0%) 
- Stomatitis and ulceration 0(  0.0%) 1(  2.0%) 1(  1.0%) 
percentages are based on the number of AE's by group 
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Table 12-104: Adverse events by HLGT Term for Level 1 (FAS) 
 
2x daily 
(N=72) 
4x daily 
(N=75) 
Total 
(N=147) 
Number of AE's (=100%) 30(100.0%) 27(100.0%) 57(100.0%) 
    
HLGT Term    
- Infections - pathogen class unspecified 15( 50.0%) 13( 48.1%) 28( 49.1%) 
- Gastrointestinal motility and defaecation 
conditions 
6( 20.0%) 7( 25.9%) 13( 22.8%) 
- Gastrointestinal signs and symptoms 6( 20.0%) 3( 11.1%) 9( 15.8%) 
- Epidermal and dermal conditions 2(  6.7%) 1(  3.7%) 3(  5.3%) 
- Bacterial infectious disorders 0(  0.0%) 1(  3.7%) 1(  1.8%) 
- Helminthic disorders 0(  0.0%) 1(  3.7%) 1(  1.8%) 
- Respiratory disorders NEC 0(  0.0%) 1(  3.7%) 1(  1.8%) 
- Urinary tract signs and symptoms 1(  3.3%) 0(  0.0%) 1(  1.8%) 
percentages are based on the number of AE's by group 
 
 
 
Table 12-105: Adverse events by HLGT Term for Level 2 (FAS) 
 
2x daily 
(N=72) 
4x daily 
(N=78) 
Total 
(N=150) 
Number of AE's (=100%) 9(100.0%) 12(100.0%) 21(100.0%) 
    
HLGT Term    
- Infections - pathogen class unspecified 3( 33.3%) 3( 25.0%) 6( 28.6%) 
- Epidermal and dermal conditions 1( 11.1%) 3( 25.0%) 4( 19.0%) 
- Gastrointestinal motility and defaecation 
conditions 
0(  0.0%) 3( 25.0%) 3( 14.3%) 
- Gastrointestinal signs and symptoms 2( 22.2%) 1(  8.3%) 3( 14.3%) 
- Central nervous system infections and 
inflammations 
1( 11.1%) 0(  0.0%) 1(  4.8%) 
- Helminthic disorders 1( 11.1%) 0(  0.0%) 1(  4.8%) 
- Oral soft tissue conditions 0(  0.0%) 1(  8.3%) 1(  4.8%) 
- Protozoal infectious disorders 0(  0.0%) 1(  8.3%) 1(  4.8%) 
- Urinary tract signs and symptoms 1( 11.1%) 0(  0.0%) 1(  4.8%) 
percentages are based on the number of AE's by group 
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Table 12-106: Adverse events by HLGT Term for Level 3 (FAS) 
 
2x daily 
(N=53) 
4x daily 
(N=62) 
Total 
(N=115) 
Number of AE's (=100%) 7(100.0%) 11(100.0%) 18(100.0%) 
    
HLGT Term    
- Infections - pathogen class unspecified 3( 42.9%) 4( 36.4%) 7( 38.9%) 
- Epidermal and dermal conditions 1( 14.3%) 2( 18.2%) 3( 16.7%) 
- Gastrointestinal motility and defaecation 
conditions 
0(  0.0%) 2( 18.2%) 2( 11.1%) 
- Respiratory disorders NEC 0(  0.0%) 2( 18.2%) 2( 11.1%) 
- Anaemias nonhaemolytic and marrow depression 0(  0.0%) 1(  9.1%) 1(  5.6%) 
- Helminthic disorders 1( 14.3%) 0(  0.0%) 1(  5.6%) 
- Protozoal infectious disorders 1( 14.3%) 0(  0.0%) 1(  5.6%) 
- Urinary tract signs and symptoms 1( 14.3%) 0(  0.0%) 1(  5.6%) 
percentages are based on the number of AE's by group 
 
 
 
Table 12-107: Adverse events by HLGT Term for all Levels (FAS) 
 
2x daily 
(N=197) 
4x daily 
(N=215) 
Total 
(N=412) 
Number of AE's (=100%) 46(100.0%) 50(100.0%) 96(100.0%) 
    
HLGT Term    
- Infections - pathogen class unspecified 21( 45.7%) 20( 40.0%) 41( 42.7%) 
- Gastrointestinal motility and defaecation 
conditions 
6( 13.0%) 12( 24.0%) 18( 18.8%) 
- Gastrointestinal signs and symptoms 8( 17.4%) 4(  8.0%) 12( 12.5%) 
- Epidermal and dermal conditions 4(  8.7%) 6( 12.0%) 10( 10.4%) 
- Helminthic disorders 2(  4.3%) 1(  2.0%) 3(  3.1%) 
- Respiratory disorders NEC 0(  0.0%) 3(  6.0%) 3(  3.1%) 
- Urinary tract signs and symptoms 3(  6.5%) 0(  0.0%) 3(  3.1%) 
- Protozoal infectious disorders 1(  2.2%) 1(  2.0%) 2(  2.1%) 
- Anaemias nonhaemolytic and marrow depression 0(  0.0%) 1(  2.0%) 1(  1.0%) 
- Bacterial infectious disorders 0(  0.0%) 1(  2.0%) 1(  1.0%) 
- Central nervous system infections and 
inflammations 
1(  2.2%) 0(  0.0%) 1(  1.0%) 
- Oral soft tissue conditions 0(  0.0%) 1(  2.0%) 1(  1.0%) 
percentages are based on the number of AE's by group 
 
 
 
